SEARCH

Search Details

YANO Ikuko
University Hospital / Department of Pharmacy
Professor

Researcher basic information

■ Research Areas
  • Life sciences / Pharmacology
  • Life sciences / Clinical pharmacy

Research activity information

■ Award
  • Nov. 2024 日本医療薬学会, JPHCS 誌論文賞, Significance of pharmacist intervention to oral antithrombotic therapy in the pharmaceutical outpatient clinic of cardiovascular internal medicine: a retrospective cohort study
    Tomoko Kurimura, Kazuhiro Yamamoto, Hidekazu Tanaka, Takayoshi Toba, Takeshi Kimura, Yasushi Habu, Kotaro Itohara, Yumi Kitahiro, Tomohiro Omura and Ikuko Yano

  • Nov. 2023 日本医療薬学会, 第33回日本医療薬学会年会 優秀演題賞（International Session）, Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-positive non-small cell lung cancer
    Hori T, Yamamoto K, Ito T, Ikushima S, Itohara K, Kitahiro Y, Omura T, Yano I

  • Nov. 2023 日本医療薬学会, JPHCS 誌論文賞, Effectiveness of pharmacist intervention for deprescribing potentially inappropriate medications: a prospective observational study
    Takeshi Kimura, Misa Fujita, Michiko Shimizu, Kasumi Sumiyoshi, Saho Bansho, Kazuhiro Yamamoto, Tomohiro Omura and Ikuko Yano

  • Mar. 2023 日本臨床腫瘍薬学会, 最優秀演題賞, 免疫チェックポイント阻害薬投与患者の好中球リンパ球比による層別化とプロトンポンプ阻害薬の併用による生命予後への影響
    堀智貴,山本和宏,伊藤武文,生島繁樹,大村友博,矢野育子

  • Mar. 2023 日本薬学会, 日本薬学会第143年会学生優秀発表賞（ポスター発表の部）, ユビキチンリガーゼHRD1を誘導する化合物の探索と神経細胞死抑制効果の検討
    西口大生,大村友博,佐登礼佳,北廣優実,山本和宏,國正淳一,矢野育子

  • 2022 日本病院薬剤師会, 第10回（令和4年度）江口記念がん優秀論文賞, Safety and Efficacy of Bis-Glyceryl Ascorbate as Prophylaxis for Hand-Foot Skin Reaction: A Single-Arm, Open-Label Phase I/II study (DGA study)
    Yamamoto K, Nishiyama S, Kunisada M, Iida M, Ito T, Ioroi T, Makimoto H, Omura T, Harada K, Fujisawa M, Nishigori C, Yano I

  • Feb. 2021 第27回日本がんチーム医療研究会優秀演題賞, 抗がん薬調製ロボット導入前後における抗がん薬関連業務の比較
    伊藤雄大, 丹田雅明, 水田直美, 丸上奈穂, 山口由加里, 植田梨沙, 山本和宏, 槇本博雄, 大村友博, 矢野育子

  • Mar. 2019 日本薬学会, 第42回佐藤記念国内賞, 医薬品適正使用のためのクリニカルファーマコメトリクス
    Yano Ikuko
    International academic award

  • Mar. 2018 神戸大学医学部附属病院, 神戸大学医学部附属病院病院長賞, 院外処方箋における疑義照会簡素化プロトコール実行チーム
    Yano Ikuko
    Others

  • Sep. 2017 日本TDM学会, 日本TDM学会「国際TDM会議」派遣賞（海老原賞）, Molecular cornifying mechanisms of multi-targeted tyrosine kinase inhibitors-induced hand-foot skin reaction based on genetic differences of STAT3
    KazuhiroYamamoto, TakahiroIshida, TsutomuNakagawa, TatsuyaNishioka, ManabuKume, HirooMakimoto, HideakiMiyake, MasatoFujisawa, ChikakoNishigori, Yano Ikuko, MidoriHirai
    Japan society

  • May 2016 神戸大学医学部附属病院薬剤部, 第10回日本ファーマシューティカルコミュニケーション学会大会 優秀発表賞, ひょっとして副作用!?見逃さない薬剤師になるための第一歩
    小出慶子, 西岡達也, 久米学, 槇本博雄, Yano Ikuko, 平井みどり
    Japan society

  • Jun. 2011 日本TDM学会, 日本TDM学会「国際TDM会議」派遣賞（海老原賞）, Significance of trough monitoring of tacrolimus blood concentration and calcineurin activity in living-donor liver transplant patients.
    Yano Ikuko, MasudaS, EgawaH, SugimotoM, FukudoM, YoshidaY, YasudaY, KaidoT, UemotoS, InuiK
    Japan society

  • Nov. 2008 公益財団法人 臨床薬理研究振興財団, 第1回臨床薬理研究振興財団研究大賞, カルシニューリン阻害剤の体内動態と薬効の速度論的解析に基づく個別化投与設計法
    Yano Ikuko, 福土将秀, 増田智先, 小倉靖弘, 尾池文隆, 田中紘一, 乾賢一
    Publisher

  • Oct. 2005 日本薬物動態学会, 日本薬物動態学会奨励賞, 薬物動態と薬効の速度論的解析に基づく個別投与設計法の確立
    Yano Ikuko
    Japan society

  • Sep. 2001 日本医療薬学会, 日本医療薬学会奨励賞, 緑内障治療薬アセタゾラミドの体内動態と薬効の速度論的解析
    Yano Ikuko
    Japan society

■ Paper
  • Yumi Kitahiro, Mari Hashimoto, Yukako Sonda, Miki Yagi, Kotaro Itohara, Takumi Kido, Kazumichi Fujioka, Hitomi Imafuku, Tomohiro Omura, Ikuko Yano
    BACKGROUND: Torasemide, a loop diuretic, is rarely used for pregnant women because of the risk of reduced placental blood flow resulting from decreased circulating plasma volume. We experienced a case of a newborn with metabolic alkalosis and mild polyuria. The mother was suspected of self-medicating as we detected torasemide in the neonatal serum by LC-MS/MS method. CASE PRESENTATION: A Japanese pregnant woman in her 20s with mental illness, symptoms of panic and eating disorders, and a history of overdosing on over-the-counter medications, was referred to our hospital for birth control. She presented with vomiting following bulimia nervosa and hypokalemia. Her baby was delivered vaginally at 36 weeks and 4 days of gestation. The baby's blood gas analysis on day 0 revealed metabolic alkalosis (pH > 7.42, HCO3- > 28 mmHg). Up to 16 h after birth, mild polyuria and a urine output of 3.3 mL/kg/h were observed without the administration of diuretics. We suspected diuretic intake by the mother before delivery, because she had a history of taking torasemide before being referred to the hospital. As expected, torasemide was detected in the baby's serum. The serum concentration on the first day after delivery (4.80 ng/mL) gradually decreased to 0.45 ng/mL on day 5, whereas torasemide was not detected in the maternal serum. Neonatal metabolic alkalosis improved by day 3 following birth. CONCLUSIONS: This case suggests close counseling and monitoring of pregnant women before childbirth regarding their past and present use of drugs, particularly in those with mental illness.
    Apr. 2025, Journal of pharmaceutical health care and sciences, 11(1) (1), 31 - 31, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Mizuki Tsuda, Masaaki Tanda, Tomohiro Omura, Takahiro Ito, Masayuki Iida, Naho Marugami, Yukari Yamaguchi, Nobuko Ohmoto, Kazuhiro Yamamoto, Ikuko Yano
    Japanese Society of Pharmaceutical Health Care and Sciences, Apr. 2025, Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 51(4) (4), 203 - 212
    Scientific journal

  • Tomoko Kurimura, Tomohiro Omura, Kazuhiro Yamamoto, Hidekazu Tanaka, Takeshi Kimura, Kotaro Itohara, Yumi Kitahiro, Yasushi Habu, Toshiyasu Sakane, Ikuko Yano
    A woman in her 70s who was taking warfarin 3.75 mg/day had a prothrombin time-international normalized ratio (PT-INR) within the therapeutic range. Her medication for pulmonary hypertension was changed from bosentan to macitentan. After 40 days, she developed respiratory distress, anorexia, and vomiting caused by common cold. When she visited the pharmaceutical outpatient clinic without reservation, the pharmacist suspected that bosentan discontinuation, which cancelled cytochrome P450 (CYP) 2C9 and CYP3A4 enzyme induction, and decreased vitamin K intake due to appetite loss had enhanced warfarin effect, causing PT-INR prolongation. The pharmacist requested the physician to examine the patient's PT-INR. Results showed that her PT-INR was >7. Hence, she was urgently hospitalized. Warfarin and macitentan were discontinued, and the patient's PT-INR decreased to 1.77 after the intravenous administration of vitamin K. Her appetite improved, and warfarin 2 mg/day was resumed. Additionally, when she had been administered macitentan, her hemoglobin levels decreased from 10.8 to 6.6 mg/dL. Therefore, the pharmacist and the physician during hospitalization planned to resume treatment with bosentan, but not with macitentan. The pharmacist proposed to increase the warfarin dose to 3.75 mg since the bosentan and warfarin interaction could lower PT-INR. Thereafter, the patient's PT-INR was controlled within the therapeutic range, and her hemoglobin level was 8-9 mg/dL. The patient was discharged on day 17 of admission. Thus, pharmacist intervention plays a significant role in warfarin control with consideration of drug-drug interaction in patients receiving pulmonary hypertension treatment.
    Feb. 2025, The Kobe journal of medical sciences, 70(4) (4), E125-E129, English, Domestic magazine
    Scientific journal

  • Kotaro Itohara, Kazuhiro Yamamoto, Shunsuke Fujinaka, Mari Hashimoto, Naoki Tamura, Yumi Kitahiro, Tomohiro Omura, Kazumichi Fujioka, Ikuko Yano
    BACKGROUND: Valganciclovir (VGCV) is administered at a dose of 16 mg/kg 2 times daily for 6 months to treat symptomatic congenital cytomegalovirus (CMV) infections. During the treatment period, approximately 20% of the patients developed grade 3 or higher neutropenia. Currently, information on the pharmacokinetics and pharmacodynamics of ganciclovir, an active metabolite of VGCV, in infants is limited. In the current study, the relationship between ganciclovir concentration and neutropenia was investigated, and a population pharmacokinetic (PPK) model of ganciclovir in infants with symptomatic congenital CMV infection was developed. METHODS: Japanese infants who were prescribed oral VGCV for symptomatic congenital CMV infections between July 2017 and January 2021 were included. The relationship between the observed trough ganciclovir concentrations and neutrophil counts was examined. PPK analysis was performed to evaluate the covariates affecting the pharmacokinetics of ganciclovir. RESULTS: Twenty-seven ganciclovir serum samples from 8 patients were analyzed. A moderate negative correlation was observed between the observed trough ganciclovir concentration and neutrophil count. PPK model analysis showed that postmenstrual age (PMA) affected the total body clearance of ganciclovir after correcting for the empirical allometric scaling of body weight. Based on PMA and body weight, a nomogram to achieve the target area under the concentration-time curve from 0 to 24 hours of 40-60 mcg·h·mL-1 of ganciclovir was calculated. CONCLUSIONS: The relationship between neutrophil count and ganciclovir trough concentration in infants was clarified. The PPK model showed that the dose of VGCV should be reduced in patients with a low PMA to achieve target exposure.
    Sep. 2024, Therapeutic drug monitoring, English, International magazine
    Scientific journal

  • Takeshi Tomida, Takeshi Kimura, Kazuhiro Yamamoto, Atsushi Uda, Yuki Matsumoto, Naoki Tamura, Masashi Iida, Akiko Tanifuji, Kumiko Matsumoto, Naomi Mizuta, Kei Ebisawa, Goh Ohji, Tomohiro Omura, Kentaro Iwata, Ikuko Yano
    PURPOSE: While nirmatrelvir/ritonavir (NMV-r) has been positioned as a first-line treatment for mild to moderate COVID-19, it has multiple and significant drug-drug interactions (DDIs). The use of NMV-r in Japan has been limited compared to the United States. This study aimed to describe the distribution of DDIs with NMV-r and their management in patients with COVID-19 under the control of a management system for the appropriate use of NMV-r. METHODS: A retrospective observational study was conducted at a Japanese university hospital. The management system included a flowchart for selecting antivirals and a list for reviewing DDI management, based on the National Institutes of Health guidelines and the guidance of the Japanese Society of Pharmaceutical Health Care and Sciences. Patients with mild to moderate COVID-19 and prescribed NMV-r or molnupiravir (MOV) were included. The primary outcome was DDI management practices, including the selected COVID-19 medications. The secondary outcome included the distribution of DDI classification and the 30-day all-cause mortality. RESULTS: This study included 241 patients (median age of 60 years, 112 [46.5%] females), of whom 126 and 115 received NMV-r and MOV, respectively. Of the 241 patients, 145 (60.2%) received concomitant medications that have DDIs with NMV-r. All 30 patients with severe renal impairment or insufficient details on concomitant medications received MOV. Forty-nine patients with concomitant medications required alternative COVID-19 therapy consideration due to DDIs, of whom 42 (85.7%) patients received MOV. Eighty-one patients had concomitant medications requiring temporary adjustment, of whom 44 (54.3%) patients received NMV-r, and 42 of these patients temporarily adjusted these concomitant medications. Five patients with concomitant medications that can continued by monitoring the effects/adverse effects, of whom 4 (80.0%) patients received NMV-r. Seventy-six patients without concomitant medications requiring DDI management, of whom 71 (93.4%) patients received NMV-r. The 30-day all-cause mortality for eligible patients was 0.9% [95% confidence interval, 0.1-3.1]. CONCLUSIONS: Most patients received appropriate antivirals according to the classification of DDIs, and most patients with concomitant medications requiring temporary adjustment received the recommended DDI management. Our management system is effective in promoting the use of NMV-r in the appropriate patients and managing problematic DDIs.
    Sep. 2024, Journal of pharmaceutical health care and sciences, 10(1) (1), 54 - 54, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • オピオイド鎮痛薬を入院中に開始した外来頭頸部がん患者を対象とした病院薬剤師による電話サポート介入の効果
    志田 有里, 飯田 真之, 番匠 咲帆, 蓼原 瞬, 大本 暢子, 山本 和宏, 大村 友博, 丹生 健一, 矢野 育子
    (一社)日本緩和医療薬学会, Sep. 2024, 日本緩和医療薬学雑誌, 17(3) (3), 87 - 94, Japanese

  • 小林 理乃, 山本 和宏, 丹田 雅明, 糸原 光太郎, 北廣 優実, 大村 友博, 矢野 育子
    (一社)日本TDM学会, Jul. 2024, TDM研究, 41(2) (2), 158 - 158, Japanese

  • Tomoki Hori, Kazuhiro Yamamoto, Takefumi Ito, Shigeki Ikushima, Tomohiro Omura, Ikuko Yano
    Osimertinib is used as the first-line therapy for patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC). However, early dose reduction is often required due to adverse events (AEs). This study aimed to evaluate the effect of early dose reduction of osimertinib on efficacy and safety. This was a retrospective study including patients with EGFR-mutated NSCLC who were started on osimertinib as the first-line therapy between August 2018 and December 2021. Patients whose doses were reduced to less than 80 mg/day within 6 months of osimertinib initiation or started at 40 mg/day were defined as the dose reduction group. The primary endpoint was progression-free survival (PFS). Factors affecting PFS were explored using the Cox proportional hazards model. A total of 85 patients were included in this study. No significant differences in patient characteristics were observed between the dose reduction (n = 25) and standard dose groups (n = 60). The median PFS in the dose reduction group was significantly prolonged compared with that in the standard dose group (26.0 months vs. 12.0 months, p = 0.03). Multivariable analysis of 84 patients, excluding a patient with unknown brain metastasis, revealed that EGFR exon 21 L858R mutation, malignant pleural effusion or pleural metastasis, liver metastasis, and dose reduction within 6 months were independent factors affecting PFS. Early dose reduction of osimertinib is an effective therapeutic strategy for prolonging PFS in patients with EGFR-mutated NSCLC.
    Jun. 2024, Investigational new drugs, 42(3) (3), 281 - 288, English, International magazine
    Scientific journal

  • 院外処方における臨床検査値を用いた2段階チェック機能の有用性 処方禁忌警告システムと処方箋への検査値印字
    冨田 猛, 山本 和宏, 木村 丈司, 宇田 篤史, 土生 康司, 大本 暢子, 山下 和彦, 大村 友博, 矢野 育子
    (一社)日本医療薬学会, Jun. 2024, 医療薬学, 50(6) (6), 277 - 286, Japanese

  • Tomoyuki Sakaue, Kazuhiro Yamamoto, Kotaro Itohara, Yumi Kitahiro, Takahito Endo, Naoki Yokoyama, Takeshi Ishimura, Tomohiro Omura, Ikuko Yano
    Elsevier BV, Jun. 2024, Drug Metabolism and Pharmacokinetics, 56, 101009 - 101009
    Scientific journal

  • Toru Konishi, Yumi Kitahiro, Naoko Fujiwara, Kazuhiro Yamamoto, Mari Hashimoto, Takahiro Ito, Kotaro Itohara, Kazumichi Fujioka, Hitomi Imafuku, Ikuo Otsuka, Tomohiro Omura, Ikuko Yano
    BACKGROUND: Brexpiprazole is a second-generation antipsychotic approved in Japan in 2018; however, information on placental passage and breast milk transfer remains limited. In this report, the patient, a 30-year-old pregnant woman with schizophrenia, was medicated with brexpiprazole, risperidone, and quetiapine. METHODS: The study used high-performance liquid chromatography-tandem mass spectrometry to determine the concentrations of brexpiprazole, quetiapine, risperidone, and its active metabolite (paliperidone) in maternal and neonatal plasma, cord venous plasma, and breast milk. Maternal plasma samples were obtained approximately 2 and 8 hours after the last administration of antipsychotics on the day of delivery and at the estimated drugs' trough time on days 1, 3, and 5 after delivery. RESULTS: The maternal plasma concentrations of brexpiprazole, quetiapine, and paliperidone increased by approximately 3.5-fold on the fifth day compared with those on the day of delivery, whereas the risperidone concentration remained almost constant. Moreover, the neonatal plasma concentrations of the 4 drugs immediately after birth were indistinguishable from the umbilical cord concentrations and gradually decreased, except for risperidone. Relative infant doses of these compounds were below 1.1%. CONCLUSIONS: Pregnancy status notably alters the pharmacokinetic properties of antipsychotics. Therefore, close and careful monitoring of clinical symptoms should be considered during pregnancy and after delivery. Although brexpiprazole is transferred to neonates through the placenta, breastfeeding is still possible because the relative infant dose value of this drug was much less than 10%.
    Apr. 2024, Therapeutic drug monitoring, 46(5) (5), 687 - 691, English, International magazine
    [Refereed]
    Scientific journal

  • 岡崎 裕太朗, 大村 友博, 上田 昌史, 武田 紀彦, 竹下 治範, 飯田 真之, 山下 和彦, 木村 丈司, 大本 暢子, 山本 和宏, 土生 康司, 宮田 興子, 矢野 育子
    (一社)日本病院薬剤師会, Apr. 2024, 日本病院薬剤師会雑誌, 60(4) (4), 395 - 401, Japanese

  • Yasumasa Kakei, Takeshi Ioroi, Keiko Miyakoda, Takahiro Ito, Masahiko Kashin, Tatsuya Shirai, Takumi Hasegawa, Toshiyasu Sakane, Ikuko Yano, Masaya Akashi
    Introduction In our previous work, we investigated the analgesic effects of ibuprofen gargle after mandibular third molar extractions. However, a subsequent detailed review of individual patient data revealed variations in postoperative pain reduction among patients. Consequently, the present study was designed to conduct post-hoc subanalyses that identified factors contributing to variation in the analgesic response to ibuprofen gargle after third molar extractions. Materials and methods This study involved thirty-five Japanese patients from a prior randomized, double-blind, placebo-controlled, crossover study, which focused on the analgesic effects of ibuprofen gargle after mandibular third molar extractions. Participants were categorized as responders (n = 13) and non-responders (n = 22) based on the within-subject difference (ibuprofen-placebo, IP) of visual analog scale (VAS) changes. Baseline characteristics were compared, along with variables, such as age, sex, the reason for extraction, extraction site, Pell Gregory (space and depth) classification, Winter's classification, surgeon's experience, and surgery time. Baseline characteristics predicting responder status were examined using multivariate logistic regression. Results In the univariate analysis, variables such as age, sex, and baseline VAS scores with p-values <0.2 were evaluated using a stepwise approach. This analysis identified age (per -10 years) with an odds ratio of 4.163 (95% confidence interval (CI): 1.170-31.952, p = 0.0233) and sex (female) with an odds ratio of 9.977 (95% CI: 1.336-208.256, p = 0.0213) as significant predictors of responder status. Conclusions In young and female patients, ibuprofen gargle decreased postoperative pain after mandibular third molar extractions.
    Apr. 2024, Cureus, 16(4) (4), e57516, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Yasumasa Kakei, Ichiro Morioka, Takumi Imai, Kotaro Itohara, Ikuko Yano, Naoto Takahashi, Tetsushi Yoshikawa, Hiroyuki Moriuchi, Yoshinori Ito, Kazumichi Fujioka, Akira Oka
    INTRODUCTION: Insurance coverage for oral valganciclovir (VGCV) began in Japan in April 2023 on the basis of results, including our clinical trials for symptomatic congenital cytomegalovirus (CMV) disease. The VGCV treatment is available throughout Japan, so clinicians must consider the likelihood of hearing improvement and the possibility of neutropenia before dosing. MATERIALS AND METHODS: We performed a substudy of an investigator-initiated, single-arm, prospective, multicenter, clinical trial in which 24 infants with symptomatic congenital CMV disease were orally administered 16 mg/kg VGCV twice daily for 6 months as an intervention. We examined the infants' baseline characteristics associated with improved hearing impairment or a severely reduced neutrophil count. RESULTS: Of the 24 patients, 4 had normal hearing on assessment of their ear with the best hearing. Hearing impairment improved in 14 patients and did not respond to VGCV treatment in 6 patients at the 6-month hearing assessment. CMV DNA levels in plasma at baseline were higher in patients in whom hearing did not respond to treatment. A neutrophil count <500/mm3 occurred in 5 (21%) patients for the first 6 weeks and in 8 (33%) patients for the first 6 months. A neutrophil count at screening and the lowest neutrophil count over the 6 months showed the highest correlation (r = 0.477, p = 0.019). CONCLUSIONS: Infants with a low plasma viral load at screening tend to have an improvement in hearing impairment. Clinicians should be aware of neutropenia during VGCV treatment particularly in patients with a low neutrophil count during screening.
    Mar. 2024, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 30(10) (10), 971 - 977, English, International magazine
    [Refereed]
    Scientific journal

  • Yumi Kitahiro, Kazuhiro Yamamoto, Kimikazu Yakushijin, Takeshi Ioroi, Masaaki Tanda, Kotaro Itohara, Tomohiro Omura, Hironobu Minami, Ikuko Yano
    BACKGROUND: Rituximab, an anti-CD20 monoclonal antibody, can cause infusion reactions (IRs), especially during the initial rituximab infusion therapy. Generally, patients are administered a histamine H1-receptor antagonist before the rituximab infusion, along with an antipyretic analgesic, to prevent or reduce IRs. Multiple retrospective case-control studies indicate that the second generation of histamine H1-receptor antagonists might be more effective than the first generation in suppressing IRs caused by the rituximab infusion. OBJECTIVE: This study aimed to assess the efficacy of first- and second-generation histamine H1-receptor antagonists for preventing IRs resulting from the initial infusion of rituximab in patients diagnosed with non-Hodgkin lymphoma. METHODS: This is a phase II, double-blind, active-controlled randomized trial. It will be a multicenter study conducted across 3 facilities that aims to enroll a total of 40 patients diagnosed with non-Hodgkin lymphoma who will receive their initial rituximab infusion. Participating patients will be administered hydroxyzine pamoate or bepotastine besilate, representing first- or second-generation histamine H1-receptor antagonists, respectively. This will be combined with 400-mg acetaminophen tablets taken approximately 30 minutes before the first infusion of rituximab. The primary end point of this trial is to assess severe IRs, equivalent to grade 2 or higher as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0, that occur within a 4-hour period after the initiation of rituximab infusion. The secondary end points include assessing the severity of the initial IR, the maximum severity of the IR, and the duration between rituximab infusion initiation and the onset of the first IR within a 4-hour period. Additionally, the trial will evaluate histamine H1-receptor antagonist-induced drowsiness using the visual analogue scale, with each patient providing their individual response. RESULTS: This study began with patient recruitment in April 2023, with 17 participants enrolled as of November 12, 2023. The anticipated study completion is set for February 2026. CONCLUSIONS: This study is the first randomized controlled trial comparing the effects of oral first- and second-generation histamine H1-receptor antagonists in preventing IRs induced by the initial administration of rituximab. The findings from this study hold the potential to establish the rationale for a phase III study aimed at determining the standard premedication protocol for rituximab infusion. TRIAL REGISTRATION: Japan Registry of Clinical Trials jRCTs051220169; https://jrct.niph.go.jp/latest-detail/jRCTs051220169. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/54882.
    Feb. 2024, JMIR research protocols, 13, e54882, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 古江 由依, 山本 和宏, 木村 丈司, 高橋 知子, 川瀬 愛子, 清水 倫子, 飯田 真之, 松本 久美子, 大本 暢子, 山下 和彦, 大村 友博, 坂根 稔康, 國正 淳一, 矢野 育子
    (一社)日本医療薬学会, Feb. 2024, 医療薬学, 50(2) (2), 75 - 83, Japanese

  • Hiroki Nishiguchi, Tomohiro Omura, Ayaka Sato, Yumi Kitahiro, Kazuhiro Yamamoto, Junichi Kunimasa, Ikuko Yano
    Parkinson's Disease (PD) is caused by many factors and endoplasmic reticulum (ER) stress is considered as one of the responsible factors for it. ER stress induces the activation of the ubiquitin-proteasome system to degrade unfolded proteins and suppress cell death. The ubiquitin ligase 3-hydroxy-3-methylglutaryl-coenzyme A reductase degradation 1 (HRD1) and its stabilizing molecule, the suppressor/enhancer lin-12-like (SEL1L), can suppress the ER stress via the ubiquitin-proteasome system, and that HRD1 can also suppress cell death in familial and nonfamilial PD models. These findings indicate that HRD1 and SEL1L might be key proteins for the treatment of PD. Our study aimed to identify the compounds with the effects of upregulating the HRD1 expression and suppressing neuronal cell death in a 6-hydroxydopamine (6-OHDA)-induced cellular PD model. Our screening by the Drug Gene Budger, a drug repositioning tool, identified luteolin as a candidate compound for the desired modulation of the HRD1 expression. Subsequently, we confirmed that low concentrations of luteolin did not show cytotoxicity in SH-SY5Y cells, and used these low concentrations in the subsequent experiments. Next, we demonsrated that luteolin increased HRD1 and SEL1L mRNA levels and protein expressions. Furthermore, luteolin inhibited 6-OHDA-induced cell death and suppressed ER stress response caused by exposure to 6-OHDA. Finally, luteolin did not reppress 6-OHDA-induced cell death when expression of HRD1 or SEL1L was suppressed by RNA interference. These findings suggest that luteolin might be a novel therapeutic agent for PD due to its ability to suppress ER stress through the activation of HRD1 and SEL1L.
    Jan. 2024, Neurochemical research, 49(1) (1), 117 - 128, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Takeshi Ioroi, Yasumasa Kakei, Takahiro Ito, Tatsuya Shirai, Yutaro Okazaki, Takumi Hasegawa, Masaya Akashi, Ikuko Yano
    OBJECTIVE: This study was designed to evaluate the postoperative efficacy and safety of using an ibuprofen gargle as a pain management strategy for patients who have undergone mandibular third molar extraction. We also ensured that the quality of treatment was not compromised throughout the study. MATERIAL AND METHODS: Patients were randomized in a 1:1 ratio into two groups: the ibuprofen-placebo (IP) group and the placebo-ibuprofen (PI) group. On postoperative Day (POD) 1, the IP group initiated ibuprofen administration, while the PI group started taking placebo. On POD 2, the IP group switched to using placebo, whereas the PI group switched to ibuprofen. From PODs 3-5, both groups were prescribed ibuprofen gargle. The primary endpoint was within-subject visual analog scale (VAS) score before and 5 min after the first use of the ibuprofen or placebo gargle on PODs 1 and 2 (ΔVAS5_ibuprofen  - ΔVAS5_placebo ). The incidence and severity of adverse events were assessed using the Common Terminology Criteria for Adverse Events version 5.0 and a subjective rating scale. RESULTS: This study enrolled 40 patients. The within-subject VAS5 of the IP and PI groups were 1.25 ± 12.0 and -5.26 ± 8.93 mm, respectively. The treatment effect of ibuprofen gargle was -2.01 ± 10.62 mm (p = .246). None of the patients in each group presented with serious adverse events or clinically significant complications (including dry sockets) after extraction. Transient adverse events, such as throat tingling and oral discomfort (grade 1), were observed in each group. CONCLUSION: Ibuprofen gargle was safe but did not provide significant pain relief when used after mandibular third molar extraction.
    Nov. 2023, Clinical and experimental dental research, 9(6) (6), 1058 - 1068, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Tomoko Kurimura, Kazuhiro Yamamoto, Hidekazu Tanaka, Takayoshi Toba, Takeshi Kimura, Yasushi Habu, Kotaro Itohara, Yumi Kitahiro, Tomohiro Omura, Ikuko Yano
    BACKGROUND: Optimised antithrombotic therapy requires clinical experience and an understanding of the current guidelines. This retrospective study aimed to evaluate whether pharmacist interviews and interventions with patients taking oral antithrombotic drugs in the pharmaceutical outpatient cardiology clinic had favourable clinical outcomes including decreased bleeding. METHODS: The participants included patients visiting the outpatient clinic of cardiovascular internal medicine at the Kobe University Hospital from January-December 2017, and were taking oral antithrombotic medication. The observation period was from the first visit to the outpatient clinic to October 2021 or death. Patients who received pharmacist intervention more than twice were defined as the pharmacist intervention group. Two control patients per one pharmacist intervention group individual were selected from the non-intervention pool matched for age, gender and antithrombotic medication type. RESULTS: Of the 895 eligible patients, 132 were in the pharmacist intervention group and 264 were selected for the matched non-intervention group. Bleeding events according to the Bleeding Academic Research Consortium criteria over type 2 were significantly lower in the pharmacist intervention group compared with the non-intervention group (17.4% versus 28.4%, P = 0.019). There were no significant differences in mortality and heart failure hospitalisation frequency, stroke, or cardiovascular events between the groups. Multivariate analysis identified age (≥ 65 years) and pharmacist intervention as factors associated with bleeding (odds ratio = 2.29 and 0.51, respectively). CONCLUSION: Pharmacist intervention in the outpatient clinic of cardiovascular internal medicine was effective in reducing the risk of bleeding in patients undergoing antithrombotic therapy.
    Sep. 2023, Journal of pharmaceutical health care and sciences, 9(1) (1), 28 - 28, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 飯田 真之, 大村 友博, 志田 有里, 番匠 咲帆, 大本 暢子, 山下 和彦, 槇本 博雄, 山本 和宏, 矢野 育子
    (一社)日本緩和医療薬学会, Sep. 2023, 日本緩和医療薬学雑誌, 16(3) (3), 65 - 71, Japanese

  • 非がん性疼痛を有する患者のオピオイド使用状況モニタリングにおける薬剤師介入の効果
    飯田 真之, 大村 友博, 志田 有里, 番匠 咲帆, 大本 暢子, 山下 和彦, 槇本 博雄, 山本 和宏, 矢野 育子
    (一社)日本緩和医療薬学会, Sep. 2023, 日本緩和医療薬学雑誌, 16(3) (3), 65 - 71, Japanese

  • Takeshi Tomida, Kotaro Itohara, Kazuhiro Yamamoto, Takeshi Kimura, Kohei Fujita, Atsushi Uda, Yumi Kitahiro, Naoki Yokoyama, Yoji Hyodo, Tomohiro Omura, Ikuko Yano
    Sep. 2023, Drug Metabolism and Pharmacokinetics, 53, 100529
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Tomoki Hori, Kazuhiro Yamamoto, Takefumi Ito, Shigeki Ikushima, Tomohiro Omura, Ikuko Yano
    Pharmaceutical Society of Japan, Jun. 2023, Biological and Pharmaceutical Bulletin, 46(6) (6), 788 - 795
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Takuya Fujimoto, Yoji Hyodo, Takeshi Ishimura, Yuki Tashiro, Takahito Endo, Shun Nisioka, Naoki Yokoyama, Kazuhiro Yamamoto, Ikuko Yano, Masato Fujisawa
    BACKGROUND: Sarcopenia is defined as the loss of skeletal muscle mass and function and is associated with increased mortality. Certain genetic polymorphisms represent risk factors used to assess the incidence of sarcopenia; however, few studies have evaluated the association between genetic polymorphisms and sarcopenia after kidney transplantation (KTx). We examined single-nucleotide polymorphisms (SNPs) in the genes involved in sarcopenia after KTx. METHODS: Sixty-five patients who underwent KTx were enrolled in this study. We used the psoas mass index (PMI; the cross-sectional area of the bilateral psoas muscle/height) as a surrogate marker for assessing the extent of sarcopenia. We determined the PMI before KTx and 1 year after KTx, and we identified 5 SNPs in 5 genes associated with sarcopenia in the general population. Finally, the link between the changes in PMI 1 year after KTx and each SNP was examined. RESULTS: The median PMI before KTx and 1 year after KTx was 7.4 (4.6-13.2) and 7.0 (3.6-13.6), respectively. The PMI decreased in 43 patients (66.2%). The alpha-actinin-3 rs1815739 genotype was associated with changes in PMI; the distribution of CT+TT genotypes in the PMI decrease group was significantly higher than that of the CC genotype (odds ratio, 4.23; 95% CI 0.05-0.97; P = 0.025). Moreover, the T allele frequency was significantly higher in the PMI decrease group than in the PMI increase group (odds ratio, 2.34; 95% CI 0.18-0.950; P = 0.025). CONCLUSION: The alpha-actinin-3 rs1815739 genotype may represent a genetic risk factor for sarcopenia after KTx.
    May 2023, Transplantation proceedings, 55(4) (4), 824 - 828, English, International magazine
    Scientific journal

  • Masaaki Tanda, Kazuhiro Yamamoto, Tomoki Hori, Hiroki Nishiguchi, Miki Yagi, Michiko Shimizu, Toru Konishi, Tomonori Ozaki, Natsue Yoshioka, Motoko Tachihara, Takefumi Ito, Shigeki Ikushima, Tomohiro Omura, Ikuko Yano
    BACKGROUND/AIM: Osimertinib is a key drug for treating epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Genetic differences may be associated to adverse events (AEs) induced by osimertinib. This retrospective observational multicenter study evaluated the association of genotypes, including STAT3 -1697C>G, CYP3A5 6986A>G, and ABCG2 421C>A, with the incidence of osimertinib-induced AEs in patients with EGFR mutation-positive NSCLC. PATIENTS AND METHODS: A total of 85 patients treated with osimertinib (Institution A: 33 patients, Institution B: 52 patients) were enrolled in the study. Single nucleotide polymorphisms were determined by real-time PCR, and the incidence of AEs was compared for each genotype. RESULTS: Paronychia incidence was 59% for the CC genotype, 19% for the CG genotype, and 19% for the GG genotype at STAT3 -1697C>G. A genotype-related trend was observed (Cochran-Armitage test, p=0.009). Multivariate analysis showed that the CC genotype at STAT3 -1697C>G and female sex were significant independent factors associated with paronychia [odds ratio (OR)=6.41, 95% confidence interval (CI)=1.94-21.20 and OR=3.40, 95%CI=1.03-11.22, respectively]. The incidence of diarrhea was 53% for the CC genotype, 30% for the AC genotype, and 29% for the AA genotype at ABCG2 421C>A, and a genotype-related trend was observed (p=0.048). However, the CC genotype at ABCG2 421C>A was not a significant independent factor associated with diarrhea in multivariate analysis. No significant associations were detected between other polymorphisms and the incidence of AEs. CONCLUSION: STAT3 -1697C>G may be a novel risk factor for osimertinib-induced paronychia in patients with NSCLC.
    Apr. 2023, Anticancer research, 43(4) (4), 1775 - 1783, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Daichi Enomoto, Kazuhiro Yamamoto, Yuki Matsumoto, Asami Morioka, Tomohiro Omura, Shohei Komatsu, Yoshihiko Yano, Takumi Fukumoto, Ikuko Yano
    BACKGROUND/AIM: Lenvatinib is a multiple-tyrosine kinase inhibitor used to treat hepatocellular carcinoma (HCC), and its systematic concentration varies according to liver function. The albumin-bilirubin (ALBI) grade is a novel indicator for predicting liver function in patients with hepatic disease. This study aimed to investigate the relationship between ALBI grade and HCC patients' lenvatinib treatment duration. PATIENTS AND METHODS: This is a retrospective cohort study of patients with HCC and Child-Pugh A treated with lenvatinib between April 2018 and December 2019. The baseline liver function was determined using the ALBI grade. The primary outcome was discontinuation owing to adverse events. The risk factors for discontinuation owing to adverse effects were analyzed using logistic regression. RESULTS: This investigation included 48 HCC patients. Patients with ALBI grade 2 had a significantly shorter time of discontinuation due to adverse events than those with grade 1 (p=0.036). However, the time of treatment failure did not differ between the groups. Multiple logistic regression analysis showed that ALBI grade 2 and non-use of antihypertensive drugs were independent factors for discontinuation due to adverse events [odds ratio (OR)=14.1, 95% confidence interval (CI)=1.46-135, p=0.022 and OR=5.48, 95% CI=1.13-23.9, p=0.024, respectively]. CONCLUSION: The ALBI grades may be useful in predicting adverse events caused by lenvatinib in patients with HCC and Child-Pugh A.
    Mar. 2023, Anticancer research, 43(3) (3), 1317 - 1323, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Walaa Y B Mahdy, Kazuhiro Yamamoto, Takahiro Ito, Naoko Fujiwara, Kazumichi Fujioka, Tadasu Horai, Ikuo Otsuka, Hitomi Imafuku, Tomohiro Omura, Kazumoto Iijima, Ikuko Yano
    This study aimed to determine the effects of pregnancy and ontogeny on risperidone and paliperidone pharmacokinetics by assessing their serum concentrations in two subjects and constructing a customized physiologically-based pharmacokinetic (PBPK) model. Risperidone and paliperidone serum concentrations were determined in a pregnant woman and her newborn. PBPK models for risperidone and paliperidone in adults, pediatric, and pregnant populations were developed and verified using the Simcyp simulator. These models were then applied to our two subjects, generating their "virtual twins." Effects of pregnancy on both drugs were examined using models with fixed pharmacokinetic parameters. In the neonatal PBPK simulation, 10 different models for estimating the renal function of neonates were evaluated. Risperidone was not detected in the serum of both pregnant woman and her newborn. Maternal and neonatal serum paliperidone concentrations were between 2.05-3.80 and 0.82-1.03 ng/ml, respectively. Developed PBPK models accurately predicted paliperidone's pharmacokinetics, as shown by minimal bias and acceptable precision across populations. The individualized maternal model predicted all observed paliperidone concentrations within the 90% prediction interval. Fixed-parameter simulations showed that CYP2D6 activity largely affects risperidone and paliperidone pharmacokinetics during pregnancy. The Flanders metadata equation showed the lowest absolute bias (mean error: 22.3% ± 6.0%) and the greatest precision (root mean square error: 23.8%) in predicting paliperidone plasma concentration in the neonatal population. Our constructed PBPK model can predict risperidone and paliperidone pharmacokinetics in pregnant and neonatal populations, which could help with precision dosing using the PBPK model-informed approach in special populations.
    Jan. 2023, Clinical and translational science, 16(4) (4), 618 - 630, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Yumi Kitahiro, Takeshi Ioroi, Yasumasa Kakei, Junya Yamashita, Akira Kimoto, Takumi Hasegawa, Asami Morioka, Kazuhiro Yamamoto, Masaya Akashi, Ikuko Yano
    Oral lichen planus (OLP) is a type of chronic and refractory stomatitis characterized by abnormal keratinization, which is often painful. There is no consensus regarding treatment options for OLP, particularly in the presence of pain. The current study protocol focuses on the short-term efficacy and long-term safety of an ibuprofen gargle for pain management in patients with OLP. Patients (n = 24) with painful OLP will be enrolled. During a crossover study period, patients in the ibuprofen–placebo (IP) group will receive an ibuprofen gargle (0.6%) on day 1, a placebo gargle on day 2, and an ibuprofen gargle on days 3–5 at least once daily. Patients in the placebo–ibuprofen (PI) group will receive a placebo gargle on day 1, an ibuprofen gargle on day 2, and an ibuprofen gargle on days 3–5 at least once daily. The primary endpoint of the crossover study period is the change in pain level as measured by a visual analogue scale score from before gargle administration to 5 min after gargle administration on days 1 and 2. The primary endpoint of the long-term extension study is assessment of long-term safety. The results of this study may support existing evidence regarding the effectiveness of ibuprofen rinses in treating OLP.
    MDPI AG, Jan. 2023, Methods and Protocols, 6(1) (1), 7 - 7
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Kotaro Itohara, Ikuko Yano, Shunsaku Nakagawa, Mitsuhiro Sugimoto, Machiko Hirai, Atsushi Yonezawa, Satoshi Imai, Takayuki Nakagawa, Daiki Hira, Takashi Ito, Koichiro Hata, Etsuro Hatano, Tomohiro Terada, Kazuo Matsubara
    Corresponding, Wiley, Nov. 2022, Clinical and Translational Science, 15(11) (11), 2652 - 2662
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 伊藤 雄大, 丹田 雅明, 水田 直美, 丸上 奈穂, 山口 由加里, 植田 梨沙, 梅山 遥, 伊藤 恵, 山本 和宏, 槇本 博雄, 大村 友博, 矢野 育子
    (一社)日本病院薬剤師会, Jun. 2022, 日本病院薬剤師会雑誌, 58(6) (6), 627 - 632, Japanese

  • Yasumasa Kakei, Takeshi Ioroi, Takahiro Ito, Yutaro Okazaki, Takumi Hasegawa, Ikuko Yano, Masaya Akashi
    BACKGROUND: Extraction of mandibular third molars is one of the most commonly performed oral surgical procedures, and nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for pain management. Oral NSAIDs are associated with adverse events such as gastrointestinal disorders, renal and hepatic dysfunction, and platelet dysfunction. Topical analgesics have been proposed as alternatives to oral and injectable medications to safely improve postoperative pain relief. We will conduct a single-center, placebo-controlled, double-blind, randomized crossover trial to assess the pain-relieving effect of an ibuprofen-containing gargle in patients undergoing extraction of mandibular third molars when compared with a placebo gargle. OBJECTIVE: This will be the first clinical study to compare the efficacy of an ibuprofen gargle with that of a placebo for relieving postoperative pain in addition to loxoprofen after mandibular third molar extraction. METHODS: This study will be performed at Kobe University Hospital. Participants (N=40) will be randomized equally to 1 of 2 groups. The ibuprofen-placebo group will receive an ibuprofen gargle on postoperative day (POD) 1 and a placebo gargle on POD 2. The placebo-ibuprofen group will receive a placebo gargle on POD 1 and an ibuprofen gargle on POD 2. Both groups will receive ibuprofen gargles on PODs 3-5 at least once daily. The primary objective is to estimate the within-subject difference on a visual analog scale (VAS) before and 5 minutes after using the ibuprofen or placebo gargle on PODs 1 and 2. The secondary objectives are to estimate the within-subject differences in ΔVAS before and 15 minutes after using the ibuprofen or placebo gargle on PODs 1 and 2, ΔVAS before and 5 or 15 minutes after using the ibuprofen gargle on PODs 3-5, overall efficacy (self-completion, 5 scales) on PODs 1-5, daily frequency of use (ibuprofen or placebo gargle and analgesics) on PODs 1-7, and the occurrence of adverse events. RESULTS: The Certified Review Board of Kobe University approved the study. The intervention was implemented in May 2021. For the primary analysis, we will calculate the mean and SD of ΔVAS5 on PODs 1 and 2 and the within-study difference in ΔVAS5. The treatment effect will be estimated by dividing the mean ΔVAS5 in the within-subject difference by 2 and calculating the P value using an unpaired t test. For the secondary analysis, we will calculate the mean and SD of ΔVAS15 on PODs 1 and 2 and the within-study difference in ΔVAS15. The treatment effect will be estimated as in the primary analysis. CONCLUSIONS: This trial will provide exploratory evidence of the efficacy and safety of an ibuprofen gargle for pain reduction after mandibular third molar extraction. TRIAL REGISTRATION: Japan Registry of Clinical Trials jRCTs051210022; https://tinyurl.com/39ej23zu. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/35533.
    May 2022, JMIR research protocols, 11(5) (5), e35533, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Takeshi Kimura, Misa Fujita, Michiko Shimizu, Kasumi Sumiyoshi, Saho Bansho, Kazuhiro Yamamoto, Tomohiro Omura, Ikuko Yano
    Abstract Background Potentially inappropriate medications (PIMs) and polypharmacy in older adults lead to increase the risk of adverse drug events. This study aimed to evaluate the effectiveness of pharmacist intervention combining the criteria for detecting PIMs with the deprescribing algorithm on correcting PIMs, reducing the number of medications, and readmissions. Methods A prospective observational study was conducted at a Japanese University Hospital enrolling new inpatients aged ≥65 years prescribed ≥1 daily medication. Pharmacists detected PIMs based on the criteria combined the screening tool of older persons’ potentially inappropriate prescriptions criteria version 2 with the screening tool for older persons’ appropriate prescriptions for Japanese, examined changes using the deprescribing algorithm, and suggested changes to the physician. The proportion of patients whose number of medications was reduced at discharge and the rate of readmissions within 30 and 90 days were compared between patients without PIMs (without PIMs group), patients who were not suggested to change PIMs (no suggestions group), and patients who were suggested to change PIMs (suggested group). Results The study enrolled 544 patients (median age 75.0 years, 54.4% males, median number of medications 6.0/patient). The number of patients with PIMs was 240 (44.1%), and 304 patients had no PIMs (without PIMs group). Among the patients with PIMs, 125 (52.1%) patients received pharmacist suggestions to change ≥1 PIMs (suggested group), and 115 patients received no suggestions for change (no suggestions group). The total number of PIMs was 432, of which changes were suggested for 189 (43.8%). Of these 189 cases, 172 (91.0%) were changed. The proportion of patients whose number of medications was reduced was significantly higher in the suggested group than in the without PIMs group and the no suggestions group [56.8% (71/125) vs. 26.6% (81/304) and 19.1% (22/115), respectively; P < 0.001 in both comparisons]. There were no significant differences in the rates of readmissions within 30 and 90 days among the three groups. Conclusions Pharmacist intervention combining the criteria for detecting PIMs with the deprescribing algorithm was effective for correcting PIMs and may be associated with a reduction in the number of medications.
    Springer Science and Business Media LLC, Apr. 2022, Journal of Pharmaceutical Health Care and Sciences, 8(1) (1), 12
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Kazuhiro Yamamoto, Satoshi Nishiyama, Makoto Kunisada, Masashi Iida, Takahiro Ito, Takeshi Ioroi, Hiroo Makimoto, Tomohiro Omura, Kenichi Harada, Masato Fujisawa, Chikako Nishigori, Ikuko Yano
    Abstract Background Hand-foot skin reaction (HFSR) induced by multiple tyrosine kinase inhibitors (TKIs) is a serious side effect that can cause treatment interruption or decreased dosing. This study was conducted to evaluate the safety and efficacy of bis-glyceryl ascorbate (Amitose bis(di)-glyceryl ascorbate [DGA])-containing cream (DGA cream) for the prevention of sunitinib-induced HFSR. Methods A single-arm, open-label phase I/II study was conducted, targeting patients with metastatic renal cell carcinoma (mRCC) who were receiving sunitinib therapy with a schedule of 2 weeks on/1 week off. The participants applied DGA cream to both palmar and plantar surfaces in combination with a moisturizing agent as standard-of-care prophylaxis during two sunitinib treatment cycles (6 weeks). The primary endpoint in phase I was safety defined as dermatological abnormalities and it was determined in the first five participants. The primary endpoint in phase II was efficacy defined as development of grade 1 or higher HFSR defined by Common Terminology Criteria for Adverse Events within 6 weeks and it was determined on a full analysis set (FAS) defined as the population including all participants who used DGA cream once in the study duration. Efficacy in the per protocol set (PPS) defined as the population excluding seven patients whose study treatment was interrupted was evaluated as a secondary endpoint. Results Twenty-four patients were enrolled as a FAS. No dermatological abnormalities occurred in the first 5 patients enrolled in the phase I study. Three patients developed HFSR (grade 1: n = 2, grade 2: n = 1) in the observation period. The HFSR incidence rate was 12.5% (3/24; 95% confidence interval [CI]: 2.7%-32.4%) in the FAS, which was significantly lower than the incidence rate predefined as a threshold of 33.3% by a previous report from our hospital (P = .030). The incidence rate in the 17 patients of the PPS was 17.6% (3/17; 95%CI: 3.8%-43.4%). Conclusion DGA cream may be safe and effective in the prophylaxis of HFSR in mRCC patients who receive sunitinib therapy (Trial ID: jRCTs051180051).
    Oxford University Press (OUP), Mar. 2022, The Oncologist, 27(5) (5), e384 - e392
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Kotaro Itohara, Ikuko Yano, Shunsaku Nakagawa, Atsushi Yonezawa, Tomohiro Omura, Satoshi Imai, Takayuki Nakagawa, Atsuro Sawada, Takashi Kobayashi, Akira Tochio, Kaoru Sakai, Kojiro Taura, Osamu Ogawa, Kazuo Matsubara
    Elsevier BV, Feb. 2022, Drug Metabolism and Pharmacokinetics, 42, 100423 - 100423
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Atsushi Uda, Kei Ebisawa, Hitomi Sakon, Mari Kusuki, Rie Izuta, Mariko Yahata, Ikuko Yano, Takayuki Miyara
    Our antimicrobial pharmacist-led intervention included: (a) a structured review of antibiotic prescriptions; (b) educating prescribers on antimicrobial therapy; (c) monthly reporting of department-level rates of blood sampling for culture. Daily review began in May 2018 and was discontinued after 10 months; however, the other interventions were conducted throughout the study period. This study aimed to evaluate the sustained impact of pharmacist's interventions on antimicrobial therapy and clinical outcomes between the baseline (May-December 2017), intervention (May-December 2018), and post-intervention (May-December 2019) periods. The rate of blood culture collections before starting antipseudomonal agent therapy was significantly increased from the baseline to post-intervention periods (71% vs. 85%, p < 0.001). Antipseudomonal agent therapy was more frequently de-escalated in the post-intervention period than in the baseline period (73% vs. 54%, p = 0.038). Total use of antipseudomonal agents was reduced from the baseline to intervention periods and persisted during the post-intervention period (50.5 vs. 41.8 and 42.6 DDD per 1000 patient-days, p = 0.016 and p = 0.022, respectively). During the study period, there were significant reductions in the incidence of hospital-acquired Clostridioides difficile infection (1.12, 0.54, and 0.51 per 10,000 patient-days, respectively, p = 0.031) and 30-day mortality with bacteremia (19%, 18%, and 12%, respectively, p = 0.005). Our pharmacist-led interventions sustainably achieved appropriate antimicrobial therapy and improved clinical outcomes.
    Jan. 2022, Journal of clinical medicine, 11(3) (3), 566, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Kazuhiro Yamamoto, Takeshi Ioroi, Kazuaki Shinomiya, Ayaka Yoshida, Kenichi Harada, Masato Fujisawa, Tomohiro Omura, Yasuaki Ikemi, Shunsaku Nakagawa, Atsushi Yonezawa, Osamu Ogawa, Kazuo Matsubara, Takuya Iwamoto, Kohei Nishikawa, Sayaka Hayashi, Daichi Tohara, Yoji Murakami, Takanobu Motoshima, Hirofumi Jono, Ikuko Yano
    We evaluated the association of signal transducer and activator of transcription 3 (STAT3) polymorphisms with the incidence of mammalian target of rapamycin (mTOR) inhibitor-induced interstitial lung disease (ILD) in patients with renal cell carcinoma (RCC). We also used lung-derived cell lines to investigate the mechanisms of this association. Japanese patients with metastatic RCC who were treated with mTOR inhibitors were genotyped for the STAT3 polymorphism, rs4796793 (-1697C/G). We evaluated the association of the STAT3 genotype with the incidence of ILD and therapeutic outcome. In the 57 patients included in the primary analysis, the ILD rate within 140 days was significantly higher in patients with the GG genotype compared with those with other genotypes (77.8% versus 23.1%, odds ratio = 11.67, 95% confidential interval = 3.06-44.46). Meanwhile, there were no significant differences in progression-free survival or time-to-treatment failure between the patients with the GG genotype and those with other genotypes. An in vitro study demonstrated that some lung-derived cell lines carrying the GG genotype exhibited an increase in the expression of mesenchymal markers, such as fibronectin, N-cadherin, and vimentin and decreases in E-cadherin, which is an epithelial marker associated with exposure to everolimus, although STAT3 expression and activity were not related to the genotype. In conclusion, the GG genotype of the STAT3 -1697C/G polymorphism increases the risk of mTOR inhibitor-induced ILD, supporting its use as a predictive marker for RCC.
    Jan. 2022, Oncology research, 29(1) (1), 11 - 23, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Yoko Kunimitsu, Kayoko Morio, Sachi Hirata, Kazuhiro Yamamoto, Tomohiro Omura, Takuto Hara, Kenichi Harada, Masato Fujisawa, Ikuko Yano
    The gut microbiome influences tumor response to immune checkpoint inhibitors (ICIs). The proton pump inhibitors (PPI) significantly impair diversity of the gut microbiota and can affect the efficacy of ICIs. Therefore, the present study aimed to evaluate the influence of PPI on survival in patients with metastatic or unresectable urothelial carcinoma receiving pembrolizumab. We conducted a retrospective cohort study of patients with metastatic or unresectable urothelial carcinoma receiving pembrolizumab. The use of PPI was defined as any administration for ≥30 d within 60 d prior and/or 30 d after treatment initiation. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method, and Cox proportional hazards regression analysis was performed to investigate prognostic factors based on patient characteristics. Seventy-nine patients were included in the analysis, and 34 patients (43.0%) received PPI. There were no significant differences in OS and PFS between PPI users and nonusers (median OS: 8.2 months vs. 11.2 months, hazard ratio (HR): 1.36, 95% confidence interval (CI): 0.75-2.42, p = 0.296; median PFS: 3.5 months vs. 5.1 months, HR: 1.63, 95% CI: 0.95-2.80, p = 0.069). In the multivariable analysis, PPI use was not associated with OS (HR 0.80, 95% CI 0.40-1.56, p = 0.526) or PFS (HR 1.44, 95% CI 0.79-2.60, p = 0.233). In conclusion, the estimated effect size of PPI use on survival in Japanese patients with metastatic or unresectable urothelial carcinoma treated with pembrolizumab was not reproducible.
    2022, Biological & pharmaceutical bulletin, 45(5) (5), 590 - 595, English, Domestic magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Yuya Matsuda, Shunsaku Nakagawa, Ikuko Yano, Satohiro Masuda, Satoshi Imai, Atsushi Yonezawa, Takashi Yamamoto, Mitsuhiro Sugimoto, Masahiro Tsuda, Tetsunori Tsuzuki, Tomohiro Omura, Takayuki Nakagawa, Toyofumi Fengshi Chen-Yoshikawa, Miki Nagao, Hiroshi Date, Kazuo Matsubara
    Invasive Aspergillus infection is a major factor for poor prognosis in patients receiving lung transplantation (LT). An antifungal agent, itraconazole (ITCZ), that has antimicrobial activity against Aspergillus species, is used as a prophylactic agent against Aspergillus infection after LT. ITCZ and its metabolite, hydroxyitraconazole (OH-ITCZ), potently inhibit CYP3A and P-glycoprotein that metabolize or excrete calcineurin inhibitors (CNIs), which are the first-line immunosuppressants used after LT; thus, concomitant use of ITCZ and CNIs could induce an increase in the blood concentration of CNIs. However, no criteria for dose reduction of CNIs upon concomitant use with ITCZ in LT recipients have been defined. In this study, the effect of ITCZ and OH-ITCZ on the blood concentrations of two CNIs, tacrolimus and cyclosporine, after LT were retrospectively evaluated. A total of 39 patients who received LT were evaluated. Effects of ITCZ and OH-ITCZ on the concentration/dosage (C/D) ratio of tacrolimus and cyclosporine were analyzed using linear mixed-effects models. The plasma concentrations of OH-ITCZ were about 2.5-fold higher than those of ITCZ. Moreover, there was a significant correlation between the plasma concentrations of ITCZ and OH-ITCZ. Based on parameters obtained in the linear regression analysis, the C/D ratios of cyclosporine and tacrolimus increase by an average of 2.25- and 2.70-fold, respectively, when the total plasma concentration of ITCZ plus OH-ITCZ is 1000 ng/mL. In conclusion, the plasma levels of ITCZ and OH-ITCZ could be key factors in drawing up the criterion for dose reduction of CNIs.
    2022, Biological & pharmaceutical bulletin, 45(4) (4), 397 - 402, English, Domestic magazine
    Scientific journal

  • Tomohiro Omura, Luna Nomura, Ran Watanabe, Hiroki Nishiguchi, Kazuhiro Yamamoto, Satoshi Imai, Shunsaku Nakagawa, Kotaro Itohara, Atsushi Yonezawa, Takayuki Nakagawa, Junichi Kunimasa, Ikuko Yano, Kazuo Matsubara
    Endoplasmic reticulum (ER) stress has been reported as a cause of Parkinson’s disease (PD). We have previously reported that the ubiquitin ligase HMG-CoA reductase degradation 1 (HRD1) and its stabilizing factor suppressor/enhancer lin-12-like (SEL1L) participate in the ER stress. In addition, we recently demonstrated that neuronal cell death is enhanced in the cellular PD model when SEL1L expression is suppressed compared with cell death when HRD1 expression is suppressed. This finding suggests that SEL1L is a critical key molecule in the strategy for PD therapy. Thus, investigation into whether microRNAs (miRNAs) regulate SEL1L expression in neurons should be interesting because relationships between miRNAs and the development of neurological diseases such as PD have been reported in recent years. In this study, using miRNA databases and previous reports, we searched for miRNAs that could regulate SEL1L expression and examined the effects of this regulation on cell death in PD models created by 6-hydroxydopamine (6-OHDA). Five miRNAs were identified as candidate miRNAs that could modulate SEL1L expression. Next, SH-SY5Y cells were exposed to 6-OHDA, following which miR-101 expression was found to be inversely correlated with SEL1L expression. Therefore, we selected miR-101 as a candidate miRNA for SEL1L modulation. We confirmed that miR-101 directly targets the SEL1L 3′ untranslated region, and an miR-101 mimic suppressed the 6-OHDA–induced increase in SEL1L expression and enhanced cell death. Furthermore, an miR-101 inhibitor suppressed this response. These results suggest that miR-101 regulates SEL1L expression and may serve as a new target for PD therapy.
    Frontiers Media SA, Dec. 2021, Frontiers in Molecular Neuroscience, 14
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Atsushi Uda, Katsumi Shigemura, Koichi Kitagawa, Kayo Osawa, Mari Kusuki, Yonmin Yan, Ikuko Yano, Takayuki Miyara
    Since 2014, several global and national guidelines have been introduced to address the problem of antimicrobial resistance. We conducted a campaign in a tertiary hospital to promote appropriate quinolone use through educational lectures in 2018. The aim of this retrospective study was to evaluate the changes in the following: prescription characteristics, trend of oral quinolone use, and antibiotic susceptibility of bacteria from 2013 to 2020. Antimicrobial use was assessed as days of therapy per 1000 patient-days. We found a significant reduction in unnecessary antibiotic prescriptions between December 2013 and December 2020. Significant negative trends were detected in the use of quinolones over 8 years (outpatients, coefficient = -0.15655, p < 0.001; inpatients, coefficient = -0.004825, p = 0.0016). In particular, the monthly mean use of quinolones among outpatients significantly decreased by 11% from 2013 to 2014 (p < 0.05) and reduced further by 31% from 2017 to 2020 (p < 0.001). A significant positive trend was observed in the susceptibility of Pseudomonas aeruginosa to levofloxacin (p < 0.001). These results demonstrate that the use of oral quinolones was further reduced following educational intervention and the bacterial susceptibility improved with optimal quinolone usage compared to that in 2013.
    Nov. 2021, Antibiotics (Basel, Switzerland), 10(11) (11), 1426, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Takahiro Ito, Kazuhiro Yamamoto, Junya Furukawa, Kenichi Harada, Masato Fujisawa, Tomohiro Omura, Ikuko Yano
    WHAT IS KNOWN AND OBJECTIVE: Sunitinib is used as a first-line therapy for metastatic renal cell carcinoma. The primary aim of this study was to determine the optimal total sunitinib (sunitinib plus N-desethyl sunitinib) trough concentration for the alternative dosing schedule: 2-week-on and 1-week-off schedule (2/1 schedule). METHODS: Patients with metastatic renal cell carcinoma treated with the 2/1 schedule of sunitinib, whose total sunitinib concentrations were available, were recruited for this study. Out of 19 patients, 17 whose sunitinib dosage was not changed until the measurement of drug concentration were eligible for the analysis of the relationship between total sunitinib concentration and clinical outcome. Individual pharmacokinetic parameters in 19 patients were estimated via the Bayesian analysis. RESULTS: The onset of severe (grade ≥3) adverse effects among 17 patients during 3 weeks as a first course of sunitinib therapy was observed in 7 (41.2%) patients. The median total sunitinib concentration in patients with severe adverse effects was significantly higher compared with that in patients without severe adverse effects [median: 119 (113-131) vs. 87.8 (77.4-102) ng/mL, p = 0.01]. According to the receiver operating characteristic analysis of the onset of severe adverse effects, the cut-off value of the total sunitinib concentration was 108 ng/mL. Patients with a total sunitinib concentration lower than 108 ng/mL had a longer time to first dose reduction or withdrawal due to adverse effects compared with those with a total sunitinib concentration of 108 ng/mL or higher (p = 0.03). The probability without treatment failure was not significantly different between the two concentration groups. In addition, the estimated sunitinib apparent oral clearance (CL/F) was significantly lower in the severe adverse effects group. Our simulation demonstrated that 0.67-time dose is needed for patients with approximately 90.0 ng/mL of sunitinib concentration on day 7 to maintain the concentration at the same level as the patients with higher CL/F. WHAT IS NEW AND CONCLUSION: Maintaining the total sunitinib trough concentrations of less than 108 ng/mL is safe to avoid the onset of serious adverse effects without increasing the treatment failure in patients with metastatic renal cell carcinoma treated with the 2/1 schedule of sunitinib.
    Oct. 2021, Journal of clinical pharmacy and therapeutics, 47(1) (1), 81 - 88, English, International magazine
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Atsushi Uda, Kenichiro Onuma, Katsumi Shigemura, Koichi Kitagawa, Yonmin Yan, Kayo Osawa, Ikuko Yano, Takayuki Miyara
    Cefazolin is an essential antibiotic used for treating bacteremia; in particular, it is recommended as a first-line agent for infections caused by methicillin-susceptible Staphylococcusaureus (MSSA). In March 2019, problems with a major antibiotic supplier caused a critical shortage of cefazolin in Japan; however, the impact of the cefazolin shortage on clinical outcomes remains unknown. This study aimed to evaluate the effect of the cefazolin shortage in patients with MSSA bacteremia. Data from 75 patients were compared between the pre-shortage (March 2018-January 2019, n = 39) and post-shortage (March 2019-January 2020, n = 36) periods. There were no significant differences in the demographic characteristics between the two groups, and the cefazolin shortage did not worsen clinical outcomes such as adverse drug reactions, treatment failure, and 30-day mortality. In the post-shortage group, ampicillin/sulbactam and benzylpenicillin were more frequently administered as alternative antibiotics for empirical and definitive therapy (10% vs. 31%, p = 0.042; 0% vs. 19%, p = 0.004, respectively). Multivariate analysis revealed that the broad-spectrum antibiotics for definitive therapy, such as antipseudomonal penicillin, were associated with treatment failure in patients with MSSA bacteremia (OR = 17, p = 0.003). Hence, narrow-spectrum antibiotics should be prescribed for MSSA bacteremia as alternatives during a cefazolin shortage.
    Oct. 2021, Antibiotics (Basel, Switzerland), 10(10) (10), 1247, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • YUKO NAKAYAMA, KOHJI TAKARA, TETSUYA MINEGAKI, KAZUHIRO YAMAMOTO, TOMOHIRO OMURA, IKUKO YANO
    Anticancer Research USA Inc., Sep. 2021, Anticancer Research, 41(9) (9), 4239 - 4248
    Scientific journal

  • 山本 和宏, Mahdy Walaa, 石井 順子, 橋本 真梨, 阪上 倫行, 藤原 尚子, 藤岡 一路, 飯島 一誠, 大村 友博, 矢野 育子
    (一社)日本TDM学会, May 2021, TDM研究, 38(2) (2), 180 - 180, Japanese

  • Kayoko Morio, Kazuhiro Yamamoto, Ikuko Yano
    OBJECTIVE: It was reported that the administration of tramadol in patients with cancer pain who have a higher interleukin 6 (IL-6) serum level led to insufficient pain relief. Cytokines produced by tumors, including IL-6, are associated with cancer cachexia. However, whether nonresponse to tramadol is related to cancer cachexia is unknown. The purpose of this study was to examine the relationship between tramadol response and cancer cachexia in patients with cancer pain. METHODS: We conducted a retrospective cohort study of patients with cancer who received tramadol treatment for mild to moderate pain from January 2016 to June 2019. Patients who experienced <20% pain reduction based on the numeric rating scale from baseline to day 7 after treatment with tramadol were defined as nonresponders. Univariate and multivariate logistic regression analyses were conducted to examine the relationships between tramadol response and various patient characteristics, including cancer cachexia. RESULTS: Of 115 patients, 79 were included in the analysis. A total of 24 patients experienced cancer cachexia, and 22 patients were nonresponders. In the univariate logistic analysis, cancer cachexia (odds ratio [OR]: 6.04, 95% confidence interval [CI]: 2.06-17.7), higher white blood cell counts (× 103/μL; OR: 1.28, 95% CI: 1.04-1.61), and lower body mass index (OR: 0.79, 95% CI: 0.66-0.96) were significantly associated with nonresponse to tramadol. The multivariate logistic analysis revealed that cancer cachexia (OR: 5.27, 95% CI: 1.75-15.9) was the only significant factor associated with nonresponse to tramadol. CONCLUSIONS: Cancer cachexia in patients with cancer pain can be associated with nonresponse to tramadol.
    Last, Mar. 2021, The American journal of hospice & palliative care, 38(3) (3), 276 - 282, English, International magazine
    [Refereed]
    Scientific journal

  • Ayaka Yoshida, Kazuhiro Yamamoto, Takahiro Ishida, Tomohiro Omura, Tomoo Itoh, Chikako Nishigori, Toshiyasu Sakane, Ikuko Yano
    Hand-foot skin reaction (HFSR) is a common side effect caused by several tyrosine kinase inhibitors, including sunitinib. However, the nature of the cornifying factors related to the molecular biological mechanisms underlying HFSR remains poorly understood. We used human keratinocyte models to investigate the key cornifying factors for dermatological and biological abnormalities induced by sunitinib. On the basis of the results of microarray analysis using the three-dimensional (3D) human epidermal model, keratin (KRT)6A, serine protease inhibitor (SERPIN)B1, KRT5, and SERPIN Kazal-type 6 were selected as candidate genes related to HFSR. Sunitinib treatment significantly decreased the expression of SERPINB1 and KRT6A in the immunohistochemical staining of the 3D epidermal model. In PSVK1 cells, but not in normal human epidermal keratinocyte cells, both of which are human normal keratinocyte cell lines, sunitinib decreased the expression of KRT6A with a concomitant decrease in levels of phosphorylated extracellular signal-regulated kinases (ERK)1/2 and phosphorylated p38 mitogen-activated protein kinase (MAPK). Inhibitors of the ERK and p38 MAPK signal pathways also significantly decreased KRT6A expression. Sunitinib-induced decrease in KRT6A expression was suppressed by the inhibition of glycogen synthase kinase-3β by enhancing ERK1/2 and p38 MAPK phosphorylation. Thus, sunitinib reduces the expression of KRT6A and SERPINB1 by inhibiting the ERK1/2 and p38 MAPK signalling pathways in the skin model. These changes in expression contribute to the pathology of HFSR.
    Last, Mar. 2021, Experimental dermatology, 30(3) (3), 337 - 346, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Atsushi Uda, Katsumi Shigemura, Koichi Kitagawa, Kayo Osawa, Kenichiro Onuma, Yonmin Yan, Tatsuya Nishioka, Masato Fujisawa, Ikuko Yano, Takayuki Miyara
    The incidence of bacteremia caused by Enterococcus faecium, which is highly resistant to multiple antibiotics, is increasing in Japan. However, risk factors for the acquisition of E. faecium infection and mortality due to enterococcal bacteremia are not well known. We compared demographic, microbiological, and clinical characteristics using a Cox regression model and univariate analysis. We performed a multivariate analysis to identify risk factors for patients treated between 2014 and 2018. Among 186 patients with enterococcal bacteremia, two groups included in the Kaplan-Meier analysis (E. faecalis (n = 88) and E. faecium (n = 94)) showed poor overall survival in the E. faecium group (HR: 1.92; 95% confidence interval: 1.01-3.66; p = 0.048). The median daily antibiotic cost per patient in the E. faecium group was significantly higher than that in the E. faecalis group ($23 ($13-$34) vs. $34 ($22-$58), p < 0.001). E. faecium strains were more frequently identified with previous use of antipseudomonal penicillins (OR = 4.04, p < 0.001) and carbapenems (OR = 3.33, p = 0.003). Bacteremia from an unknown source (OR = 2.79, p = 0.025) and acute kidney injury (OR = 4.51, p = 0.004) were associated with higher risks of 30-day mortality in patients with enterococcal bacteremia. Therefore, clinicians should provide improved medical management, with support from specialized teams such as those assisting antimicrobial stewardship programs.
    Jan. 2021, Antibiotics (Basel, Switzerland), 10(1) (1), 64, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 経口抗がん薬治療における情報共有ツールおよびチーム基盤型学習を用いた病診薬連携の有用性の評価
    植田梨沙, 丹田雅明, 伊藤雄大, 榎本彩花, 飯田真之, 水田直美, 山本和宏, 槇本博雄, 大村友博, 矢野育子
    (一社)日本医療薬学会, Dec. 2020, 医療薬学, 46(12) (12), 681 - 691, Japanese
    [Refereed]
    Scientific journal

  • Takahiro Ito, Kazuhiro Yamamoto, Satoshi Ogawa, Junya Furukawa, Kenichi Harada, Masato Fujisawa, Tomohiro Omura, Ikuko Yano
    The safety of the coadministration of sunitinib with tacrolimus and everolimus with regard to therapeutic drug monitoring has not been demonstrated. Here, we report a patient who showed high sunitinib concentrations, in addition to pharmacokinetic changes in tacrolimus and everolimus after sunitinib therapy. A living-donor renal transplant patient treated with tacrolimus and everolimus was diagnosed with pulmonary and pleural metastases of renal cell carcinoma. The patient received sunitinib therapy (37.5 mg/day, 2 weeks on and 1 week off). This patient exhibited a high total sunitinib concentration (sunitinib, 105.8 ng/mL; N-desethyl sunitinib, 27.9 ng/mL) on day 10 postinitiation and experienced grade 3 diarrhea. The observed sunitinib concentrations were a little higher than those reported in the 421C>A polymorphism of the ATP-binding cassette subfamily G member 2 gene carrier. The observed concentrations of both tacrolimus and everolimus gradually decreased compared with the Bayesian-predicted values after the onset of sunitinib therapy, and the doses of tacrolimus and everolimus were increased. Careful therapeutic drug monitoring of sunitinib, tacrolimus, and everolimus concentrations is necessary during combination therapy, especially after episodes of diarrhea.
    Oct. 2020, Drug metabolism and pharmacokinetics, 35(5) (5), 405 - 409, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Association between dexamethasone treatment and alterations in serum concentrations of trace metals.
    Yamashita K, Ogihara T, Hayashi M, Nakagawa T, Ishizaki Y, Kume M, Yano I, Niigata R, Hiraoka J, Yasui H, Nakamura T
    May 2020, Pharmazie, 75(5) (5), 218 - 222
    [Refereed]
    Scientific journal

  • Atsushi Uda, Katsumi Shigemura, Koichi Kitagawa, Kayo Osawa, Kenichiro Onuma, Shigeaki Inoue, Joji Kotani, Yonmin Yan, Yuzo Nakano, Tatsuya Nishioka, Ikuko Yano, Takayuki Miyara, Masato Fujisawa
    Antimicrobial stewardship teams (ASTs) have been well-accepted in recent years; however, their clinical outcomes have not been fully investigated in urological patients. The purpose of this study was to evaluate the outcomes of intervention via a retrospective review of urological patients, as discussed in the AST meetings, who were treated with broad-spectrum antibiotics between 2014 and 2018 at the Department of Urology, Kobe University Hospital in Japan. Interventions were discussed in AST meetings for patients identified by pharmacists as having received inappropriate antibiotic therapy. The annual changes in numbers of inappropriate medications and culture submissions over five years at the urology department were statistically analyzed. Among 1,033 patients audited by pharmacists, inappropriate antibiotic therapy was found in 118 cases (11.4%). The numbers of inappropriate antibiotic use cases and of interventions for indefinite infections had significantly decreased during the study period (p = 0.012 and p = 0.033, respectively). However, the number of blood and drainage culture submissions had significantly increased (p = 0.009 and p = 0.035, respectively). Our findings suggest that urologists have probably become more familiar with infectious disease management through AST intervention, leading to a decrease in inappropriate antibiotic use and an increase in culture submissions.
    Feb. 2020, Antibiotics (Basel, Switzerland), 9(2) (2), 63, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Takeshi Ioroi, Naomi Kiyota, Yoshinori Imamura, Masaaki Tanda, Shiori Aoki, Mamoru Okuno, Kazuhiro Yamamoto, Ryohei Sasaki, Ken-Ichi Nibu, Hironobu Minami, Midori Hirai, Ikuko Yano
    Background: Oral mucositis frequently occurs in cancer patients treated with chemotherapy and chemoradiotherapy (CRT). This study examined the safety and efficacy of ibuprofen gargle in healthy volunteers and patients with chemotherapy- and concomitant CRT-induced oral mucositis. Methods: We enrolled healthy volunteers and patients with chemotherapy- and CRT-induced oral mucositis. In cohort I, single and multiple doses of ibuprofen gargle (0.6% or 1.0%) were administered to healthy volunteers on day 1 and days 4-10. In cohort II, multiple doses of ibuprofen gargle (0.6%) were administered to patients with complicated grade 2-3 oral mucositis based on the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The primary endpoint of cohort I was the treatment-related adverse events (TRAEs) as defined by CTCAE version 4.0. The primary endpoint of cohort II was the change in the visual analogue scale (VAS) pain score from before to 15 min after gargle use on day 3. The incidence and severity of TRAEs were assessed based on the CTCAE version 4.0 and a subjective rating scale completed by healthy volunteers and patients. Results: In cohort I, 9 of 10 healthy volunteers were evaluable for safety. All 9 healthy volunteers reported the TRAE of oral irritation with single or multiple use of the gargle. In cohort II, 10 patients were enrolled and evaluable for safety and 7 of 10 patients were evaluable for efficacy. The mean change in the VAS pain score from before to 15 min after using the gargle on day 3 was - 1.28 (95% confidence interval: - 2.06, - 0.51), and all patients experienced some degree of pain relief (range: - 0.2 to - 2.5). All 10 patients reported the TRAE of oral irritation. No other TRAEs of ibuprofen gargle were observed in the healthy volunteers and patients. Conclusion: Despite oral irritation, the ibuprofen gargle appeared to be safe and effective for the pain related to chemo- or CRT-induced oral mucositis. However, ibuprofen-related oral irritation warrants further formulation improvement. Trial registration: This study was registered with the University Hospital Medical Information Network Clinical Trials Registry (UMIN000014433).
    2020, Journal of pharmaceutical health care and sciences, 6, 12 - 12, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 吉田優子, 佐藤夕紀, 傳田将也, 池見泰明, 杉本充弘, 山際岳朗, 中川俊作, 今井哲司, 大村友博, 尾崎淳子, 深津祥央, 矢野育子, 北田徳昭, 米澤淳, 中川貴之, 松原和夫
    (一社)日本病院薬剤師会, 2020, 日本病院薬剤師会雑誌, 56(6) (6), 643 - 650, Japanese
    [Refereed]
    Scientific journal

  • PETINIA法による血中ミコフェノール酸測定試薬の基準測定法LC-MS/MS法との比較
    大籔 智奈美, 佐藤 伊都子, 山本 和宏, 矢野 育子, 中町 祐司, 三枝 淳
    (一社)日本臨床衛生検査技師会, Jan. 2020, 医学検査, 69(1) (1), 36 - 43, Japanese
    [Refereed]

  • Atsushi Uda, Takeshi Kimura, Sho Nishimura, Kei Ebisawa, Goh Ohji, Mari Kusuki, Mariko Yahata, Rie Izuta, Tomoyuki Sakaue, Tatsuya Nakamura, Chihiro Koike, Issei Tokimatsu, Ikuko Yano, Kentaro Iwata, Takayuki Miyara
    PURPOSE: This study aimed to evaluate the efficacy of an educational intervention on reducing the inappropriate use of oral third-generation cephalosporins, the prevalence of resistant bacteria, and clinical outcomes. METHODS: A before-after study was conducted to compare the data for 1 year before and after intervention at a Japanese university hospital. Educational intervention included lectures for all medical staff on oral antibiotics and educational meetings with each medical department. The primary outcome was the use of oral third-generation cephalosporins in inpatients as measured by the monthly median days of therapy (DOTs) per 1000 patient days. Secondary outcomes included the use of each oral antibiotic in inpatients and outpatients, proportion of β-lactamase-nonproducing ampicillin-resistant Haemophilus influenzae (BLNAR), penicillin-resistant Streptococcus pneumoniae (PRSP) and extended-spectrum β-lactamase producing Escherichia coli (ESBLEC), the incidence of hospital-acquired Clostridioides difficile infection (HA-CDI), and hospital mortality. RESULTS: The use of oral third-generation cephalosporins in inpatients was significantly decreased after intervention [DOTs (interquartile range): 24.2 (23.5-25.1) vs. 3.7 (0.0-7.1), P < 0.001], and the value in outpatients was also decreased significantly. The use of fluoroquinolones and macrolides did not increase after intervention. The proportion of BLNAR, PRSP and ESBLEC did not change significantly during the study period. The incidence of HA-CDI was significantly decreased, and hospital mortality did not change after intervention. CONCLUSION: Educational intervention was effective in reducing the use of oral third-generation cephalosporins without increasing the use of broad-spectrum antibiotics and worsening clinical outcome. The prevalence of resistant bacteria did not change during the study period.
    Dec. 2019, Infection, 47(6) (6), 1037 - 1045, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Kazuhiro Yamamoto, Sachiyo Fukushima, Yui Mishima, Mari Hashimoto, Kei Yamakawa, Kazumichi Fujioka, Kazumoto Iijima, Ikuko Yano
    Sustained benzodiazepine use during pregnancy can induce neonatal abstinence syndrome (NAS). In this study, the association between NAS and plasma alprazolam concentration was examined using the measured neonatal concentrations in the time series as well as simulated plasma concentrations of pregnant woman and neonate by physiologically based pharmacokinetic (PBPK) modeling. A neonate born to a mother taking alprazolam daily throughout pregnancy exhibited symptoms such as apnea and vomiting from 9 h to 4 days after birth. Finnegan score was 7 at birth and decreased to 0 by day 4. Apnea improved by 24 h post-delivery and gastrointestinal symptoms disappeared by day 4. The plasma alprazolam concentration in the neonate was 15.2 ng/mL immediately after birth and gradually decreased over 3 days. Measured neonate and estimated maternal plasma alprazolam concentrations were within the 90% prediction intervals of each concentration by PBPK simulation using "pregnancy" and "pediatrics" population parameters including in Simcyp population-based ADME simulator. In conclusion, NAS symptoms such as apnea and digestive events disappeared in parallel with the decrease of the neonate's plasma alprazolam concentrations. Moreover, PBPK modeling and simulation is a useful methodology for toxicological assessment in special characteristics populations lacking specific experimental data.
    Dec. 2019, Drug metabolism and pharmacokinetics, 34(6) (6), 400 - 402, English, International magazine
    [Refereed]
    Link to Kobe Univ. Repository (Kernel)

  • Atsushi Uda, Issei Tokimatsu, Chihiro Koike, Kayo Osawa, Katsumi Shigemura, Takeshi Kimura, Takayuki Miyara, Ikuko Yano
    Background De-escalation therapy is recommended as an effective antibiotic treatment strategy for several infectious diseases. While there is limited evidence supporting its clinical and cost-effective outcomes in patients with community-acquired bacteremic pneumonia, there is no evidence in patients with nonbacteremic pneumonia. Objective This study aimed to evaluate the antibiotic costs in patients who did and did not receive de-escalation therapy, based on the 2017 Japanese guidelines for the management of community-acquired nonbacteremic pneumococcal pneumonia of the Japanese Respiratory Society (JRS). Setting Kobe university hospital, Japan. Methods A retrospective case series review including antibiotic use and length of hospital stay was conducted using the medical records from April 2008 to May 2019 at a university hospital in Japan. Main outcome measure Impact of antibiotic de-escalation therapy on the antibiotic costs. Results Among 55 patients who were eligible, the treating physicians de-escalated antibiotics in 28 (51%). The differences in the median length of hospital stay and the incidence of adverse drug reactions between the two groups were not statistically significant (p = 0.67 and 1.0, respectively). However, the median total antibiotic cost per infected patient in the de-escalated group was significantly lower than that in the non-de-escalated group [$269.8 ($195-$389) vs. $420.5 ($221-$799), p = 0.048]. Conclusion Antibiotic de-escalation based on the 2017 JRS guidelines leads to a reduction in total antibiotic costs for the management of community-acquired nonbacteremic pneumococcal pneumonia.
    Dec. 2019, International journal of clinical pharmacy, 41(6) (6), 1611 - 1617, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 疑義照会における検査値連動型の処方チェックシステムの有用性
    冨田 猛, 山本 和宏, 山下 和彦, 大本 暢子, 槇本 博雄, 矢野 育子
    (一社)日本医療薬学会, Dec. 2019, 医療薬学, 45(12) (12), 698 - 705, Japanese
    [Refereed]

  • Takeshi Kimura, Fumie Ogura, Yukiko Kukita, Tomoko Takahashi, Kazuhiro Yamamoto, Takeshi Ioroi, Ikuko Yano
    AIM: This study aimed to evaluate the efficacy of pharmacists' assessment and intervention using the Screening Tool for Older Persons' Appropriate Prescriptions for Japanese (STOPP-J) to detect and correct potentially inappropriate medications (PIM) compared with the Screening Tool of Older Persons' Potentially Inappropriate Prescriptions (STOPP) criteria version 2. METHODS: A prospective observational study was carried out at a medical unit of Cardiovascular Surgery and Cardiovascular Internal Medicine in a Japanese university hospital involving new inpatients aged ≥65 years prescribed one or more daily medication. Pharmacists detected PIM based on STOPP-J and STOPP criteria version 2, and corrected them with physicians. The number of patients with PIM, the content and changes in PIM were compared between both criteria. RESULTS: Overall, 230 patients were included (mean age 75.4 years, 162 men, mean number of medications 8.3). STOPP-J detected significantly more patients with PIM than STOPP criteria version 2 (122 [53%] vs 75 [33%], P < 0.001). The number of PIM based on STOPP-J was 232, the physicians were recommended to change 61 (26%) and 50 (22%) were changed. Meanwhile, the number of PIM based on STOPP criteria version 2 was 133, the physicians were recommended to change 61 (46%) and 54 (41%) were changed. Several medications detected as PIM using STOPP-J were not detected using STOPP criteria version 2. CONCLUSIONS: STOPP-J detected significantly more patients with PIM than STOPP criteria version 2, and pharmacists' assessment and intervention based on STOPP-J were suggested to be effective for detecting and correcting PIM. Geriatr Gerontol Int 2019; 19: 1101-1107.
    Nov. 2019, Geriatrics & gerontology international, 19(11) (11), 1101 - 1107, English, Domestic magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Kazuhiro Yamamoto, Takeshi Ioroi, Kenichi Harada, Satoshi Nishiyama, Chikako Nishigori, Ikuko Yano
    BACKGROUND: Hand-foot skin reaction (HFSR) is a serious side effect induced by multiple-tyrosine kinase inhibitors (TKIs). HFSR can cause treatment interruption or decreased dosing. HFSR also markedly decreases quality of life and is associated with the therapeutic efficacy of multiple-TKIs. Therefore, the management and prevention of HFSR is an important issue; however, an effective method for its prevention has not been established. Specific ascorbic acid derivatives can reverse multiple-TKI-induced keratinocyte growth and pathological changes in vitro. OBJECTIVE: This study was designed to evaluate the safety of bis-glyceryl ascorbate (Amitose DGA), a novel, hydrosoluble, and moisturizing ascorbic acid derivative, in patients with renal cell carcinoma (RCC) receiving sunitinib therapy. This study was also designed to evaluate Amitose DGA's preventive efficacy for sunitinib-induced HFSR. METHODS: This is a Phase I/II, single-center, uncontrolled, single-arm, open-label trial. We will recruit a total of 30 patients with RCC receiving sunitinib therapy, with a 2-week-on and 1-week-off schedule. The participants will apply Amitose DGA-containing cream over both palmar and plantar surfaces within two treatment cycles (ie, 6 weeks) of sunitinib in combination with a general moisturizing agent, in addition to standard-of-care processes. Safety assessments will include dermatological abnormalities, clinical laboratory tests, and incidence of adverse events. Efficacy assessments will include development of HFSR and therapeutic outcomes associated with sunitinib. RESULTS: Recruitment to the study began in August 2017 and is ongoing in Japan. To date, 21 subjects have been recruited. Study completion is expected in 2021. CONCLUSIONS: This is the first clinical study of Amitose DGA-containing cream in patients with RCC who are receiving sunitinib therapy. The single-center, single-arm, open-label design was selected to maximize subject exposure and increase the likelihood of achieving our study endpoints. The results will provide valuable and preliminary evidence of the effects of Amitose DGA-containing cream on HFSR. TRIAL REGISTRATION: UMIN Clinical Trials Registry UMIN000027209; https://upload.umin.ac.jp/cgi-open-bin/ctr /ctr_view.cgi?recptno=R000031174. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/14636.
    Aug. 2019, JMIR research protocols, 8(8) (8), e14636, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Antimicrobial Stewardship Team専従薬剤師による抗菌薬適正使用への介入効果
    宇田 篤史, 木村 丈司, 出田 理恵, 楠木 まり, 西岡 達也, 八幡 眞理子, 矢野 育子, 宮良 高維
    (一社)日本医療薬学会, Aug. 2019, 医療薬学, 45(8) (8), 460 - 469, Japanese
    [Refereed]

  • オピオイド服用患者における酸化マグネシウムの緩下作用に対してプロトンポンプ阻害薬併用が与える影響
    岡田 美咲, 飯田 真之, 伊藤 雄大, 五百蔵 武士, 山本 和宏, 矢野 育子
    (一社)日本病院薬剤師会, Aug. 2019, 日本病院薬剤師会雑誌, 55(8) (8), 964 - 968, Japanese
    [Refereed]

  • Kotaro Itohara, Ikuko Yano, Tetsunori Tsuzuki, Miwa Uesugi, Shunsaku Nakagawa, Atsushi Yonezawa, Hideaki Okajima, Toshimi Kaido, Shinji Uemoto, Kazuo Matsubara
    In adult patients after living-donor liver transplantation, postoperative days and the cytochrome P450 3A5 (CYP3A5) genotype are known to affect tacrolimus pharmacokinetics. In this study, we constructed a physiologically-based pharmacokinetic model adapted to the clinical data and evaluated the contribution of liver regeneration as well as hepatic and intestine CYP3A5 genotypes on tacrolimus pharmacokinetics. As a result, liver function recovered immediately and affected the total body clearance of tacrolimus only during a limited period after living-donor liver transplantation. The clearance was about 1.35-fold higher in the recipients who had a liver with the CYP3A5*1 allele than in those with the CYP3A5*3/*3 genotype, whereas bioavailability was ~0.7-fold higher in the recipients who had intestines with the CYP3A5*1 allele than those with CYP3A5*3/*3. In conclusion, the constructed physiologically-based pharmacokinetic model clarified that the oral clearance of tacrolimus was affected by the CYP3A5 genotypes in both the liver and intestine to the same extent.
    Aug. 2019, CPT: pharmacometrics & systems pharmacology, 8(8) (8), 587 - 595, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 全自動錠剤ハーフカッターカセットの導入による調剤業務の効率性および経済性に関する検討
    澤田 有記美, 山下 和彦, 榎本 大智, 久米 学, 桑原 晶子, 大本 暢子, 平井 みどり, 矢野 育子
    (一社)日本病院薬剤師会, Jun. 2019, 日本病院薬剤師会雑誌, 55(6) (6), 643 - 648, Japanese
    [Refereed]

  • Atushi Yonezawa, Yuki Otani, Toshiyuki Kitano, Mayuko Mori, Sho Masui, Yui Isomoto, Masahiro Tsuda, Satoshi Imai, Yasuaki Ikemi, Masaya Denda, Yuki Sato, Shunsaku Nakagawa, Tomohiro Omura, Takayuki Nakagawa, Ikuko Yano, Makoto Hayakari, Akifumi Takaori-Kondo, Kazuo Matsubara
    PURPOSE: Therapeutic antibodies have heterogeneities in their structures, although its structural alteration in the body is unclear. Here, we analyzed the change of amino acid modifications and carbohydrate chains of rituximab after administration to patients. METHODS: Twenty B cell non-Hodgkin's lymphoma patients who were treated with rituximab for the first time or after more than one year's abstinence were recruited. Structural analysis of rituximab was carried out at 1 h after administration and at the trough by using liquid chromatography/time-of-flight-mass spectrometry. Plasma rituximab concentration and pharmacodynamic markers were also determined. RESULTS: Of recruited twenty, 3 patients exhibited rapid rituximab clearance. Nine types of carbohydrate chains were detected in rituximab isolated from the blood. The composition ratios in some glycoforms were significantly different between at 1 h after administration and at the trough, although consisted amino acids remained unchanged. The patients with high clearance showed extensive alterations of glycoform composition ratios. However, pharmacodynamics makers were not different. CONCLUSION: Inter-individual variations in plasma concentrations of rituximab were found in some B-NHL patients. We could analyze a change in glycoforms of rituximab in the patients, and this finding may affect the pharmacokinetics of rituximab.
    Apr. 2019, Pharmaceutical research, 36(6) (6), 82 - 82, English, International magazine
    [Refereed]
    Scientific journal

  • Yoshiki Katada, Shunsaku Nakagawa, Akiko Nishimura, Yu-Ki Sato, Hiromi Taue, Katsuyuki Matsumura, Kazuhiro Yamazaki, Kenji Minakata, Ikuko Yano, Tomohiro Omura, Satoshi Imai, Atsushi Yonezawa, Yuki Sato, Takayuki Nakagawa, Kenji Minatoya, Kazuo Matsubara
    PURPOSE: Warfarin shows large inter- and intra-individual variabilities in its pharmacokinetics and pharmacodynamics. Sufficient understanding of factors affecting the response to warfarin is necessary to achieve improved outcomes for warfarin therapy. In this study, we evaluated effects of fasting on the anticoagulant properties of warfarin. METHODS: We conducted a retrospective observational study involving a total of 58 patients, who received cardiovascular surgeries and subsequent warfarin therapy. The effect of dietary intake on the anticoagulant properties with warfarin was assessed by measurement of the international normalized ratio of prothrombin time (PT-INR): the anticoagulant activities of warfarin were expressed as the warfarin sensitivity index (WSI). Additionally, fluctuations in WSI during the study period were obtained as differences between the maximum and minimum WSI. RESULTS: The maximum PT-INR and WSI values were significantly higher for patients who were fasting for different reasons during the postoperative period than those in the group without reduced dietary intake. The differences between maximum and minimum WSI in the fasting group significantly increased compared with those in the groups with moderate or no reduced dietary intake. Meanwhile, effects of other markers of clinical conditions including the baseline Child-Pugh score and Charlson Comorbidity Index on WSI were not significant. CONCLUSIONS: Our results indicate that postoperative fasting was significantly associated with the anticoagulation activity of warfarin. In patients fasting for different reasons during the postoperative period, closer control of PT-INR values and warfarin adjustments may be required to avoid adverse effects such as bleeding in warfarin treatment.
    Apr. 2019, European journal of clinical pharmacology, 75(4) (4), 561 - 568, English, International magazine
    [Refereed]
    Scientific journal

  • Miyako Yoshida, Honami Kojima, Atsushi Uda, Tamami Haraguchi, Minoru Ozeki, Ikuo Kawasaki, Kazuhiro Yamamoto, Ikuko Yano, Midori Hirai, Takahiro Uchida
    The purpose of the study was to evaluate the ability of different beverages to mask the bitterness of zopiclone and eszopiclone in tablet formulations using the artificial taste sensor and human gustatory sensation testing. The beverages tested for bitterness-masking effects were: Mugicha, Sports beverage, Lactic acid drink, Orange juice and a diluted simple syrup (an 8.5% sucrose solution). The bitterness intensities estimated by the taste sensor of zopiclone or eszopiclone one-tablet solutions mixed with the various beverages, corresponded well with the observed bitterness intensities measured by gustatory sensation testing. The Sports beverage, Lactic acid drink and Orange juice significantly suppressed the bitterness intensity of both zopiclone and eszopiclone 1-tablet solutions compared with water when tested in the artificial taste sensor. Sports beverage, Lactic acid drink and Orange juice all contain citric acid as acidifier, so it was postulated that citric acid was involved in the mechanism of bitterness intensity suppression of zopiclone and eszopiclone 1-tablet solutions by these three beverages. It was then shown that citric acid suppressed the bitterness intensity of a zopiclone one-tablet sample solution in a dose-dependent manner. 1H-NMR spectroscopic analysis of mixtures of citric acid with zopiclone suggested that the carboxyl groups of citric acid interact with the amine group on zopiclone. This study therefore showed that the bitterness intensities of zopiclone and eszopiclone can be suppressed by citric-acid-contained beverages and suggests that this bitterness suppression is due to a direct electrostatic interaction between citric acid and the two drugs.
    2019, Chemical & pharmaceutical bulletin, 67(5) (5), 404 - 409, English, Domestic magazine
    [Refereed]

  • Pharmacokinetics and Pharmacodynamics of Once-Daily Tacrolimus Compared With Twice-Daily Tacrolimus in the Early Stage After Living Donor Liver Transplantation
    Iwasaki M, Yano Ikuko, Fukatsu S, Hashi S, Yamamoto Y, Sugimoto M, Fukudo M, Masuda S, Nakagawa S, Yonezawa A, Kaido T, Uemoto S, Matsubara K
    Dec. 2018, Ther Drug Monit, 40(6) (6), 675 - 681, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Ubiquitin ligase HMG-CoA reductase degradation 1 (HRD1) prevents cell death in a cellular model of Parkinson's disease
    Omura T, Matsuda H, Nomura L, Imai S, Denda M, Nakagawa S, Yonezawa A, Nakagawa T, Yano Ikuko, Matsubara K
    Nov. 2018, Biochem Biophys Res Commun, 506(3) (3), 516 - 521, English
    [Refereed]
    Scientific journal

  • Ito T, Yamamoto Kazuhiro, Ohsawa F, Otsuka I, Hishimoto Akitoyo, Ichiro Sora, Hirai M, Yano Ikuko
    Background: Risperidone is mainly metabolized by cytochrome P450 (CYP) 2D6 in the liver. The gene encoding CYP2D6 is highly polymorphic. The average steady-state plasma concentration of risperidone active moiety is higher in the CYP2D6 intermediate metabolizers (IMs) compared with that in the extensive metabolizers (EMs). An association between drug-induced extrapyramidal symptoms scale (DIEPSS) score and CYP2D6 polymorphisms has not been reported to date. This study investigates the association of CYP2D6 polymorphisms with the severity of extrapyramidal symptoms in schizophrenia patients receiving risperidone therapy. Methods: Schizophrenia patients undergoing risperidone treatment were recruited for the study in the Kobe University Hospital. We evaluated extrapyramidal symptoms of schizophrenia using the DIEPSS. CYP2D6*10 and CYP2D6*14 were analyzed using TaqMan® assays, and CYP2D6*5 was analyzed using the long-PCR method. Patients with CYP2D6*1/*5, *1/*14, *5/*10, *10/*10, and *10/*14 were classified as IMs, and patients with CYP2D6*1/*1 and *1/*10 were classified as EMs. Patients with CYP2D6*5/*5, *5/*14, and *14/*14 were classified as poor metabolizers (PMs). Results: A total of 22 patients were included in the study. No patients were classified as PMs. The dose of risperidone (mg/day) was not significantly different between EMs (n = 15) and IMs (n = 7) (median with the interquartile range: 4.0 (2.0-6.0) vs. 4.0 (2.0-7.0) mg, p = 0.31). The age and disease duration of schizophrenia were not significantly different between the EMs and IMs. The DIEPSS score in the IMs was significantly higher than that in the EMs (median with the interquartile range: 5.0 (3.5-6.5) vs. 0.0 (0.0-3.0), p < 0.001). The multiple regression analysis showed that CYP2D6 IMs is a significant risk factor for the DIEPSS (p < 0.05). Conclusion: Special attentions should be paid to the onset of extrapyramidal symptoms in schizophrenia patients identified as CYP2D6 IM undergoing risperidone therapy.
    Nov. 2018, J Pharm Health Care Sci, 4, 28 - 28, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Omura T, Sasaoka M, Hashimoto G, Imai S, Yamamoto J, Sato Y, Nakagawa S, Yonezawa A, Nakagawa T, Yano Ikuko, Tasaki Y, Matsubara K
    We have previously reported that oxicam-derived non-steroidal anti-inflammatory drugs (oxicam-NSAIDs), including meloxicam, piroxicam and tenoxicam, elicit protective effects against 1-methyl-4-phenyl pyridinium (MPP+)-induced cell death in a fashion independent of cyclooxygenase (COX) inhibition. We have also demonstrated that oxicam-NSAIDs suppress the decrease in phosphorylation of Akt caused by MPP+. The molecular mechanism through which oxicam-NSAIDs provide cytoprotection remains unclear. In this study, we speculated a possibility that endoplasmic reticulum (ER) stress and/or mitochondrial dysfunction, which are both causative factors of Parkinson's disease (PD), may be involved in the neuroprotective mechanism of oxicam-NSAIDs. We demonstrated here that oxicam-NSAIDs suppressed the activation of caspase-3 and cell death caused by MPP+ or ER stress-inducer, tunicamycin, in SH-SY5Y cells. Furthermore, oxicam-NSAIDs suppressed the increases in the ER stress marker CHOP (apoptosis mediator) caused by MPP+ or tunicamycin, beside suppressing eukaryotic initiation factor 2α (eIF2α) phosphorylation and the increase in ATF4 caused by MPP+. Taken together, these results suggest that oxicam-NSAIDs suppress the eIF2α-ATF4-CHOP pathway, one of the three signaling pathways in the ER stress response. Oxicam-NSAIDs suppressed the decrease in mitochondrial membrane potential depolarization caused by MPP+, indicating they also rescue cells from mitochondrial dysfunction. Akt phosphorylation levels were suppressed after the incubation with MPP+, whereas phosphorylation of eIF2α was enhanced. These results suggest that oxicam-NSAIDs prevented eIF2α phosphorylation and mitochondrial dysfunction by maintaining Akt phosphorylation (reduced by MPP+), thereby preventing cell death.
    Sep. 2018, Biochem Biophys Res Commun, 503(4) (4), 2963 - 2969, English, International magazine
    [Refereed]
    Scientific journal

  • Kazuhiro Yamamoto, Takuto Hara, Tsutomu Nakagawa, Midori Hirai, Hideaki Miyake, Masato Fujisawa, Ikuko Yano
    Springer-Verlag France, Jun. 2018, Targeted Oncology, 13(3) (3), 371 - 378, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 伊藤雄大, 高田麻季, 飯田真之, 宇田篤史, 住吉霞美, 秋山恵里, 丸上奈穂, 丹田雅明, 野間千尋, Yamamoto Kazuhiro, 五百蔵武士, 木村丈司, 西岡達也, 久米学, 槇本博雄, Yano Ikuko
    (一社)日本医療薬学会, May 2018, 医療薬学, 44(5号) (5号), 236 - 243, Japanese
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 院外処方せんにおける疑義照会簡素化プロトコールの運用とアンケートによる評価
    石川愛子, 宇田篤史, Yano Ikuko, 冨田猛, 阪上倫行, 野崎晃, 西岡達也, 久米学, 槇本博雄, 濱口常男, 岩川精吾, 北河修治, 平井みどり
    Apr. 2018, 医療薬学, 44(4号) (4号), 157 - 164, Japanese
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Takeshi Kimura, Atsushi Uda, Tomoyuki Sakaue, Kazuhiko Yamashita, Tatsuya Nishioka, Sho Nishimura, Kei Ebisawa, Manabu Nagata, Goh Ohji, Tatsuya Nakamura, Chihiro Koike, Mari Kusuki, Takeshi Ioroi, Akira Mukai, Yasuhisa Abe, Hiroyuki Yoshida, Midori Hirai, Soichi Arakawa, Ikuko Yano, Kentaro Iwata, Issei Tokimatsu
    OBJECTIVE: To evaluate the long-term effects of comprehensive antibiotic stewardship programs (ASPs) on antibiotic use, antimicrobial-resistant bacteria, and clinical outcomes. DESIGN: Before-after study. SETTING: National university hospital with 934 beds. INTERVENTION: Implementation in March 2010 of a comprehensive ASPs including, among other strategies, weekly prospective audit and feedback with multidisciplinary collaboration. METHODS: The primary outcome was the use of antipseudomonal antibiotics as measured by the monthly mean days of therapy per 1000 patient days each year. Secondary outcomes included overall antibiotic use and that of each antibiotic class, susceptibility of Pseudomonas aeruginosa, the proportion of patients isolated methicillin-resistant Staphylococcus aureus (MRSA) among all patients isolated S. aureus, the incidence of MRSA, and the 30-day mortality attributable to bacteremia. RESULTS: The mean monthly use of antipseudomonal antibiotics significantly decreased in 2011 and after as compared with 2009. Susceptibility to levofloxacin was significantly increased from 2009 to 2016 (P = 0.01 for trend). Its susceptibility to other antibiotics remained over 84% and did not change significantly during the study period. The proportion of patients isolated MRSA and the incidence of MRSA decreased significantly from 2009 to 2016 (P < 0.001 and = 0.02 for trend, respectively). There were no significant changes in the 30-day mortality attributable to bacteremia during the study period (P = 0.57 for trend). CONCLUSION: The comprehensive ASPs had long-term efficacy for reducing the use of the targeted broad-spectrum antibiotics, maintaining the antibiotic susceptibility of P. aeruginosa, and decreasing the prevalence of MRSA, without adversely affecting clinical outcome.
    Apr. 2018, Infection, 46(2) (2), 215 - 224, English, International magazine
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Akiko Hanai, Hiroshi Ishiguro, Takashi Sozu, Moe Tsuda, Ikuko Yano, Takayuki Nakagawa, Satoshi Imai, Yoko Hamabe, Masakazu Toi, Hidenori Arai, Tadao Tsuboyama
    Feb. 2018, JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 110(2) (2), 141 - 148, English
    [Refereed]
    Scientific journal

  • K. Yoshimura, I. Yano, T. Yamamoto, M. Kawanishi, Y. Isomoto, A. Yonezawa, T. Kondo, A. Takaori-Kondo, K. Matsubara
    Corresponding, Nature Publishing Group, 2018, Bone Marrow Transplantation, 53(1) (1), 44 - 51, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Kazuaki Yoshimura, Ikuko Yano, Takashi Yamamoto, Tadakazu Kondo, Misaki Kawanishi, Yui Isomoto, Atsushi Yonezawa, Akifumi Takaori-Kondo, Kazuo Matsubara
    Elsevier Inc., 2018, Biology of Blood and Marrow Transplantation, 24(7) (7), 1441 - 1448, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • インスリンカートリッジの破損により著明な血糖上昇を来した1型糖尿病の1例
    谷藤亜希子, 岡田裕子, 西岡達也, 久米学, 槇本博雄, Yano Ikuko, 小川渉, Hirai Midori
    Dec. 2017, くすりと糖尿病, 6(2号) (2号), 207 - 211, Japanese
    [Refereed]
    Scientific journal

  • Y. Katada, S. Nakagawa, K. Minakata, M. Odaka, H. Taue, Y. Sato, A. Yonezawa, Y. Kayano, I. Yano, T. Nakatsu, K. Sakamoto, K. Uehara, H. Sakaguchi, K. Yamazaki, K. Minatoya, R. Sakata, K. Matsubara
    Oct. 2017, JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 42(5) (5), 591 - 597, English
    [Refereed]
    Scientific journal

  • Kazuhiro Yamamoto, Hiroaki Shichiri, Takahiro Ishida, Kenta Kaku, Tatsuya Nishioka, Manabu Kume, Hiroo Makimoto, Tsutomu Nakagawa, Takeshi Hirano, Toshinori Bito, Chikako Nishigori, Ikuko Yano, Midori Hirai
    Sep. 2017, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 40(9) (9), 1530 - 1536, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • MizutaN, Nakagawa Tsutomu, YamamotoK, NishiokaT, KumeM, MakimotoH, Yano Ikuko, MinamiH, Hirai Midori
    Albumin-bound paclitaxel (Abraxane®, nab-paclitaxel) is not recommended to be administered concurrently or sequentially with other drugs due to concern for instability. The need to administer drugs separately increases infusion time. We evaluated the comp
    神戸大学医学部, Jul. 2017, Kobe J Med Sci, 63(1) (1), E9 - E16, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • 冨田猛, 野崎晃, 宇田篤史, 山本和宏, 西岡達也, 久米学, 槇本博雄, Yano Ikuko, Hirai Midori
    日本医薬品情報学会, May 2017, 医薬品情報学, 19(1号) (1号), 1 - 7, Japanese
    [Refereed]
    Scientific journal

  • Aimi Watanabe, Kazuhiro Yamamoto, Takeshi Ioroi, Sachi Hirata, Kenichi Harada, Hideaki Miyake, Masato Fujisawa, Tsutomu Nakagawa, Ikuko Yano, Midori Hiraiab
    Apr. 2017, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 40(4) (4), 458 - 464, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • Hiroaki Shichiri, Kazuhiro Yamamoto, Maya Tokura, Takahiro Ishida, Atsushi Uda, Toshinori Bito, Chikako Nishigori, Tsutomu Nakagawa, Takeshi Hirano, Ikuko Yano, Midori Hirai
    Apr. 2017, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 485(2) (2), 227 - 233, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • T. Kimura, F. Ogura, K. Yamamoto, A. Uda, T. Nishioka, M. Kume, H. Makimoto, I. Yano, M. Hirai
    Apr. 2017, JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 42(2) (2), 209 - 214, English
    [Refereed]
    Scientific journal

  • Population Pharmacokinetics of Topiramate in Japanese Pediatric and Adult Patients With Epilepsy Using Routinely Monitored Data
    Masato Takeuchi, Ikuko Yano, Satoko Ito, Mitsuhiro Sugimoto, Shota Yamamoto, Atsushi Yonezawa, Akio Ikeda, Kazuo Matsubara
    Apr. 2017, THERAPEUTIC DRUG MONITORING, 39(2) (2), 124 - 131, English
    [Refereed]
    Scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • DVDを用いた副作用研修会の取り組みと評価
    小出慶子, 西岡達也, 五百蔵武士, 久米学, 槇本博雄, Yano Ikuko, Hirai Midori
    日本ファーマシューティカルコミュニケーション学会, Apr. 2017, 日本ファーマシューティカルコミュニケーション学会会誌, 15(1号) (1号), 6 - 12, Japanese
    [Refereed]
    Scientific journal

  • 「薬剤師外来」における薬学的処方介入とその評価
    栗村 朋子, 山本 和宏, 池田 剛久, 橋本 正良, 西岡 達也, 久米 学, 槇本 博雄, 矢野 育子, 平井 みどり
    (一社)日本医療薬学会, Mar. 2017, 医療薬学, 43(3) (3), 169 - 175, Japanese
    [Refereed]
    Link to Kobe Univ. Repository (Kernel)

  • Yuki Otani, Atushi Yonezawa, Masahiro Tsuda, Satoshi Imai, Yasuaki Ikemi, Shunsaku Nakagawa, Tomohiro Omura, Takayuki Nakagawa, Ikuko Yano, Kazuo Matsubara
    Jan. 2017, PLOS ONE, 12(1) (1), e0169588, English
    [Refereed]
    Scientific journal

  • Atsuko Tanaka, Ikuko Yano, Keiko Shinsako, Eriko Sato, Masahide Fukudo, Satohiro Masuda, Toshinari Yamasaki, Tomomi Kamba, Osamu Ogawa, Kazuo Matsubara
    Dec. 2016, THERAPEUTIC DRUG MONITORING, 38(6) (6), 663 - 669, English
    [Refereed]
    Scientific journal

  • テモゾロミド点滴静注用製剤の輸液希釈時における安定性の検討
    古俵孝明, 山際岳朗, 石橋直哉, 深津祥央, Yano Ikuko, 中村敏明, 松原和夫
    Sep. 2016, 日本病院薬剤師会雑誌, 52(9号) (9号), 1140 - 1143, Japanese
    [Refereed]
    Scientific journal

  • 松村健吾, 大谷祐基, 大村友博, 米澤淳, 津田真弘, 池見泰明, 中川俊作, 今井哲司, 中川貴之, Yano Ikuko, 吉貴達寛, 松原和夫

    Many biosimilars have been launched recently, however, a precise analytical method to evaluate their characteristics has not been developed. In this study, we established a new qualitative analysis technology for biomedicines using liquid chromatography coupled with quadrupole time-of-flight mass spectrometer (LC/QTOF-MS), and assessed the original product and 4 biosimilars of filgrastim. Three peaks (Peak 1-3) appeared in total ion chromatogram by LC/QTOF-MS in the original brand-named drug. Filgrastim appeared as the main peak (Peak 1), and its molecular weight was calculated to be 18798.96 ± 0.02. When the original product was reduced by dithiothreitol, the molecular weight was 18802.19 ± 0.47, which was identical to the theoretical value based on amino acid sequence. These results indicate that it is possible to measure and distinguish molecular weights of untreated and reduced forms of filgrastim by LC/QTOF-MS. In addition, main peaks from all products including biosimilars showed exactly the same mass spectra and calculated molecular weights, suggesting that the main components (filgrastim) in these 4 products were considered to be qualitatively equal. On the other hand, the area ratios of 2 secondary peaks (Peaks 2 and 3) against the main peak (Peak 1) in 2 biosimilars were higher than those in the original product. The calculated molecular weights in Peaks 2 and 3 corresponded to that of polysorbate 80, which was one of the additives in the formulation. In conclusion, LC/QTOF-MS is a useful technique for qualitative component analysis of biomedicines.

    Japanese Society of Pharmaceutical Health Care and Sciences, Sep. 2016, 医療薬学, 42(9号) (9号), 613 - 619, Japanese
    [Refereed]
    Scientific journal

  • Effect of vitamin K2 on the anticoagulant activity of warfarin during the perioperative period of catheter ablation: Population analysis of retrospective clinical data
    ZhouZ, Yano Ikuko, OdakaS, MoritaY, ShizutaS, YanoI, KimuraT, AkaikeA, InuiK, MatsubaraK
    Aug. 2016, J Pharm Health Care Sci, 2, 17, English
    [Refereed]
    Scientific journal

  • Haruka Onoue, Ikuko Yano, Atsuko Tanaka, Kotaro Itohara, Akiko Hanai, Hiroshi Ishiguro, Hideyuki Motohashi, Satohiro Masuda, Kazuo Matsubara
    Jun. 2016, EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 72(6) (6), 703 - 710, English
    [Refereed]
    Scientific journal

  • Satoko Ito, Ikuko Yano, Sachiyo Hashi, Masahiro Tsuda, Mitsuhiro Sugimoto, Atsushi Yonezawa, Akio Ikeda, Kazuo Matsubara
    Jun. 2016, THERAPEUTIC DRUG MONITORING, 38(3) (3), 371 - 378, English
    [Refereed]
    Scientific journal

  • Hiroki Yoshimatsu, Atsushi Yonezawa, Kaori Yamanishi, Yoshiaki Yao, Kumiko Sugano, Shunsaku Nakagawa, Satoshi Imai, Tomohiro Omura, Takayuki Nakagawa, Ikuko Yano, Satohiro Masuda, Ken-ichi Inui, Kazuo Matsubara
    Jun. 2016, SCIENTIFIC REPORTS, 6, English
    [Refereed]
    Scientific journal

  • 櫻井香織, 尾崎淳子, Yano Ikuko, 安達昂一郎, 木村嘉彦, 松村勝之, 西脇布貴, 吉田優子, 池見泰明, 萱野勇一郎, 米澤淳, 深津祥央, 松原和夫
    (一社)日本医療薬学会, May 2016, 医療薬学, 42(5号) (5号), 336 - 342, Japanese
    [Refereed]
    Scientific journal

  • 抗てんかん薬との薬物相互作用を検討したエファビレンツおよびドルテグラビル服用症例
    尾崎淳子, Yano Ikuko, 山本崇, 小林正行, 高折晃史, 松原和夫
    日本エイズ学会, May 2016, 日本エイズ学会誌, 18(2号) (2号), 163 - 167, Japanese
    [Refereed]
    Scientific journal

  • Everolimus blood concentrations did not predict interstitial lung disease in patients with metastatic renal cell carcinoma
    Shinsako Keiko, Yano Ikuko, Tanaka Atsuko, Fukudo Masahide, Tsuda Masahiro, Sato Eriko, Kobayashi Takashi, Yamasaki Toshinari, Okubo Kazutoshi, Kamba Tomomi, Yoshimura Koji, Ogawa Osamu, Matsubara Kazuo
    (一社)日本TDM学会, Mar. 2016, TDM研究, 33(1) (1), 1 - 8, English
    [Refereed]

  • 薬剤師の介入による向精神薬適正使用と転倒・転落事故数への影響
    重面雄紀, 小池眞菜美, 萱野勇一郎, 深津祥央, 石塚良子, 杉原玄一, 今井哲司, Yano Ikuko, 中川貴之, 村井俊哉, 松原和夫
    (一社)日本医療薬学会, Mar. 2016, 医療薬学, 42(3) (3), 174 - 184, Japanese
    [Refereed]
    Scientific journal

  • 片田佳希, 中川俊作, 田上裕美, 津田真弘, 都築徹教, 端幸代, 小高瑞穂, 米澤淳, 萱野勇一郎, Yano Ikuko, 南方謙二, 坂田隆造, 松原和夫
    (一社)日本医療薬学会, Jan. 2016, 医療薬学, 42(1号) (1号), 14 - 22, Japanese
    [Refereed]
    Scientific journal

  • Kazuaki Yoshimura, Ikuko Yano, Misaki Kawanishi, Shunsaku Nakagawa, Atsushi Yonezawa, Kazuo Matsubara
    Dec. 2015, DRUG METABOLISM AND PHARMACOKINETICS, 30(6) (6), 441 - 448, English
    [Refereed]
    Scientific journal

  • Misaki Kawanishi, Ikuko Yano, Kazuaki Yoshimura, Takashi Yamamoto, Sachiyo Hashi, Satohiro Masuda, Tadakazu Kondo, Akifumi Takaori-Kondo, Kazuo Matsubara
    Sep. 2015, BIOMEDICAL CHROMATOGRAPHY, 29(9) (9), 1309 - 1316, English
    [Refereed]
    Scientific journal

  • Satoshi Koyama, Tomohiro Omura, Atsushi Yonezawa, Satoshi Imai, Shunsaku Nakagawa, Takayuki Nakagawa, Ikuko Yano, Kazuo Matsubara
    Aug. 2015, PLOS ONE, 10(8) (8), English
    [Refereed]
    Scientific journal

  • 野田幸裕, Yano Ikuko, 青山隆夫, 渡邊美智留, 今田愛也, 中村均, 松下良, 森田邦彦, 三宅勝志, 瀬尾量, 上村直樹, 富岡佳久, 木津純子, 望月眞弓
    In 2012 we conducted a questionnaire survey to clarify the current state of pharmacy-related universities and clinical faculties and identify problem areas in pharmacy education and research. The survey was sent to 74 universities nationwide; responses were received from 488 out of 530 faculties distributed at 59 universities. The male/female ratio of the respondents was 3:1 and the age breakdown was 24% aged 30-years or younger, 61% aged 40-50-years. Regarding interest in education and research, 62% of the respondents emphasized education over research; the weekly average time devoted to these respective activities was 21 hours for education and 13 hours for research. Of the respondents, 46% had not even practiced once in 2012, while 61% out of the responders who had practiced (52%) had engaged in practice in a clinical setting one day per week or more. As for research, 83% and 20% of respondents supervised undergraduate and PhD students, respectively. Despite the fact that roughly half of all respondents do not fully engage in practice and research, satisfaction with the current situation on a 5-point scale was 35% for "satisfied" and "somewhat satisfied" combined, and 40% for "acceptable." Clinical faculties should not be content with the present situation and should strive to advance education and research by enhancing motivation to train the next generation. It is hoped that future discussions will lead to the revitalization of practice/education/research among clinical faculties, and also to the training of staff in clinical faculties, in whose footsteps the pharmacy students and/or next generation pharmacists can aspire to follow.
    Japanese Society of Pharmaceutical Health Care and Sciences, Apr. 2015, 医療薬学, 41(4号) (4号), 223 - 235, Japanese
    [Refereed]
    Scientific journal

  • Y. Arai, T. Kondo, T. Kitano, M. Hishizawa, K. Yamashita, N. Kadowaki, T. Yamamoto, I. Yano, K. Matsubara, A. Takaori-Kondo
    Feb. 2015, BONE MARROW TRANSPLANTATION, 50(2) (2), 312 - 314, English
    [Refereed]
    Scientific journal

  • 元井玲子, 矢野育子, 尾崎淳子, 鋒山香苗, 山本 崇, 深津祥央, 石塚良子, 松村由美, 谷口正洋, 東村享治, 松原和夫
    (公社)日本薬学会, 2015, 薬学雑誌, 135(10) (10), 1177 - 1184, Japanese
    [Refereed]

  • Sachiyo Hashi, Ikuko Yano, Mai Shibata, Satohiro Masuda, Masako Kinoshita, Riki Matsumoto, Akio Ikeda, Ryosuke Takahashi, Kazuo Matsubara
    Jan. 2015, EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 71(1) (1), 51 - 58, English
    [Refereed]
    Scientific journal

  • Shunsaku Nakagawa, Tomohiro Omura, Atsushi Yonezawa, Ikuko Yano, Takayuki Nakagawa, Kazuo Matsubara
    American Physiological Society, Dec. 2014, American Journal of Physiology - Renal Physiology, 307(12) (12), F1404 - F1411, English
    [Refereed]
    Scientific journal

  • Comparison of the Effects of Azole Antifungal Agents on the Anticoagulant Activity of Warfarin
    Hiroki Yamamoto, Yasushi Habu, Ikuko Yano, Junko Ozaki, Yoshihiko Kimura, Eriko Sato, Ayumi Shida, Sachio Fukatsu, Kazuo Matsubara
    Dec. 2014, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 37(12) (12), 1990 - 1993, English
    [Refereed]
    Scientific journal

  • Shunsaku Nakagawa, Tomohiro Omura, Atsushi Yonezawa, Ikuko Yano, Takayuki Nakagawa, Kazuo Matsubara
    Dec. 2014, AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 307(12) (12), F1404 - F1411, English
    [Refereed]
    Scientific journal

  • Moe Tsuda, Hiroshi Ishiguro, Ikuko Yano, Masakazu Toi
    Jul. 2014, JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 106(7) (7), English
    [Refereed]

  • プロトコルに基づいた薬物治療管理の実践 病棟専任薬剤師が参画したチーム医療による持参薬管理
    杉本充弘, 米澤淳, 蓼原昌美, 森田洋亮, 吉田優子, 尾上雅英, 大村友博, 萱野勇一郎, 深津祥央, Yano Ikuko, 松原和夫
    May 2014, 医療薬学, 40(5号) (5号), 297 - 303, Japanese
    [Refereed]
    Scientific journal

  • Hashi S, Masuda S, Kikuchi M, Uesugi M, Yano I, Omura T, Yonezawa A, Fujimoto Y, Ogawa K, Kaido T, Uemoto S, Matsubara K
    Apr. 2014, Transplant Proc., 71(1) (1), 51 - 58, English
    [Refereed]

  • S. Hashi, S. Masuda, M. Kikuchi, M. Uesugi, I. Yano, T. Omura, A. Yonezawa, Y. Fujimoto, K. Ogawa, T. Kaido, S. Uemoto, K. Matsubara
    Apr. 2014, TRANSPLANTATION PROCEEDINGS, 46(3) (3), 758 - 760, English
    [Refereed]
    Scientific journal

  • 悪性神経膠腫患者に対するtemozolomide・放射線併用療法における有害反応解析
    山際岳朗, 古俵孝明, Yano Ikuko, 石橋直哉, 深津祥央, 小林政彦, 桂敏也, 荒川芳輝, 宮本享, 松原和夫
    Mar. 2014, 日本病院薬剤師会雑誌, 50(3号) (3号), 299 - 304, Japanese
    [Refereed]
    Scientific journal

  • Effectiveness of Everolimus in Combination with Cyclosporine as Treatment for Chronic Rejection in a Pediatric Patient Undergoing Liver Transplantation
    Sato Eriko, Hashi Sachiyo, Taniguchi Risa, Yano Ikuko, Matsubara Kazuo, Ogawa Eri, Yoshizawa Atsushi, Okamoto Shinya, Uemoto Shinji, Masuda Satohiro
    (一社)日本TDM学会, Jan. 2014, TDM研究, 31(1) (1), 1 - 5, English
    [Refereed]

  • 胆道がんに対するゲムシタビン シスプラチン療法の有害反応解析と治療継続に関する影響因子の検討
    高橋克之, 尾上雅英, 福土将秀, 池見泰明, 小林政彦, 深津祥央, Yano Ikuko, 永山勝也, 松原和夫
    Dec. 2013, 日本病院薬剤師会雑誌, 49(12号) (12号), 1305 - 1309, Japanese
    [Refereed]
    Scientific journal

  • 高田哲也, 池見泰明, 福土将秀, 杉本充弘, 石橋直哉, 小林政彦, Yano Ikuko, 金永学, 三嶋理晃, 芦原英司, 松原和夫
    (一社)日本医療薬学会, Sep. 2013, 医療薬学, 39(9号) (9号), 565 - 570, Japanese
    [Refereed]
    Scientific journal

  • Haruka Nakanishi, Atsushi Yonezawa, Kazuo Matsubara, Ikuko Yano
    Jun. 2013, European Journal of Pharmacology, 710(1-3) (1-3), 20 - 28, English
    [Refereed]
    Scientific journal

  • 腎移植後の維持免疫抑制患者におけるカルシニューリン活性の検討
    山崎 俊成, 大久保 和俊, 福士 将秀, 小林 恭, 清水 洋祐, 神波 大己, 吉村 耕治, 兼松 明弘, 矢野 育子, 松原 和夫, 小川 修
    (一社)日本泌尿器科学会, Mar. 2013, 日本泌尿器科学会雑誌, 104(2) (2), 372 - 372, Japanese

  • Mai Shibata, Sachiyo Hashi, Haruka Nakanishi, Satohiro Masuda, Toshiya Katsura, Ikuko Yano
    Dec. 2012, BIOMEDICAL CHROMATOGRAPHY, 26(12) (12), 1519 - 1528, English
    [Refereed]
    Scientific journal

  • Mai Shibata, Sachiyo Hashi, Haruka Nakanishi, Satohiro Masuda, Toshiya Katsura, Ikuko Yano
    Dec. 2012, BIOMEDICAL CHROMATOGRAPHY, 26(12) (12), 1519 - 1528, English
    [Refereed]
    Scientific journal

  • H. Ishiguro, S. Takashima, K. Yoshimura, I. Yano, T. Yamamoto, M. Niimi, H. Yamashiro, T. Ueno, M. Takeuchi, T. Sugie, K. Yanagihara, M. Toi, M. Fukushima
    Sep. 2012, SUPPORTIVE CARE IN CANCER, 20(9) (9), 2017 - 2024, English
    [Refereed]
    Scientific journal

  • Ikuko Yano, Satohiro Masuda, Hiroto Egawa, Mitsuhiro Sugimoto, Masahide Fukudo, Yuko Yoshida, Sachiyo Hashi, Atsushi Yoshizawa, Yasuhiro Ogura, Kohei Ogawa, Akira Mori, Toshimi Kaido, Shinji Uemoto, Ken-ichi Inui
    Mar. 2012, EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 68(3) (3), 259 - 266, English
    [Refereed]
    Scientific journal

  • タクロリムス血中濃度測定法の差異に関する臨床的評価：M E I A，C L I A，A C M I A，E M I T 間の比較検討
    端 幸代, 増田智先, 山本 崇, 吉田優子, 矢野育子, 海道利実, 上本伸二, 桂 敏也, 乾 賢一
    2012, 移植, 47(1) (1), 75 - 81
    [Refereed]

  • Hosokawa Mio, Habu Yasushi, Yano Ikuko, Fukatsu Sachio, Kishimoto Norifumi, Yokode Masayuki, Katsura Toshiya
    Japanese Society of Pharmaceutical Health Care and Sciences, 2012, Japanese Journal of Hospital Pharmacy, 38(4) (4), 258 - 264, Japanese

  • 難治性てんかん患者のクロバザム治療におけるCYP2C19遺伝子多型の寄与
    柴田 茉衣, 端 幸代, 増田 智先, 桂 敏也, 池田 昭夫, 松本 理器, 高橋 良輔, 矢野 育子
    (一社)日本臨床薬理学会, Oct. 2011, 臨床薬理, 42(Suppl.) (Suppl.), S229 - S229, Japanese
    [Refereed]

  • 新規抗てんかん薬ラモトリギンの血中濃度測定と相互作用に関する検討
    端 幸代, 矢野 育子, 増田 智先, 柴田 茉衣, 中西 晴香, 桂 敏也, 松本 理器, 池田 昭夫, 高橋 良輔
    (一社)日本TDM学会, Jun. 2011, TDM研究, 28(3) (3), s196 - s196, Japanese
    [Refereed]

  • Shimogai Aya, Fukudo Masahide, Fukatsu Sachio, Yano Ikuko, Katsura Toshiya
    Sorafenib is an oral multikinase inhibitor for the treatment of patients with advanced hepatocellular carcinoma (HCC). However, it produces various adverse reactions (hand-foot syndrome, hypertension, diarrhea, etc.) that often lead to discontinuation of treatment, a clinical problem that needs to be addressed.In this study, we retrospectively reviewed the medical records of 50 patients with HCC who had been treated with sorafenib at Kyoto University Hospital to investigate factors influencing discontinuation of treatment continuation as well as development of adverse events. The overall rate for discontinuation of treatment (including treatment termination and dose reduction/interruption) due to adverse events was 56%, and that for treatment termination due to progressive disease was 30%. The frequency of discontinuation due to any reason within the first month was significantly higher in patients starting with 800 mg / day (19/35, 54.3%) than with 400 mg/day (3/15, 20.0%). In addition, the median duration of successful treatment with the starting dose was longer in patients on 400 mg/day than 800 mg/day (89 days vs. 29 days). The development of hand-foot syndrome (grade>2)or diar
    Japanese Society of Pharmaceutical Health Care and Sciences, 2011, Japanese Journal of Hospital Pharmacy, 37(11) (11), 631 - 636, Japanese

  • Pharmacokinetics of Vancomycin after Intravenous Administration in 3 Patients Implanted with Vancomycin-loaded Cement Beads
    Shinsako Keiko, Yano Ikuko, Okui Yasufumi, Matsuda Yasutaka, Kunimasa Jun-ichi
    (一社)日本医療薬学会, Nov. 2010, 医療薬学, 36(11) (11), 826 - 831, English
    [Refereed]

  • Kana Toyama, Atsushi Yonezawa, Masahiro Tsuda, Satohiro Masuda, Ikuko Yano, Tomohiro Terada, Riyo Osawa, Toshiya Katsura, Masaya Hosokawa, Shimpei Fujimoto, Nobuya Inagaki, Ken-Ichi Inui
    Feb. 2010, PHARMACOGENETICS AND GENOMICS, 20(2) (2), 135 - 138, English
    [Refereed]
    Scientific journal

  • Masahide Fukudo, Ikuko Yano, Toshiya Katsura, Noriyuki Ito, Shingo Yamamoto, Toshiyuki Kamoto, Osamu Ogawa, Ken-ichi Inui
    2010, DRUG METABOLISM AND PHARMACOKINETICS, 25(5) (5), 411 - 417, English
    [Refereed]
    Scientific journal

  • Iwai Chikako, Kobayashi Masahiko, Terada Tomohiro, Yano Ikuko, Matumoto Shigemi, Yanagihara Kazuhiro, Fukushima Masanori, Inui Ken-ichi
    Japanese Society of Pharmaceutical Health Care and Sciences, Dec. 2009, Japanese Journal of Hospital Pharmacy, 35(12) (12), 866 - 874, Japanese

  • Akira Yokomasu, Ikuko Yano, Eriko Sato, Satohiro Masuda, Toshiya Katsura, Ken-ichi Inui
    Dec. 2009, BIOPHARMACEUTICS & DRUG DISPOSITION, 30(9) (9), 517 - 523, English
    [Refereed]
    Scientific journal

  • Yoshitaka Yano, Takaaki Kodawara, Haruyuki Hongo, Ikuko Yano, Yo Kishi, Jun Takahashi, Ken-Ichi Inui
    Nov. 2009, JOURNAL OF PHARMACEUTICAL SCIENCES, 98(11) (11), 4402 - 4412, English
    [Refereed]
    Scientific journal

  • Masahide Fukudo, Ikuko Yano, Keiko Shinsako, Toshiya Katsura, Yasutsugu Takada, Shinji Uemoto, Ken-ichi Inui
    Jul. 2009, JOURNAL OF CLINICAL PHARMACOLOGY, 49(7) (7), 789 - 797, English
    [Refereed]
    Scientific journal

  • Masahide Fukudo, Ikuko Yano, Keiko Shinsako, Toshiya Katsura, Yasutsugu Takada, Shinji Uemoto, Ken-ichi Inui
    Jul. 2009, JOURNAL OF CLINICAL PHARMACOLOGY, 49(7) (7), 789 - 797, English
    [Refereed]
    Scientific journal

  • ビンカアルカロイド系抗がん剤の物理化学的特性に及ぼす温度変化の影響
    小島一晃, 寺田智祐, 津田真弘, 橋田亨, Yano Ikuko, 乾賢一
    May 2009, 日本病院薬剤師会雑誌, 45(5号) (5号), 681 - 684, Japanese
    [Refereed]
    Scientific journal

  • 新規抗悪性腫瘍薬テモゾロミドのカプセル開封後の溶液中での安定性に関する評価
    古俵孝明, 水野知行, 田上裕美, 橋田亨, Yano Ikuko, 桂敏也, 乾賢一
    Mar. 2009, 薬学雑誌, 129(3号) (3号), 353 - 357, Japanese
    [Refereed]
    Scientific journal

  • Yano Ikuko, Iseki Ken, Shoji Tohru, Aoyama Takao, Kizu Junko, Nakamura Hitoshi, Fujii Toshiyuki, Watanabe Michiru, Noda Yukihiro, Wakiya Yoshifumi, Morita Kunihiko, Teshima Daisuke, Futagami Koujiro
    With the introduction of 6-year pharmacy educational program in 2006, a provision was made to assign pharmacist faculties having working experience as pharmacists in pharmacy schools. In October 2007, we conducted a survey to investigate the situation of pharmacist faculties. We sent a questionnaire to 247 pharmacist faculties in 66 pharmacy schools and the response rate was 84.9%. The faculties consisted of professors (43%), associate professors (23%) and lecturers (23%), and 77% of them had a Ph.D. degree. In a typical week, the major activities they engaged in were educational activities (20.6hrs), research (12.2hrs) and management (9.6hrs). While the average time they were occupied by clinical practice was 3.5hrs, 67% of them did not do any. Half of the faculties did not conduct any research with students or graduate students in their own schools, and in 2007 only 55% applied for Grant-in-aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan. Twenty-six percent said they were very satisfied or satisfied with their work on a five-point scale, and 44% rated their degree of satisfaction as fair. In conclusion, our survey showe
    日本医療薬学会, Jan. 2009, Japanese journal of pharmaceutical health care and sciences, 35(1) (1), 43 - 49, Japanese

  • Shinsako Keiko, Wakasugi Hiroko, Yasuda Sachiyo, Kawasaki Ikuyo, Adachi Naomi, Hiratsuka Rie, Yano Ikuko, Inui Ken-ichi
    At Kyoto University Hospital,we introduced an electronic medical recording system in October 2005.We then investigated interventions in the dispensing room as well as the usage of electronic medical records in our satellite-like pharmacy from June through August 2007.The number of prescriptions in this period was 29,618,and we had questions concerning 840 of them,a quarter of which could be answered using electronic medical records.Of the 640 prescriptions that we contacted physicians about,either asking questions or making recommendations,82.5% were changed.On comparing the pharmaceutical interventions in the dispensing room made this time with those made in the course of conducting pharmaceutical care services in our previous report of 2003,when an electronic medical recording system had not be introduced,pharmacists mainly made recommendations to physicians based on standard pharmacotherapy,such as those concerning inappropriate dosages,indications and drug interactions (69%),and pointed out errors in prescriptions (15%).However,pharmaceutical care interventions had also been based on standard therapy in consideration of individual patient backgrounds,such as those concerning do
    Japanese Society of Pharmaceutical Health Care and Sciences, 2009, Japanese Journal of Hospital Pharmacy, 35(8) (8), 558 - 564, Japanese

  • Takashima Miki, Taniguchi Risa, Yano Ikuko, Kono Takahisa, Hashida Tohru, Masuda Satohiro, Ishikawa Takayuki, Uchiyama Takashi, Inui Ken-ichi
    Calcineurin inhibitors are used as immunosuppressive agents for graft-versus-host disease (GVHD) prophylaxis in hematopoietic stem cell transplantation.Since azole antifungals are frequently used for prophylaxis and treatment of infection under immunosuppressive therapy,it is highly possible that azole antifungals will affect blood concentrations of calcineurin inhibitors by inhibiting the drug metabolizing enzyme cytochrome P450 (CYP) 3A4.However,dosage adjustment with individual azole antifungals when administered by different routes has yet to be fully examined.In this study,we examined the effect of azole antifungals on blood concentrations of tacrolimus administered by intravenous constant infusion and cyclosporine administered orally in hematopoietic stem cell transplant patients.Oral voriconazole increased the blood concentration/dose (C/D) ratio of tacrolimus 2.7-fold,a significant increase.Oral itraconazole and intravenous voriconazole increased the C/D ratio 2.4-fold and 2-fold,respectively,but these changes were not statistically significant.The effects of oral and intravenous fluconazole were less potent than those of voriconazole and itraconazole,and tended to increase
    Japanese Society of Pharmaceutical Health Care and Sciences, 2009, Japanese Journal of Hospital Pharmacy, 35(4) (4), 233 - 239, Japanese

  • Kodama Yukinobu, Terada Tomohiro, Takahashi Kazushige, Yano Ikuko, Inui Ken-ichi
    It has been reported that antiemetic therapy based on the guidelines produced by the National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) is effective in reducing emetic risk.However,while the effect of antiemetic therapy has been much reported for the intermittent administration of anticancer drugs,there have been few reports on such therapy in the case of the daily administration of anticancer drugs.In the present study,we investigated antiemetic therapy used for the prevention of nausea and vomiting induced by the daily administration of ICE combination chemotherapy (ifosphamide,carboplatin,and etoposide : ICE group) or DeVIC combination chemotherapy (dexamethasone,etoposide,ifosphamide,and carboplatin : DeVIC group) in 30 eligible patients.All patients received 5-HT3 serotonin receptor antagonists prophylactically during the daily administration of both types of chemotherapy but no patient received such prophylactic therapy after the administration of the anticancer drugs.The incidences of nausea and vomiting during chemotherapy for the ICE group (60.0% and 46.7%,respectively) were significantly higher than that in the DeVIC group (6.7%
    Japanese Society of Pharmaceutical Health Care and Sciences, 2009, Japanese Journal of Hospital Pharmacy, 35(9) (9), 609 - 614, Japanese

  • Larger Dosage Required for Everolimus than Sirolimus to Maintain Same Blood Concentration in Two Pancreatic Islet Transplant Patients with Tacrolimus
    Eriko Sato, Ikuko Yano, Masahiro Shimomura, Satohiro Masuda, Toshiya Katsura, Shin-ichi Matsumoto, Teru Okitsu, Yasuhiro Iwanaga, Shinji Uemoto, Ken-ichi Inui
    2009, DRUG METABOLISM AND PHARMACOKINETICS, 24(2) (2), 175 - 179, English
    [Refereed]
    Scientific journal

  • Shinobu Omote, Yoshitaka Yano, Tohru Hashida, Satohiro Masuda, Ikuko Yano, Toshiya Katsura, Ken-ichi Inui
    Jan. 2009, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 32(1) (1), 99 - 104, English
    [Refereed]
    Scientific journal

  • Eriko Sato, Ikuko Yano, Masahiro Shimomura, Satohiro Masuda, Toshiya Katsura, Shin-ichi Matsumoto, Teru Okitsu, Yasuhiro Iwanaga, Shinji Uemoto, Ken-ichi Inui
    2009, DRUG METABOLISM AND PHARMACOKINETICS, 24(2) (2), 175 - 179, English
    [Refereed]
    Scientific journal

  • Important drug interactions for clinical oncologists
    H. Ishiguro, I. Yano, M. Toi
    2009, Frontiers in Drug Design and Discovery, 4(1) (1), 97 - 121, English
    [Refereed]

  • Pharmacogenomic considerations in breast cancer management
    H. Ishiguro, I. Yano, M. Toi
    2009, Frontiers in Drug Design and Discovery, 4(1) (1), 122 - 134, English
    [Refereed]

  • A Retrospective Analysis of Vancomycin Pharmacokinetics in Japanese Cancer and Non-cancer Patients Based on Routine Trough Monitoring Data
    Shinobu Omote, Yoshitaka Yano, Tohru Hashida, Satohiro Masuda, Ikuko Yano, Toshiya Katsura, Ken-ichi Inui
    Jan. 2009, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 32(1) (1), 99 - 104, English
    [Refereed]
    Scientific journal

  • 薬学教育六年制に向けた外来薬剤交付実習の取り組みとその評価
    安孫子芙美, 高橋一栄, 岡村みや子, 橋田亨, Yano Ikuko, 乾賢一
    Nov. 2008, 日本病院薬剤師会雑誌, 44(11号) (11号), 1629 - 1632, Japanese
    [Refereed]
    Scientific journal

  • 成人難治性てんかん患者におけるクロバザムおよび活性代謝物の体内動態に関する解析
    安田幸代, Yano Ikuko, 北村朋子, 橋田亨, 木下真幸子, 池田昭夫, 高橋良輔, 乾賢一
    Oct. 2008, TDM研究, 25(4号) (4号), 165 - 169, Japanese
    [Refereed]
    Scientific journal

  • Akazawa Maiko, Hashida Tohru, Yano Ikuko, Katsura Toshiya, Takashima Sachie, Teramukai Satoshi, Matsumoto Shigemi, Yanagihara Kazuhiro, Fukushima Masanori, Inui Ken-ichi
    Japanese Society of Pharmaceutical Health Care and Sciences, Aug. 2008, Japanese Journal of Hospital Pharmacy, 34(8) (8), 742 - 747, Japanese

  • 尾上雅英, 谿有紀, 寺田智祐, 橋田亨, Yano Ikuko, 角山正博, 乾賢一
    Patients admitted for surgical procedures have often taken a variety of medicines for heart disease or hypertension in addition to those for their underlying diseases. In this study, we examined the withdrawal periods for anticoagulants and antihypertensive medicines before surgery, and investigated the effect of angiotensin II receptor (ATII) antagonists on blood pressure during surgery. In July 2005, 300 patients underwent surgical procedures in the Day-Surgery Unit and 314 in the surgical wards (excluding ophthalmology). We prepared a chart of recommended withdrawal periods before surgery, and based on it investigated the withdrawal periods for these patients. Furthermore, patients were assigned to 2 groups : Group I in which ATII antagonists were withdrawn 24 hours prior to surgery or earlier (n=10) ; and Group II, in which ATII antagonists were administered in the morning of the day of surgery day (n=9), and compared blood pressures between two groups. Forty-four patients (16.7%) in the Day-Surgery Unit and 47 patients (15.0%) in the surgery wards had been taking anticoagulants, angiotensin converting enzyme inhibitors or ATII antagonists. In the case of 10 patients in the Day-Surgery Unit and 12 patients in the surgery wards, anticoagulants were not discontinued sufficiently long enough before surgery. Further, patients who had been taking ATII antagonists had lower systemic blood pressures and more frequent episodes of hypotension than those not on ATII antagonists, although these differences were not statistically significant. In conclusion, pharmacists should provide doctors with adequate information regarding times of drug withdrawal to reduce risks while patients are under anesthesia.
    Japanese Society of Pharmaceutical Health Care and Sciences, Aug. 2008, 医療薬学, 34(8号) (8号), 773 - 780, Japanese
    [Refereed]
    Scientific journal

  • 高眼圧患者におけるアセタゾラミド投与量と副作用発現の危険因子に関する検討
    木寺康裕, 甲野貴久, Yano Ikuko, 田辺晶代, 吉村長久, 乾賢一
    May 2008, 日本病院薬剤師会雑誌, 44(5号) (5号), 744 - 746, Japanese
    [Refereed]
    Scientific journal

  • Masahide Fukudo, Ikuko Yano, Atsushi Yoshimura, Satohiro Masuda, Miwa Uesugi, Keiko Hosohata, Toshiya Katsura, Yasuhiro Ogura, Fumitaka Oike, Yasutsugu Takada, Shinji Uemoto, Ken-ichi Inui
    May 2008, PHARMACOGENETICS AND GENOMICS, 18(5) (5), 413 - 423, English
    [Refereed]
    Scientific journal

  • 電子カルテ導入に伴う疑義照会の質的向上と薬剤師の役割
    木下里紗, 古田祐美子, 岡村みや子, 丸山志穂子, 尾崎淳子, 高橋一栄, Yano Ikuko, 乾賢一
    Feb. 2008, 日本病院薬剤師会雑誌, 44(2号) (2号), 265 - 267, Japanese
    [Refereed]
    Scientific journal

  • Ikuko Yano
    2008, DRUG METABOLISM AND PHARMACOKINETICS, 23(3) (3), 150 - 157, English
    [Refereed]

  • Akira Yokomasu, Ikuko Yano, Eriko Sato, Satohiro Masuda, Toshiya Katsura, Ken-ichi Inui
    2008, DRUG METABOLISM AND PHARMACOKINETICS, 23(6) (6), 469 - 475, English
    [Refereed]
    Scientific journal

  • 加齢黄斑変性症の光線力学的療法における薬剤業務 ベルテポルフィンの調製と患者指導
    甲野貴久, 橋田亨, 若杉博子, Yano Ikuko, 田村寛, 辻川明孝, 大谷篤史, 吉村長久, 乾賢一
    Oct. 2007, 日本病院薬剤師会雑誌, 43(10号) (10号), 1377 - 1380, Japanese
    [Refereed]
    Scientific journal

  • Mari Jiko, Ikuko Yano, Eriko Sato, Kazushige Takahashi, Hideyuki Motohashi, Satohiro Masuda, Masahiro Okuda, Noriyuki Ito, Eijiro Nakamura, Takehiko Segawa, Toshiyuki Kamoto, Osamu Ogawa, Ken-Ichi Inui
    Aug. 2007, INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 12(4) (4), 284 - 290, English
    [Refereed]
    Scientific journal

  • Kodawara Takaaki, Yoshida Yuko, Sawada Kyoko, Masuda Satohiro, Yano Ikuko, Inui Ken-ichi
    EMIT,a homogeneous enzyme immunoassay for the quantitative analysis of mycophenolic acid (MPA) in human plasma,was evaluated in comparison with high-performance liquid chromatography (HPLC).For EMIT,coefficients of variation (CV) for within-run measurements (1~12μg/mL,n=20)varied from 4.07% to 5.16% and CVs for between-day measurements (1~12μg/mL,n=20)ranged from 2.23% to 5.63%.The lower limit of detection was 0.20μg/mL.When MPA plasma concentrations were simultaneously measured using EMIT and HPLC,there was a good linear relationship between the 2 assay methods showing a high degree of correlation : EMIT=1.13×HPLC+0.164 ; r2=0.967,51 points in 16 liver transplant recipients,EMIT=1.10×HPLC+0.305 ; r2=0.948,55 points in 15 renal transplant recipients and EMIT=1.06×HPLC-0.014 ; r2=0.887,300 points in 8 islet transplant recipients.These results indicate that EMIT is a convenient means of measuring MPA in plasma.
    Japanese Society of Pharmaceutical Health Care and Sciences, 2007, Japanese Journal of Hospital Pharmacy, 33(9) (9), 804 - 808, Japanese

  • Iwai Chikako, Yano Ikuko, Katsura Toshiya, Sonobe Makoto, Tanaka Fumihiro, Wada Hiromi, Inui Ken-ichi
    Gefitinib (Iressa®), a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is effective in patients with advanced non-small cell lung cancer (NSCLC). However, since interstitial lung disease, a fatal adverse event, has occurred more frequently since gefitinib came on to the market, and ISEL and SWOG 0023 examinations have not shown any significant life-extending efficacy, patients have started to feel uneasy about being treated with it. In these circumstances, in the present study, we created a system under which pharmacists can be directly involved in treatment with gefitinib and monitor for adverse events. The subjects were 98 patients with NSCLC who were treated at our hospital, and received gefitinib at a dose of 250 mg once daily. We made a leaflet describing gefitinib and a check sheet for adverse events, and using them, explained the expected adverse events to patients and monitored their conditions. Common drug-related adverse events occurring were rash (54%), pruritus (29%) and diarrhea (23%), and most were graded as mild in degree (grade 1 or 2). Interstitial lung disease was observed in 10 of the 98 patients (10.2%), but none died. Liver injury
    Japanese Society of Pharmaceutical Health Care and Sciences, 2007, Japanese Journal of Hospital Pharmacy, 33(1) (1), 1 - 7, Japanese

  • Kazushige Takahashi, Ikuko Yano, Yuga Fukuhara, Toshiya Katsura, Takeshi Takahashi, Noriyuki Ito, Shingo Yamamoto, Osamu Ogawa, Ken-ichi Inui
    2007, DRUG METABOLISM AND PHARMACOKINETICS, 22(6) (6), 441 - 444, English
    [Refereed]
    Scientific journal

  • 新規抗精神病薬の臨床導入に伴う処方内容の変化 大学病院精神科外来における検討
    武田光加, 小林政彦, 河崎育代, 淡野芳久, 若杉博子, 大野明洋, Yano Ikuko, 岡田俊, 林拓二, 乾賢一
    (一社)日本医療薬学会, Jan. 2007, 医療薬学, 33(1) (1), 60 - 65, Japanese
    [Refereed]
    Scientific journal

  • Distinct effects of omeprazole and rabeprazole on the tacrolimus blood concentration in a kidney transplant recipient
    Kazushige Takahashi, Ikuko Yano, Yuga Fukuhara, Toshiya Katsura, Takeshi Takahashi, Noriyuki Ito, Shingo Yamamoto, Osamu Ogawa, Ken-ichi Inui
    2007, DRUG METABOLISM AND PHARMACOKINETICS, 22(6) (6), 441 - 444, English
    [Refereed]
    Scientific journal

  • Masahide Fukudo, Ikuko Yano, Satohiro Masuda, Maki Goto, Miwa Uesugi, Toshiya Katsura, Yasuhiro Ogura, Fumitaka Oike, Yasutsugu Takada, Hiroto Egawa, Shinji Uemoto, Ken-ichi Inui
    Oct. 2006, CLINICAL PHARMACOLOGY & THERAPEUTICS, 80(4) (4), 331 - 345, English
    [Refereed]
    Scientific journal

  • Eriko Sato, Ikuko Yano, Mari Jiko, Kazushige Takahashi, Hideyuki Motohashi, Satohiro Masuda, Toshiya Katsura, Hiroyuki Nishiyama, Takehiko Segawa, Noriyuki Ito, Toshiyuki Kamoto, Osamu Ogawa, Ken-ichi Inui
    Jul. 2006, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 29(7) (7), 1441 - 1444, English
    [Refereed]
    Scientific journal

  • 古俵孝明, Yano Ikuko, 桂敏也, 片岡大治, 北条雅人, 高木康志, 高橋潤, 橋本信夫, 乾賢一
    We prepared data sheets to consolidate information on adverse reactions occurring in combination chemotherapy. Using them, we monitored adverse reactions due to combination therapy consisting of vincristine, nimustine, carboplatin, interferon-β and radiation therapy (VAC-F-R) in 50 patients with brain tumors, and evaluated their severity using the Common Terminology Criteria for Adverse Events v.3.0. The incidences of adverse reactions due to the VAC-F-R protocol were then compared with that for adverse reactions due to existing monotherapy. With VAC-F-R, a high incidences were observed for appetite loss (86%), nausea (68%) and vomiting (34%), and the incidences of leucopenia and thrombocytopenia with grade 3 or higher were 60% and 24%, respectively. Vomiting and fever could be prevented by pretreatment with a 5HT_3 receptor antagonist and non-steroidal anti-inflammatory drugs. While the incidences of the unpreventable adverse reactions were 1.5-to 5-fold greater than those seen with monotherapy, there was no difference in the time of the nadir for leucopenia and thrombocytopenia as compared to monotherapy with nimusitine. Our efforts to consolidate information on adverse reactions due to a particular chemotherapy regimen have helped decrease their severity in cancer patients and improve their quality of life.
    Japanese Society of Pharmaceutical Health Care and Sciences, Jul. 2006, 医療薬学, 32(7号) (7号), 599 - 606, Japanese
    [Refereed]
    Scientific journal

  • Eriko Sato, Ikuko Yano, Mari Jiko, Kazushige Takahashi, Hideyuki Motohashi, Satohiro Masuda, Toshiya Katsura, Hiroyuki Nishiyama, Takehiko Segawa, Noriyuki Ito, Toshiyuki Kamoto, Osamu Ogawa, Ken-ichi Inui
    Jul. 2006, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 29(7) (7), 1441 - 1444, English
    [Refereed]
    Scientific journal

  • 赤澤麻衣子, 橋田亨, Yano Ikuko, 桂敏也, 北野俊行, 植野正也, 松本繁己, 柳原一広, 福島雅典, 乾賢一
    The Outpatient Oncology Unit of Kyoto University Hospital, which has a full-time staff, was established in October 2003. Before it was established, different kinds of regimens for outpatient chemotherapy were independently used by various departments for the same types of cancer. In order to further improve the safety of chemotherapy for outpatients, we unified the regimens under the control of the oncology Unit and registered the set prescriptions for them in the ordering system. These regimens were checked by pharmacists as to whether they were suitable as infusions and complied with health insurance indications. Sixty-three regimens were registered when the Unit was established. There was a further increase in the number of prescriptions during the half-year period after the Unit was established, and they were registered between June and December 2004, bringing the total number of registered regimens to 79. The registration of chemotherapy regimens has enabled all the medical staff of the Unit to have access to the same information, and pharmacists are able to check them easily. The use of such set prescriptions has helped prevent simple mistakes and allowed chemotherapy to be conducted more safely. In addition, the rate of questions about prescriptions decreased from 10% at the time of establishing the Unit to 3% in January 2005 due to the introduction of a prescription support system. In conclusion, the registration of the regimens has helped the Outpatient Oncology Unit to conduct standard chemotherapy more safely and improve cooperation with each department on outpatient chemotherapy.
    Japanese Society of Pharmaceutical Health Care and Sciences, Apr. 2006, 医療薬学, 32(4号) (4号), 327 - 333, Japanese
    [Refereed]
    Scientific journal

  • Cyclosporine exposure and calcineurin phosphatase activity in living-donor liver transplant patients: Twice daily vs. once daily dosing
    M Fukudo, I Yano, S Masuda, T Katsura, Y Ogura, F Oike, Y Takada, K Tanaka, KI Inui
    Feb. 2006, LIVER TRANSPLANTATION, 12(2) (2), 292 - 300, English
    [Refereed]
    Scientific journal

  • Sachio Fukatsu, Masahide Fukudo, Satohiro Masuda, Ikuko Yano, Toshiya Katsura, Yasuhiro Ogura, Fumitaka Oike, Yasutsugu Takada, Ken-ichi Inui
    2006, DRUG METABOLISM AND PHARMACOKINETICS, 21(2) (2), 122 - 125, English
    [Refereed]
    Scientific journal

  • Eriko Sato, Masahiro Shimomura, Satohiro Masuda, Ikuko Yano, Toshiya Katsura, Shin-Ichi Matsumoto, Teru Okitsu, Yasuhiro Iwanaga, Hirofurni Nocuch, Hideo Nagata, Yukihide Yonekawa, Ken-Ichi Inui
    2006, DRUG METABOLISM AND PHARMACOKINETICS, 21(6) (6), 492 - 500, English
    [Refereed]
    Scientific journal

  • 全診療科を対象とした「がん化学療法説明書」の作成とその運用
    高柳和伸, 高橋一栄, 尾上雅英, 古俵孝明, 若杉博子, 橋田亨, Yano Ikuko, 奥田真弘, 桂敏也, 乾賢一
    Jan. 2006, 日本病院薬剤師会雑誌, 42(1号) (1号), 49 - 52, Japanese
    [Refereed]
    Scientific journal

  • Temporal decline in Sirolimus elimination immediately after pancreatic islet transplantation
    Eriko Sato, Masahiro Shimomura, Satohiro Masuda, Ikuko Yano, Toshiya Katsura, Shin-Ichi Matsumoto, Teru Okitsu, Yasuhiro Iwanaga, Hirofurni Nocuch, Hideo Nagata, Yukihide Yonekawa, Ken-Ichi Inui
    2006, DRUG METABOLISM AND PHARMACOKINETICS, 21(6) (6), 492 - 500, English
    [Refereed]
    Scientific journal

  • A Yonezawa, S Masuda, K Nishihara, Yano, I, T Katsura, K Inui
    Dec. 2005, BIOCHEMICAL PHARMACOLOGY, 70(12) (12), 1823 - 1831, English
    [Refereed]
    Scientific journal

  • M Fukudo, Yano, I, S Masuda, S Fukatsu, T Katsura, Y Ogura, F Oike, Y Takada, K Tanaka, K Inui
    Aug. 2005, CLINICAL PHARMACOLOGY & THERAPEUTICS, 78(2) (2), 168 - 181, English
    [Refereed]
    Scientific journal

  • Ohtani Kayoko, Hashida Tohru, Iwai Chikako, Ohtsuka Kana, Onoue Masahide, Ozaki Junko, Ishizu Masahiro, Yano Ikuko, Kitano Toshiyuki, Ueno Masaya, Matsumoto Shigemi, Yanagihara Kazuhiro, Fukushima Masanori, Inui Ken-ichi
    Japanese Society of Pharmaceutical Health Care and Sciences, Apr. 2005, Japanese Journal of Hospital Pharmacy, 31(4) (4), 301 - 306, Japanese

  • Y Habu, Yano, I, M Okuda, A Fukatsu, K Inui
    Mar. 2005, BIOCHEMICAL PHARMACOLOGY, 69(6) (6), 993 - 999, English
    [Refereed]
    Scientific journal

  • M Fukudo, Yano, I, S Masuda, M Okuda, K Inui
    Feb. 2005, JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 312(2) (2), 816 - 825, English
    [Refereed]
    Scientific journal

  • M Jiko, Yano, I, M Okuda, K Inui
    Feb. 2005, PHARMACEUTICAL RESEARCH, 22(2) (2), 228 - 234, English
    [Refereed]
    Scientific journal

  • Clinical pharmacokinetics of immunosuppressants: Tacrolimus
    I. Yano
    2005, Japanese Journal of Clinical Pharmacology and Therapeutics, 36(2) (2), 58 - 62, English
    [Refereed]

  • チオペンタール血中濃度測定と脳死判定時の緊急体制システムの整備
    五十嵐敏明, 古俵孝明, Yano Ikuko, 奥田真弘, 宮本享, 菊田健一郎, 橋本信夫, 乾賢一
    Oct. 2004, TDM研究, 21(4号) (4号), 313 - 319, Japanese
    [Refereed]
    Scientific journal

  • H Yamaguchi, Yano, I, H Saito, K Inui
    Feb. 2004, PHARMACEUTICAL RESEARCH, 21(2) (2), 330 - 338, English
    [Refereed]
    Scientific journal

  • Akazawa Maiko, Onoue Masahide, Wakasugi Hiroko, Yano Ikuko, Okuda Masahiro, Inui Ken-ichi
    It is important for the clinical pharmacist to maintain the safety and efficacy of drug therapy for individual patients. In order to improve prescribing and help patients to understand their medication better, we began checking prescriptions and providing medicines to patients individually in the oncology surgery ward of our hospital in January 2003. Before preparing medications, we investigated the compliance of each patient through counseling, checked their prescriptions, and pointed out prescription errors to physicians. On the following day, after filling the prescriptions, we handed them to individual patients and explained the medication to each patient. Half a year after introducing this system, we calculated pharmacist prescription intervention rates and analyzed the results. We found a 49% error rate in prescriptions and pointed out the errors to physicians, 93% of which they acknowledged. To evaluate our system, we conducted a questionnaire survey of the doctors and nurses in the oncology surgery ward on the provision of medication by clinical pharmacists. We obtained a 95% response rate and the results were very satisfactory. The checking of prescriptions by clinical pha
    Japanese Society of Pharmaceutical Health Care and Sciences, 2004, Japanese Journal of Hospital Pharmacy, 30(7) (7), 445 - 450, Japanese

  • T Igarashi, Yano, I, H Saito, K Inui
    Nov. 2003, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 26(11) (11), 1591 - 1595, English
    [Refereed]
    Scientific journal

  • 高カロリー輸液(TPN)無菌調製の完全実施とその評価
    橋田亨, 小林政彦, 大塚哉, 上井優一, 家永嘉子, Yano Ikuko, 石津雅弘, 乾賢一
    Oct. 2003, 日本病院薬剤師会雑誌, 39(10号) (10号), 1251 - 1254, Japanese
    [Refereed]
    Scientific journal

  • Y Habu, Yano, I, A Takeuchi, H Saito, M Okuda, A Fukatsu, K Inui
    Sep. 2003, BIOCHEMICAL PHARMACOLOGY, 66(6) (6), 1107 - 1114, English
    [Refereed]
    Scientific journal

  • Wakasugi Hiroko, Nakagiri Makiko, Ishii Junko, Kaneko Ikuyo, Takahasi Kazusige, Yano Ikuko, Inui Ken-ichi
    Although clinical pharmacists participate in delivering safe and effective drug therapy to individual patients, there has so far been little assessment of the importance and quality of clinical pharmacy services. Physicians need drug information in order to practice safe and effective drug therapy. Previously, pharmacists provided drug information to physicians at the drug information section of the hospital pharmacy. At present, clinical pharmacists in most hospitals consult with patients regarding the drug therapy, and sometimes recommend the dosage regimen and provide drug information regarding the drug therapy to the physicians directly. We analyzed the records providing drug information to physicians and clinical interventions from March through May in 2002, and evaluated the acceptance ratio of pharmacists' recommendation for drug therapy. Clinical interventions included advice regarding drug therapy and pointing out prescription errors, inappropriate dosage, adverse drug reactions, drug interactions, and other aspects. In our survey, 73.8% of all interventions by the pharmacists were accepted by the physicians. For advice based on therapeutic drug monitoring, pharmacokinetic
    Japanese Society of Pharmaceutical Health Care and Sciences, 2003, Japanese Journal of Hospital Pharmacy, 29(4) (4), 415 - 420, Japanese

  • M Fukudo, Yano, I, S Fukatsu, H Saito, S Uemoto, T Kiuchi, K Tanaka, K Inui
    2003, CLINICAL PHARMACOKINETICS, 42(13) (13), 1161 - 1178, English
    [Refereed]

  • Y Habu, Yano, I, Y Hashimoto, H Saito, K Inui
    Dec. 2002, PHARMACEUTICAL RESEARCH, 19(12) (12), 1822 - 1826, English
    [Refereed]
    Scientific journal

  • M Jiko, Yano, I, H Wakasugi, H Saito, K Inui
    Sep. 2002, PHARMACEUTICAL RESEARCH, 19(9) (9), 1362 - 1367, English
    [Refereed]
    Scientific journal

  • H Yamaguchi, Yano, I, H Saito, KI Inui
    Mar. 2002, JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 300(3) (3), 1063 - 1069, English
    [Refereed]
    Scientific journal

  • Yano Ikuko
    Although acetazolamide, a carbonic anhydrase inhibitor, has an effect of lowering the intraocular pressure, a number of side effects have been reported with its use. We therefore investigated the pharmacokinetics and pharmacodynamics of acetazolamide in patients with an intraocular pressure (IOP) elevation. The plasma acetazolamide concentration and IOP in 17 patients with a transient IOP elevation were simultaneously measured after the last acetazolamide administration, and the findings were analyzed by nonlinear mixed effect modeling using the NONMEM software program. The plasma concentration profile of acetazolamide was characterized by a one-compartment model with first-order absorption. The apparent oral clearance (L/hr) showed a correlation with the creatinine clearance (CCR, mL/min), as estimated by the Cockcroft and Gault equation, as follows:0. 0468・CCR. The estimated apparent oral volume of the distribution, first-order absorption rate constant, and absorption lag time were 0.231 L/kg, 0.821 hr^-1, and 0.497 hr, respectively. The intraocular pressure after oral acetazolamide administration was characterized by an E_max model. The maximal effect in lowering the IOP (E_max)was 7.2 mmHg, and the concentration corresponding to 50% of E_max (EC_50) was 1.64 μg/mL. We next investigated the relationship between the acetazolamide concentration and its side effects in 23 glaucomatous patients who received repeated doses of oral acetazolamide for one week or more. The serum concentration of chloride ion was found to be higher than the normal range, and also showed a significant correlation with the acetazolamide concentration in the erythrocytes. The patients with an erythrocyte acetazolamide concentration of more than 20μg/mL had higher incidents of the side effects. Based on these results, the recommended dosage of acetazolamide was calculated so that the minimum plasma concentration at steady-state exceeded 4 μg/mL. The dosage regimen desired in this study is expected to contribute to the safe and effective pharmacotherapeutic use of acetazolamide.
    Japanese Society of Pharmaceutical Health Care and Sciences, 2002, Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 28(1) (1), 1 - 8, Japanese

  • H Okabe, Yano, I, Y Hashimoto, H Saito, KI Inui
    Jan. 2002, JOURNAL OF PHARMACY AND PHARMACOLOGY, 54(1) (1), 65 - 70, English
    [Refereed]
    Scientific journal

  • H Yamaguchi, Yano, I, H Saito, KI Inui
    Nov. 2001, EUROPEAN JOURNAL OF PHARMACOLOGY, 431(3) (3), 297 - 303, English
    [Refereed]
    Scientific journal

  • S Fukatsu, Yano, I, T Igarashi, T Hashida, K Takayanagi, H Saito, S Uemoto, T Kiuchi, K Tanaka, K Inui
    Sep. 2001, EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 57(6-7) (6-7), 479 - 484, English
    [Refereed]
    Scientific journal

  • The need for mixed-effects modeling with population dichotomous data
    Yano, I, SL Beal, LB Sheiner
    Aug. 2001, JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 28(4) (4), 389 - 412, English
    [Refereed]
    Scientific journal

  • Y Matsuo, Yano, I, Y Habu, T Katsura, Y Hashimoto, K Inui
    May 2001, PHARMACEUTICAL RESEARCH, 18(5) (5), 573 - 578, English
    [Refereed]
    Scientific journal

  • Kodawara, T., Yano, I., Masuda, S., Ito, T., Wakasugi, H., Futami, T., Hashimoto, Y., Saito, H., and Inui, K.
    Itraconazole is known to interact with digoxin, a substrate of P-glycoprotein, in clinical situations. In this study, the interactions of the azole antifungal agents, miconazole, fluconazole, ketoconazole as well as itraconazole, with P-glycoprotein were examined using a transfected kidney epithelial cell line, LLC-GA5-COL150, which expresses human P-glycoprotein on the apical membrane.
    Itraconazole decreased the transcellular transport of digoxin from the basolateral to apical side in LLC-GA5-COL150 cell monolayers, that was accompanied by increased cellular accumulation. The basolateralto-apical transcellular transport of digoxin in the host LLC-PK1 cell monolayers was not affected by itraconazole. Ketoconazole and fluconazole also significantly inhibited P-glycoprotein-mediated transport of digoxin, although miconazole was not effective. The inhibitory effects of itraconazole and ketoconazole on digoxin transport in LLC-GA5-COL150 monolayers were as strong as that of cyclosporin A, a typical P-glycoprotein modulator, and neither quinidine nor cimetidine inhibited digoxin transport at the same concentration (10 μM). In addition, the viability of LLC-GA5-COL150 cells against itraconazole was higher than that of LLC-PK1 cells, but viability against the other three azoles was similar to that of LLC-PK1 cells.
    In conclusion, ketoconazole and fluconazole as well as itraconazole inhibited the transport of digoxin via human P-glycoprotein, and itraconazole could be a substrate of P-glycoprotein.
    The Japanese Society for the Study of Xenobiotics, Jan. 2001, Xenobiotic Metabolism and Disposition, 16(1) (1), 5 - 11, English
    [Refereed]

  • Secretory mechanisms of grepafloxacin and levofloxacin in the human intestinal cell line caco-2.
    H Yamaguchi, I Yano, Y Hashimoto, K I Inui
    Grepafloxacin and levofloxacin transport by Caco-2 cell monolayers was examined to characterize the intestinal behavior of these quinolones. The levels of transcellular transport of [(14)C]grepafloxacin and [(14)C]levofloxacin from the basolateral to the apical side were greater than those in the opposite direction. The unidirectional transport was inhibited by the presence of excess unlabeled quinolones, accompanied by increased accumulation. The inhibitory effects of cyclosporin A plus grepafloxacin on basolateral-to-apical transcellular transport and cellular accumulation of [(14)C]grepafloxacin were comparable to those of cyclosporin A alone, indicating that the transport of grepafloxacin across the apical membrane was mainly mediated by P-glycoprotein. On the other hand, basolateral-to-apical transcellular transport of [(14)C]levofloxacin in the presence of cyclosporin A was decreased by unlabeled levofloxacin, grepafloxacin, and enoxacin, accompanied by significantly increased cellular accumulation. The organic cation cimetidine, organic anion p-aminohippurate, and the multidrug resistance-related protein (MRP) modulator probenecid did not affect the transcellular transport of [(14)C]grepafloxacin or [(14)C]levofloxacin in the presence of cyclosporin A. The basolateral-to-apical transcellular transport of levofloxacin in the presence of cyclosporin A showed concentration-dependent saturation with an apparent Michaelis constant of 5.6 mM. In conclusion, these results suggested that basolateral-to-apical flux of quinolones was mediated by P-glycoprotein and a specific transport system distinct from organic cation and anion transporters and MRP.
    Oct. 2000, The Journal of pharmacology and experimental therapeutics, 295(1) (1), 360 - 6, English, International magazine
    [Refereed]

  • H Wakasugi, R Ishizuka, N Koreeda, Yano, I, T Futami, R Nohara, S Sasayama, K Inui
    Sep. 2000, YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 120(9) (9), 807 - 811, Japanese
    [Refereed]
    Scientific journal

  • Y Habu, I Yano, M Okuda, Y Hashimoto, K Inui
    Sep. 2000, Pharmaceutical research, 17(9) (9), 1155 - 7, English, International magazine
    [Refereed]

  • T Ito, Yano, I, Y Hashimoto, K Inui
    Feb. 2000, PHARMACEUTICAL RESEARCH, 17(2) (2), 236 - 241, English
    [Refereed]
    Scientific journal

  • Inhibitory effect of KW-3902, an adenosine A(1) receptor antagonist, on p-aminohippurate transport in OK cells.
    J Nagai, I Yano, Y Habu, T Katsura, Y Hashimoto, K Inui
    KW-3902 (8-(noradamantan-3-yl)-1,3-dipropylxanthine) is a novel potent and selective adenosine A(1) receptor antagonist. We examined the effect of KW-3902 on p-aminohippurate (PAH) transport in opossum kidney (OK) epithelial cells. Pretreatment for 3 h with KW-3902 inhibited the transcellular transport of PAH across OK cell monolayers from the basal to the apical side. The uptake of PAH across the basolateral membrane of OK cells was inhibited by KW-3902 pretreatment in a time- and concentration-dependent manner. A kinetic analysis revealed that the inhibitory effect of KW-3902 on the basolateral PAH uptake was due to an increase in the Michaelis constant (K(m)) as well as a decrease in the maximum uptake rate (V(max)), showing that the inhibition was a mixed type. Pretreatment with adenosine deaminase or 8-cyclopentyl-1,3-dipropylxanthine, another selective adenosine A(1) receptor antagonist, also decreased the basolateral PAH uptake. KW-3902 pretreatment had no effect on the concentration of intracellular alpha-ketoglutarate which exchanges for PAH across the basolateral membrane of OK cells. These results suggest that KW-3902 has an inhibitory effect on PAH transport in OK epithelial cells.
    Jul. 1999, Biochimica et biophysica acta, 1419(2) (2), 164 - 72, English, International magazine
    Scientific journal

  • JY Nagai, Yano, I, Y Habu, T Katsura, Y Hashimoto, K Inui
    Jul. 1999, BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1419(2) (2), 164 - 172, English
    [Refereed]
    Scientific journal

  • M Inatani, Yano, I, H Tanihara, Y Ogura, Y Honda, KI Inui
    Apr. 1999, JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 15(2) (2), 97 - 105, English
    [Refereed]
    Scientific journal

  • T Ito, I Yano, S Masuda, Y Hashimoto, K Inui
    PURPOSE: To elucidate the renal distribution of quinolones, we examined the uptake of levofloxacin and grepafloxacin in vivo and in rat renal cortical slices. METHODS: The plasma and various tissue concentrations of levofloxacin and grepafloxacin were measured after a bolus injection in rats, and tissue uptake clearance was calculated. Transport characteristics of quinolones in rat renal cortical slices were evaluated. RESULTS: The tissue distribution of levofloxacin and grepafloxacin in the kidney was greater than in any other tissue, and the tissue uptake clearances of levofloxacin and grepafloxacin in the kidney cortex were 1.2 and 4.6 ml/min/g tissue, respectively. The uptake of levofloxacin and grepafloxacin in rat renal cortical slices was concentrative, as indicated by slice/medium ratios of 2.3 and 9.6 at 60 min, respectively. The uptake of levofloxacin and grepafloxacin in rat renal cortical slices showed saturation, and was significantly inhibited in the presence of quinidine (p<.05), but not of tetraethylammonium or p-aminohippurate. CONCLUSIONS: Renal distribution of levofloxacin and grepafloxacin may be mediated by a specific transport system for quinolones, distinct from the organic cation and organic anion transport systems in the kidney.
    Apr. 1999, Pharmaceutical research, 16(4) (4), 534 - 9, English, International magazine
    [Refereed]

  • Transport of quinolone antibacterial drugs in a kidney epithelial cell line, LLC-PK1
    Y Matsuo, Yano, I, T Ito, Y Hashimoto, KI Inui
    Nov. 1998, JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 287(2) (2), 672 - 678, English
    [Refereed]
    Scientific journal

  • H Wakasugi, Yano, I, T Ito, T Hashida, T Futami, R Nohara, S Sasayama, K Inui
    Jul. 1998, CLINICAL PHARMACOLOGY & THERAPEUTICS, 64(1) (1), 123 - 128, English
    [Refereed]
    Scientific journal

  • Efflux of intracellular alpha-ketoglutarate via p-aminohippurate/dicarboxylate exchange in OK kidney epithelial cells
    J Nagai, Yano, I, Y Hashimoto, M Takano, K Inui
    May 1998, JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 285(2) (2), 422 - 427, English
    [Refereed]
    Scientific journal

  • Yano, I, A Takayama, M Takano, M Inatani, H Tanihara, Y Ogura, Y Honda, K Inui
    Mar. 1998, EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 54(1) (1), 63 - 68, English
    [Refereed]
    Scientific journal

  • Inhibition PAH transport by parathyroid hormone in OK cells: involvement of protein kinase C pathway
    J Nagai, Yano, I, Y Hashimoto, M Takano, K Inui
    Nov. 1997, AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 273(5) (5), F674 - F679, English
    [Refereed]
    Scientific journal

  • Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1
    T Ito, Yano, I, K Tanaka, K Inui
    Aug. 1997, JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 282(2) (2), 955 - 960, English
    [Refereed]
    Scientific journal

  • Yano, I, T Ito, M Takano, K Inui
    Apr. 1997, PHARMACEUTICAL RESEARCH, 14(4) (4), 508 - 511, English
    [Refereed]
    Scientific journal

  • Inhibition of PAH transport by parathyroid hormone in OK cells: Involvement of protein kinase C pathway
    Junya Nagai, Ikuko Yano, Yukiya Hashimoto, Mikihisa Takano, Ken-Ichi Inui
    1997, American Journal of Physiology - Renal Physiology, 273(5) (5), F674 - F679, English
    [Refereed]
    Scientific journal

  • Clinical significance of monitoring plasma concentrations of acetazolamide
    M Inatani, H Tanihara, Y Ogura, Yano, I, A Takayama, M Takano, K Inui
    Feb. 1996, INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 37(3) (3), 5075 - 5075, English
    [Refereed]

  • Y TANIGAWARA, YANO, I, K KAWAKATSU, K NISHIMURA, M YASUHARA, R HORI
    Feb. 1994, JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 22(1) (1), 59 - 71, English
    [Refereed]
    Scientific journal

  • YANO, I, Y TANIGAWARA, M YASUHARA, K OKUMURA, K KAWAKATSU, K NISHIMURA, R HORI
    May 1993, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 16(5) (5), 501 - 505, English
    [Refereed]
    Scientific journal

  • Population pharmacokinetics of theophylline. I: Intravenous infusion to children in the acute episode of asthma.
    I Yano, Y Tanigawara, M Yasuhara, H Mikawa, R Hori
    The population pharmacokinetics of theophylline during constant-rate intravenous infusion has been studied in 66 children (8.7 +/- 4.7 year of age; 26.0 +/- 12.8 kg, mean +/- S.D.) with an episode of acute asthma. One hundred and twelve theophylline serum concentrations (13.9 +/- 4.8 micrograms/ml) collected retrospectively were analyzed using a nonlinear mixed-effect model. The influence of hepatic dysfunction, age, gender, days after admission, blood gas measurements (PaO2, PaCO2, blood pH) and clinical analyses data (total serum protein, albumin concentration, haemoglobin concentration, haematocrit) on theophylline clearance was examined by the likelihood ratio test. A final estimate of population mean clearance was 58.6 ml/kg/h, which was decreased by 36% in patients with hepatic dysfunction. Other factors tested displayed no statistically significant effect on theophylline clearance. The inter-individual variability in clearance was 26% while the intra-individual variability in theophylline concentrations was 2.6 micrograms/ml as a standard deviation, which was almost double that observed for stable patients. Taking into account that the therapeutic window of this drug is 10-20 micrograms/ml, this value indicates a relatively large intra-individual variability and suggests that frequent (daily) monitoring of serum concentrations is necessary for patients with an episode of acute asthma.
    Jan. 1993, Biological & pharmaceutical bulletin, 16(1) (1), 59 - 62, English, Domestic magazine
    [Refereed]

  • Y TANIGAWARA, YANO, I, M YASUHARA, R HORI
    Sep. 1992, AMERICAN REVIEW OF RESPIRATORY DISEASE, 146(3) (3), 616 - 620, English
    [Refereed]
    Scientific journal

  • Blood oxygen tension-related change of theophylline clearance in experimental hypoxemia
    I. Kishimoto, Y. Tanigawara, K. Okumura, R. Hori
    Lead, 1989, Journal of Pharmacology and Experimental Therapeutics, 248(3) (3), 1237 - 1242, English
    [Refereed]
    Scientific journal

  • Kazutaka Higaki, Ikuko Kishimoto, Hideo Komatsu, Mitsuru Hashida, Hitoshi Sezaki
    1987, International Journal of Pharmaceutics, 36(2-3) (2-3), 131 - 139, English
    [Refereed]
    Scientific journal

  • Effect of medium-chain glycerides (MGK) on the intestinal absorption and the hepatobiliary transport of bromthymol blue.
    K Higaki, I Kishimoto, H Komatsu, M Hashida, H Sezaki
    The effect of medium chain glyceride (MGK) emulsion on the intestinal absorption and the biliary excretion of bromthymol blue (BTB) was investigated in rats. Extensive tissue accumulation of BTB was reduced when BTB was administered with MGK emulsion formulation. HCO-100, an emulsifier, was also important for the decrease in the tissue accumulation of BTB. The ratios of absorption percent to tissue accumulation percent and to free fraction, not contained in the droplet of emulsion, in MGK emulsion were much greater than that of the control. Pretreatment with BTB-free emulsion reduced BTB absorption under the control, although tissue accumulation was not affected. The absorption appeared to decrease with increase in the time of pretreatment. The effect of leaving treatment after pretreatment on the absorption of BTB was also investigated. With the increase in leaving time after pretreatment, reduced absorption tended to resume to the level of control. The change in monocaprylate content from 54 to 60% in MGK made a difference in BTB absorption and it was suggested that monocaprylate content in MGK was one of the significant factors of MGK emulsion on drug absorption. Bile recovery study was simultaneously carried out with an in situ recirculation experiment. The recovery of BTB into bile tended to decrease. The ratio of recovery percent of BTB into bile to the absorption percent of BTB also decreased extensively, which is possibly another effect of MGK on drug disposition.
    Jun. 1986, Journal of pharmacobio-dynamics, 9(6) (6), 532 - 9, English, Domestic magazine
    [Refereed]

■ MISC
  • 小林 理乃, 山本 和宏, 丹田 雅明, 糸原 光太郎, 北廣 優実, 大村 友博, 矢野 育子
    (一社)日本TDM学会, Jul. 2024, TDM研究, 41(2) (2), 158 - 158, Japanese

  • 錠剤同士の接触により生じるテルミサルタン錠の着色とそのメカニズムの解析
    岡崎裕太朗, 大村友博, 上田昌史, 武田紀彦, 竹下治範, 飯田真之, 山本和宏, 土生康司, 宮田興子, 矢野育子
    2024, 医療薬学フォーラム講演要旨集, 32nd

  • 藤田 浩平, 山本 和宏, 宇田 篤史, 荻原 孝史, 阪上 倫行, 田村 直暉, 木村 丈司, 糸原 光太郎, 北廣 優実, 大村 友博, 矢野 育子
    (一社)日本TDM学会, Jun. 2023, TDM研究, 40(2) (2), 176 - 176, Japanese

  • ニルマトレルビル/リトナビル併用時にタクロリムス濃度の異常高値を認めた腎移植症例
    冨田 猛, 木村 丈司, 山本 和宏, 宇田 篤史, 藤田 浩平, 荻原 孝史, 糸原 光太郎, 北廣 優実, 大村 友博, 矢野 育子
    (一社)日本医薬品情報学会, Jun. 2023, 日本医薬品情報学会総会・学術大会講演要旨集, 25回, 147 - 147, Japanese

  • 藤田 浩平, 山本 和宏, 宇田 篤史, 荻原 孝史, 阪上 倫行, 田村 直暉, 木村 丈司, 糸原 光太郎, 北廣 優実, 大村 友博, 矢野 育子
    (一社)日本TDM学会, Jun. 2023, TDM研究, 40(2) (2), 176 - 176, Japanese

  • Search for compounds increasing the expression of ubiquitin ligase HRD1 and suppressing neuronal cell death
    西口大生, 大村友博, 佐登礼佳, 北廣優実, 山本和宏, 國正淳一, 矢野育子
    2023, 日本薬学会年会要旨集(Web), 143rd

  • パーキンソン病発症に関連する小胞体ストレス関連分子SEL1Lを制御するmicroRNAの探索と血漿中microRNA発現量の検討
    西口大生, 大村友博, 大村友博, 野村月渚, 渡邉蘭, 北廣優実, 糸原光太郎, 山本和宏, 國正淳一, 松原和夫, 松原和夫, 矢野育子
    2023, 医療薬学フォーラム講演要旨集, 31st

  • 糸原 光太郎, 矢野 育子, 中川 俊作, 杉本 充弘, 平井 真智子, 米澤 淳, 平 大樹, 伊藤 孝司, 秦 浩一郎, 波多野 悦朗, 寺田 智祐, 松原 和夫
    (一社)日本臨床薬理学会, Dec. 2022, 日本臨床薬理学会学術総会抄録集, 43回, 1 - 5, Japanese

  • 基本的技術トレーニング研修における初期臨床研修医に対する医療安全教育の実践
    木村 真希, 坂口 一彦, 木戸 正浩, 小林 成美, 小林 和幸, 宮良 高雄, 大路 剛, 八幡 眞理子, 矢野 育子, 今西 孝充, 横山 朋大, 加藤 博史, 大原 彰子, ウィリアムソン 彰子, 河野 誠司
    (一社)日本医学教育学会, Jul. 2022, 医学教育, 53(Suppl.) (Suppl.), 187 - 187, Japanese

  • Atsushi Uda, Takeshi Kimura, Mari Kusuki, Rie Izuta, Mariko Yahata, Ikuko Yano, Takayuki Miyara
    MDPI, 15 Sep. 2021, ECCM 2021, 9(1) (1), 12

  • 消化管上皮細胞モデルにおけるABCB1発現・機能に及ぼすエベロリムス長期曝露の影響
    中山 優子, 高良 恒史, 山本 和宏, 大村 友博, 矢野 育子
    (公社)日本薬学会, Mar. 2021, 日本薬学会年会要旨集, 141年会, 29P01 - 289, Japanese

  • 巻頭言：薬剤師が研究するということ
    矢野育子
    Lead, Mar. 2021, 日本病院薬剤師会雑誌, 57(3) (3), 305
    [Invited]

  • 薬剤師が主導する非がん疼痛患者へのオピオイド使用状況モニタリングの評価
    飯田真之, 志田有里, 番匠咲帆, 西岡達也, 松沼亮, 坂下明大, 木澤義之, 大村友博, 矢野育子
    2021, 日本緩和医療薬学会年会プログラム・要旨集, 14th

  • オピオイド鎮痛薬使用がん患者への薬剤師による外来電話サポートの介入効果
    志田有里, 飯田真之, 番匠咲帆, 蓼原瞬, 坂下明大, 久米学, 大村友博, 丹生健一, 木澤義之, 矢野育子
    2021, 日本緩和医療薬学会年会プログラム・要旨集, 14th

  • 巻頭言：個別化投与設計から精密医療の時代に〜変わるものと変わらないもの〜
    矢野育子
    Lead, Dec. 2020, TDM研究, 37(4) (4)
    [Invited]

  • 腎移植患者におけるタクロリムスPBPKモデル構築と肝移植患者の薬物動態との比較
    糸原 光太郎, 矢野 育子, 中川 俊作, 米澤 淳, 中川 貴之, 今井 哲司, 小川 修, 小林 恭, 坂井 薫, 松原 和夫
    (一社)日本臨床薬理学会, Oct. 2020, 臨床薬理, 51(Suppl.) (Suppl.), S293 - S293, Japanese

  • がん悪液質に対する補中益気湯による改善効果に関する調査
    北廣 優実, 山本 和宏, 大本 暢子, 久米 学, 芝野 真喜雄, 大村 友博, 矢野 育子
    (公社)日本薬学会, Mar. 2020, 日本薬学会年会要旨集, 140年会, 28P - am038, Japanese

  • ナトリウム・グルコース共輸送体2(SGLT2)阻害剤ipragliflozinによる重篤な皮膚障害に関する基礎的検討
    松尾 直弥, 片山 英人, 鈴木 悠実, 豊田 凌大, 河渕 真治, 山本 和宏, 伊藤 由佳子, 矢野 育子, 栄田 敏之
    (公社)日本薬学会, Mar. 2020, 日本薬学会年会要旨集, 140年会, 28J - am02S, Japanese

  • 【調剤業務Update 薬剤師の貢献と発信されたエビデンス総まとめ】調剤の自動化とその効果
    山下 和彦, 矢野 育子
    (株)南山堂, Feb. 2020, 薬局, 71(2) (2), 285 - 290, Japanese

  • 新生児の先天性サイトメガロウイルス感染症患者におけるガンシクロビル血中濃度測定と生理学的薬物動態モデルを用いたシミュレーション
    山本 和宏, 大山 正平, 福嶋 祥代, 橋本 真梨, 山川 恵, 藤原 尚子, 藤岡 一路, 飯島 一誠, 大村 友博, 矢野 育子
    (一社)日本臨床薬理学会, Nov. 2019, 臨床薬理, 50(Suppl.) (Suppl.), S297 - S297, Japanese

  • 新生児の先天性サイトメガロウイルス感染症患者におけるガンシクロビル血中濃度測定と生理学的薬物動態モデルを用いたシミュレーション
    山本 和宏, 大山 正平, 福嶋 祥代, 橋本 真梨, 山川 恵, 藤原 尚子, 藤岡 一路, 飯島 一誠, 大村 友博, 矢野 育子
    (一社)日本臨床薬理学会, Nov. 2019, 臨床薬理, 50(Suppl.) (Suppl.), S297 - S297, Japanese

  • 医薬品適正使用のためのクリニカルファーマコメトリクス
    矢野 育子
    (公社)日本薬学会, Oct. 2019, 薬学雑誌, 139(10) (10), 1227 - 1234, Japanese
    Link to Kobe Univ. Repository (Kernel)

  • 薬物動態学の観点から見る免疫抑制薬
    矢野 育子
    (一社)日本臓器保存生物医学会, Jul. 2019, Organ Biology, 26(2) (2), 41 - 47, Japanese
    Link to Kobe Univ. Repository (Kernel)

  • 【がん治療と薬物相互作用 ピットフォールに陥らないための基礎と実践】併存疾患のあるがん患者における薬物相互作用のピットフォール てんかん
    丹田 雅明, 矢野 育子
    (株)南山堂, Jun. 2019, 薬局, 70(7) (7), 1481 - 1487, Japanese

  • 抗てんかん薬TDMガイドライン
    矢野 育子
    (一社)日本TDM学会, May 2019, TDM研究, 36(2) (2), 49 - 49, Japanese

  • ラモトリギンTDMの現状と血中濃度の変動因子に関する調査
    松田 美玖, 山本 和宏, 阪上 倫行, 高橋 知子, 矢野 育子
    (一社)日本TDM学会, May 2019, TDM研究, 36(2) (2), 188 - 188, Japanese

  • 新規Bcl-2選択的阻害剤の長期間曝露がヒト白血病細胞株に及ぼす影響
    中山 優子, 高良 恒史, 峯垣 哲也, 山本 和宏, 矢野 育子
    (公社)日本薬学会, Mar. 2019, 日本薬学会年会要旨集, 139年会(4) (4), 133 - 133, Japanese

  • 【高齢患者のOveruse/Underuse 過剰でも過少でもない薬剤の適正使用を考える】 Overuse/Underuseに対する薬学管理の実践ポイント 病院薬剤師のOveruse/Underuseへの関わり
    飯田真之, Yano Ikuko
    Feb. 2019, 薬局, 70(2号) (2号), 287 - 292, Japanese
    [Invited]
    Introduction commerce magazine

  • クロザピン及び活性代謝物の母集団薬物動態解析:入院・外来の影響
    小岸かれん, 小岸かれん, 大村友博, 大村友博, 山本将太, 中川俊作, 米沢淳, 米沢淳, 糸原光太郎, 糸原光太郎, 竹内理人, 竹内理人, 松尾研志, 松尾研志, 橋本凱朝, 橋本凱朝, 諏訪太朗, 佐藤夕紀, 今井哲司, 中川貴之, 村井俊哉, 矢野育子, 矢野育子, 松原和夫
    2019, 日本医療薬学会年会講演要旨集(Web), 29

  • 【診療に活かす薬理・ブラッシュアップ】 日常診療に直結する薬理学 治療薬物モニタリング(TDM)
    阪上倫行, Yamamoto Kazuhiro, Yano Ikuko
    2019, 診断と治療, 107(2) (2), 173 - 179, Japanese
    Introduction commerce magazine

  • Coverings avoid frostbites and do not reduce efficacy of cryotherapy for prevention of chemotherapy-induced neuropathy
    Akiko Hanai, Hiroshi Ishiguro, Takashi Sozu, Moe Tsuda, Ikuko Yano, Takayuki Nakagawa, Satoshi Imai, Yoko Hamabe, Masakazu Toi, Hidenori Arai, Tadao Tsuboyama
    Oct. 2018, ANNALS OF ONCOLOGY, 29, English
    Summary international conference

  • Risk factors for Pseudomonas aeruginosa-causing urosepsis: How does urological intervention contribute to lower mortality rate ?
    Katsumi Shigemura, Yuzo Nakano, Teruo Fukuda, Atsushi Uda, Kayo Osawa, Ikuko Yano, Soichi Arakawa, Issei Tokimtasu, Masato Fujisawa
    Oct. 2018, INTERNATIONAL JOURNAL OF UROLOGY, 25, 240 - 240, English
    Summary international conference

  • 【専門・認定薬剤師を知る】 我が国における認定・専門薬剤師制度の現状と今後の展望
    Yano Ikuko
    Aug. 2018, ファルマシア, 54(8号) (8号), 757 - 761, Japanese
    [Refereed][Invited]
    Introduction scientific journal

  • 【てんかん診療Update】 薬物療法 臨床薬理学的解説
    Yano Ikuko
    Aug. 2018, Pharma Medica, 36(8号) (8号), 29 - 33, Japanese
    [Invited]
    Introduction commerce magazine

  • ポリファーマシー対策の取り組み ポリファーマシー対策の取り組み
    Yano Ikuko
    Aug. 2018, 薬事新報, (3058号) (3058号), 19 - 22, Japanese
    [Invited]
    Introduction commerce magazine

  • シグナル伝達因子に起因する間質性肺炎発症メカニズム
    山本和宏, 中川勉, Yano Ikuko, Hirai Midori
    Jan. 2018, Medical Science Digest, 44(1号) (1号), 49 - 53, Japanese
    [Invited]
    Introduction commerce magazine

  • Genetic polymorphisms associated with adverse reactions of molecular-targeted therapies in renal cell carcinoma
    Yamamoto K, Yano Ikuko
    Jan. 2018, Med Oncol, 35(2) (2), 16, English
    [Refereed]
    Introduction scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • B細胞リンパ腫患者における、リツキシマブのPK/PD解析
    森 万優子, 米澤 淳, 大谷 祐基, 磯本 唯, 津田 真弘, 池見 泰明, 今井 哲司, 大村 友博, 北野 俊行, 高折 晃史, 矢野 育子, 松原 和夫
    (一社)日本臨床薬理学会, Nov. 2017, 臨床薬理, 48(Suppl.) (Suppl.), S278 - S278, Japanese

  • 小児におけるトリクロロエタノールの薬物動態・薬力学の発達・成長に伴う変化の解析
    井上 美帆, 糸原 光太郎, 佐藤 博貴, 加藤 祐子, 石井 祥代, 伊藤 由起, 那須 民江, 上島 通浩, 矢野 育子, 松原 和夫, 佐和 貞治, 橋本 悟
    (一社)日本臨床薬理学会, Nov. 2017, 臨床薬理, 48(Suppl.) (Suppl.), S274 - S274, Japanese

  • B細胞リンパ腫患者における、リツキシマブのPK/PD解析
    森 万優子, 米澤 淳, 大谷 祐基, 磯本 唯, 津田 真弘, 池見 泰明, 今井 哲司, 大村 友博, 北野 俊行, 高折 晃史, 矢野 育子, 松原 和夫
    (一社)日本臨床薬理学会, Nov. 2017, 臨床薬理, 48(Suppl.) (Suppl.), S278 - S278, Japanese

  • 薬剤師による処方設計(61)薬剤師主導のバンコマイシン処方設計に向けた取り組み
    住吉 霞美, 山本 和宏, 矢野 育子
    医薬ジャーナル社, Oct. 2017, 医薬ジャーナル, 53(10) (10), 131 - 135, Japanese

  • The effects of icing on paclitaxel-induced peripheral neuropathy among breast cancer patients: a self-controlled trial
    Akiko Hanai, Hiroshi Ishiguro, Takashi Sozu, Moe Tsuda, Ikuko Yano, Takayuki Nakagawa, Satoshi Imai, Masakazu Toi, Hidenori Arai, Tadao Tsuboyama
    Oct. 2017, ANNALS OF ONCOLOGY, 28, 90 - 90, English
    Summary international conference

  • 薬剤師による処方設計 薬剤師主導のバンコマイシン処方設計に向けた取り組み
    住吉霞美, 山本和宏, Yano Ikuko
    (株)医薬ジャーナル社, Oct. 2017, 医薬ジャーナル, 53(10) (10), 2315 - 2319, Japanese
    Introduction commerce magazine

  • 質量分析法を駆使した最新薬物動態研究 LC/TOF-MSを用いた抗体医薬品の体内動態解析
    大谷 祐基, 米澤 淳, 津田 真弘, 今井 哲司, 池見 泰明, 大村 友博, 中川 俊作, 中川 貴之, 矢野 育子, 松原 和夫
    (一社)日本医用マススペクトル学会, Aug. 2017, JSBMS Letters, 42(Suppl.) (Suppl.), 43 - 43, Japanese

  • リツキシマブの体内動態とその変動因子の考察
    大谷祐基, 米澤淳, 礒本唯, 津田真弘, 池見泰明, 今井哲司, 大村友博, 中川俊作, 中川貴之, 矢野育子, 北野俊行, 高折晃史, 松原和夫
    Jun. 2017, 医療薬学フォーラム講演要旨集, 25th, 233, Japanese

  • 井上美帆, 佐藤博貴, 糸原光太郎, 加藤祐子, 石井祥代, 伊藤由起, 中平有紀, 那須民江, 上島通浩, Yano Ikuko, 松原和夫, 佐和貞治, 橋本悟
    (公財)臨床薬理研究振興財団, Jun. 2017, 臨床薬理の進歩, (38号) (38号), 71 - 78, Japanese
    [Invited]
    Introduction other

  • 抗てんかん薬TDM標準化ガイドライン(STATEMENT) 2017 Version 1.0
    谷川原祐介, 千堂年昭, 今村知世, 河崎陽一, 末丸克矢, 村木優一, Yano Ikuko, 伊藤智, 田中亮裕, 林雅彦, 小林勝弘
    (一社)日本TDM学会, Jun. 2017, TDM研究, 34(2) (2), 67 - 95, Japanese
    [Refereed]
    Introduction scientific journal

  • 小児におけるテイコプラニンの薬物動態解析
    松尾 研志, 近藤 美貴, 吉村 和晃, 中川 俊作, 米澤 淳, 中川 貴之, 矢野 育子, 松原 和夫
    (公社)日本薬学会, Mar. 2017, 日本薬学会年会要旨集, 137年会(4) (4), 74 - 74, Japanese

  • 小児におけるテイコプラニンの薬物動態解析
    松尾 研志, 近藤 美貴, 吉村 和晃, 中川 俊作, 米澤 淳, 中川 貴之, 矢野 育子, 松原 和夫
    (公社)日本薬学会, Mar. 2017, 日本薬学会年会要旨集, 137年会(4) (4), 74 - 74, Japanese

  • シグナル伝達因子に起因する間質性肺炎発症メカニズム
    山本和宏, 中川勉, Yano Ikuko, Hirai Midori
    Mar. 2017, 別冊Bio Clinica: 慢性炎症と疾患, 6(1号) (1号), 121 - 125, Japanese
    [Invited]
    Introduction commerce magazine

  • 小児および成人てんかん患者におけるトピラマートの母集団薬物動態解析とその臨床応用
    竹内理人, Yano Ikuko, 松原和夫
    医薬ジャーナル社, 2017, 医薬ジャーナル, 53(3) (3), 899 - 903, Japanese
    [Invited]
    Introduction scientific journal

  • ポリファーマシーに関連する問題と、STOPP criteriaを活用した高齢者に対する不適切処方のスクリーニング
    木村丈司, Yano Ikuko, Hirai Midori
    日本病院薬剤師会, 2017, 日本病院薬剤師会雑誌, 53(3) (3), 273 - 278, Japanese
    [Invited]
    Introduction scientific journal
    Link to Kobe Univ. Repository (Kernel)

  • シグナル伝達因子に起因する間質性肺炎発症メカニズム
    山本和宏, 中川勉, Yano Ikuko, Hirai Midori
    2017, 別冊Bio Clinica, 6(1) (1), 121 - 125, Japanese
    [Invited]
    Introduction scientific journal

  • 【新薬展望2017】(第III部)治療における最近の新薬の位置付け＜薬効別＞ 新薬の広場 抗てんかん薬
    Yano Ikuko, 池田昭夫
    Jan. 2017, 医薬ジャーナル, 53(増刊) (増刊), 463 - 470, Japanese
    [Invited]
    Introduction scientific journal

  • 生体肝移植術後における1日1回製剤のタクロリムス薬物動態と薬効
    岩崎 真実, 矢野 育子, 端 幸代, 山本 由貴, 杉本 充弘, 福土 将秀, 増田 智先, 中川 俊作, 米澤 淳, 海道 利実, 上本 伸二, 松原 和夫
    (一社)日本臨床薬理学会, Oct. 2016, 臨床薬理, 47(Suppl.) (Suppl.), S214 - S214, Japanese

  • 臍帯血移植患者におけるミコフェノール酸血中濃度と急性GVHD発症との関連
    吉村 和晃, 矢野 育子, 山本 崇, 川西 美咲, 磯本 唯, 米澤 淳, 近藤 忠一, 高折 晃史, 松原 和夫
    (一社)日本臨床薬理学会, Oct. 2016, 臨床薬理, 47(Suppl.) (Suppl.), S252 - S252, Japanese

  • 【処方箋検査値トレーシングレポート活用術 地域医療連携に薬立つ「知恵」と「コツ」】 まずはしっかりと押さえよう!臨床検査値Q&A 院外処方箋に記載されている検査項目にはどのようなものがありますか? またそれからどのような情報を得ることができるのでしょうか?
    Yano Ikuko
    Sep. 2016, 薬局, 67(10号) (10号), 2820 - 2825, Japanese
    [Invited]
    Introduction commerce magazine

  • 待ったなし!求められるエビデンス 薬剤師が関わるチーム医療のアウトカム
    松原和夫, 米澤淳, 池見泰明, Yano Ikuko
    Jul. 2016, 東京都病院薬剤師会雑誌, 65(4号) (4号), 287 - 294, Japanese
    Introduction scientific journal

  • 社会的敗北ストレス負荷によるうつ病モデルマウスにおけるブロチゾラム誘発睡眠作用の効力変化に関する行動薬理学的研究
    宮山 大, 今井哲司, 辻 光貴, 重面雄紀, 米澤 淳, 大村友博, 中川俊作, 矢野育子, 中川貴之, 松原和夫
    Jun. 2016, 医療薬学フォーラム2016

  • 術前外来における薬剤師の取り組み 術前休薬基準の作成と運用
    尾崎 淳子, 山本 浩貴, 櫻井 香織, 上杉 美和, 石塚 良子, 矢野 育子, 小石 奈月, 竹下 麻美, 安彦 郁, 松村 由美, 松原 和夫
    (一社)日本医薬品情報学会, May 2016, 日本医薬品情報学会総会・学術大会講演要旨集, 19回, 116 - 116, Japanese

  • 生体肝移植術後のタクロリムス静脈内投与から経口投与への切り替え換算量に関する検討
    都築 徹教, 矢野 育子, 中川 俊作, 杉本 充弘, 佐藤 裕紀, 津田 真弘, 上杉 美和, 岡島 英明, 海道 利実, 上本 伸二, 松原 和夫
    (一社)日本TDM学会, May 2016, TDM研究, 33(2) (2), 135 - 135, Japanese

  • Yano Ikuko, 福田剛史, 佐藤淳子, 尾崎雅弘, 長谷川真裕美, 塩崎友美, 今井康彦, 中村秀文
    May 2016, 臨床薬理, 47(3) (3), 104, Japanese
    [Refereed]
    Introduction scientific journal

  • シクロスポリンおよびタクロリムスの血中濃度測定系に対するアゾール系抗真菌薬の影響
    岩上 智香, 津田 真弘, 杉本 充弘, 米澤 淳, 都築 徹教, 松原 惇起, 中川 俊作, 矢野 育子, 中川 貴之, 松原 和夫
    (公社)日本薬学会, Mar. 2016, 日本薬学会年会要旨集, 136年会(4) (4), 79 - 79, Japanese

  • シクロスポリンおよびタクロリムスの血中濃度測定系に対するアゾール系抗真菌薬の影響
    岩上 智香, 津田 真弘, 杉本 充弘, 米澤 淳, 都築 徹教, 松原 惇起, 中川 俊作, 矢野 育子, 中川 貴之, 松原 和夫
    (公社)日本薬学会, Mar. 2016, 日本薬学会年会要旨集, 136年会(4) (4), 79 - 79, Japanese

  • 小児及び成人てんかん患者におけるトピラマートの母集団薬物動態解析
    竹内 理人, 伊藤 聡子, 矢野 育子, 杉本 充弘, 米澤 淳, 池田 昭夫, 松原 和夫
    (公社)日本薬学会, Mar. 2016, 日本薬学会年会要旨集, 136年会(4) (4), 79 - 79, Japanese

  • インフリキシマブ先行品と後続品における糖鎖構造の比較
    津田 真弘, 大谷 祐基, 米澤 淳, 池見 泰明, 大村 友博, 中川 俊作, 今井 哲司, 中川 貴之, 矢野 育子, 松原 和夫
    (公社)日本薬学会, Mar. 2016, 日本薬学会年会要旨集, 136年会(4) (4), 82 - 82, Japanese

  • 小児及び成人てんかん患者におけるトピラマートの母集団薬物動態解析
    竹内 理人, 伊藤 聡子, 矢野 育子, 杉本 充弘, 米澤 淳, 池田 昭夫, 松原 和夫
    (公社)日本薬学会, Mar. 2016, 日本薬学会年会要旨集, 136年会(4) (4), 79 - 79, Japanese

  • インフリキシマブ先行品と後続品における糖鎖構造の比較
    津田 真弘, 大谷 祐基, 米澤 淳, 池見 泰明, 大村 友博, 中川 俊作, 今井 哲司, 中川 貴之, 矢野 育子, 松原 和夫
    (公社)日本薬学会, Mar. 2016, 日本薬学会年会要旨集, 136年会(4) (4), 82 - 82, Japanese

  • これからの院外処方せんの在り方
    松原和夫, 深津祥央, 尾崎淳子, Yano Ikuko
    Jan. 2016, 日本病院薬剤師会雑誌, 52(1号) (1号), 29 - 33, Japanese
    [Invited]
    Introduction scientific journal

  • 造血幹細胞移植患者におけるミコフェノール酸の母集団PK‐PDモデル解析
    YOSHIMURA KAZUAKI, YANO IKUKO, KAWANISHI MISAKI, YOSHIMURA KAZUAKI, YANO IKUKO, KAWANISHI MISAKI, YAMAMOTO TAKASHI, KANEYOSHI MACHIKO, YONEZAWA ATSUSHI, KONDO TADAKAZU, TAKAORI AKIFUMI, MATSUBARA KAZUO
    (一社)日本臨床薬理学会, 16 Nov. 2015, 臨床薬理, 46(Supplement) (Supplement), S144 - S144, Japanese

  • EFFECT OF PROTEIN BINDING ON PHARMACOKINETICS AND PHARMACODYNAMICS OF MYCOPHENOLIC ACID USING A POPULATION-MODELING APPROACH
    Kazuaki Yoshimura, Ikuko Yano, Misaki Kawanishi, Kazuo Matsubara
    Nov. 2015, DRUG METABOLISM REVIEWS, 47, 234 - 234, English
    Summary international conference

  • 潰瘍性大腸炎の治療効果に及ぼす患部組織中タクロリムス濃度及びCYP3A5多型の影響
    西岡 由貴, 増田 智先, 中川 俊作, 矢野 育子, 松浦 稔, 仲瀬 裕志, 松原 和夫
    (一社)日本臨床薬理学会, Nov. 2015, 臨床薬理, 46(Suppl.) (Suppl.), S149 - S149, Japanese

  • 【ポリファーマシー】 ポリファーマシーとは
    松原和夫, Yano Ikuko
    Nov. 2015, 日本病院薬剤師会雑誌, 51(11号) (11号), 1305 - 1307, Japanese
    [Invited]
    Introduction scientific journal

  • 23-2-S35-1 大学病院の立場から : 外来患者におけるチーム医療の実践(外来において薬物治療マネージメントを考える,シンポジウム35,医療薬学の進歩と未来-次の四半世紀に向けて-)
    矢野 育子, 松原 和夫
    日本医療薬学会, 23 Oct. 2015, 日本医療薬学会年会講演要旨集, 25, 162 - 162, Japanese

  • 22-8-O45-02 臨床検査値を印字した院外処方せんの有用性評価(薬薬連携,口頭発表,一般演題,医療薬学の進歩と未来-次の四半世紀に向けて-)
    萱野 勇一郎, 深津 祥央, 木村 嘉彦, 尾崎 淳子, 石塚 良子, 矢野 育子, 松原 和夫
    日本医療薬学会, 23 Oct. 2015, 日本医療薬学会年会講演要旨集, 25, 242 - 242, Japanese

  • 23-4-O52-06 イホスファミド脳症のリスク因子に関する調査(がん薬物療法(副作用対策),口頭発表,一般演題,医療薬学の進歩と未来-次の四半世紀に向けて-)
    川田 将義, 中川 俊作, 西村 綾, 矢野 育子, 中川 貴之, 岡本 健, 松田 秀一, 松原 和夫
    日本医療薬学会, 23 Oct. 2015, 日本医療薬学会年会講演要旨集, 25, 250 - 250, Japanese

  • 21-6-O9-03 院外処方せんにおける疑義照会一部不要プロトコルの効果(医療安全・薬学教育他,口頭発表,一般演題,医療薬学の進歩と未来-次の四半世紀に向けて-)
    安達 昂一郎, 櫻井 香織, 尾崎 淳子, 木村 嘉彦, 松村 勝之, 西脇 布貴, 萱野 勇一郎, 深津 祥央, 矢野 育子, 松原 和夫
    日本医療薬学会, 23 Oct. 2015, 日本医療薬学会年会講演要旨集, 25, 204 - 204, Japanese

  • 21-5-O6-09 非イオン性ヨード造影剤によるアレルギー様症状の有害事象に及ぼす水分摂取推奨の影響(有害事象・副作用,口頭発表,一般演題,医療薬学の進歩と未来-次の四半世紀に向けて-)
    鋒山 香苗, 元井 玲子, 矢野 育子, 尾崎 淳子, 山本 崇, 深津 祥央, 石塚 良子, 松村 由美, 谷口 正洋, 東村 享治, 松原 和夫
    日本医療薬学会, 23 Oct. 2015, 日本医療薬学会年会講演要旨集, 25, 201 - 201, Japanese

  • 21-7-O13-04 悪性黒色腫に対するニボルマブ治療における免疫関連有害反応の検討(がん薬物療法(副作用対策),口頭発表,一般演題,医療薬学の進歩と未来-次の四半世紀に向けて-)
    山本 将太, 長谷川 真理, 吉良 俊彦, 池見 泰明, 大村 友博, 矢野 育子, 藤澤 章弘, 椛島 健治, 松原 和夫
    日本医療薬学会, 23 Oct. 2015, 日本医療薬学会年会講演要旨集, 25, 208 - 208, Japanese

  • P0183-21-PM 円滑なC型肝炎治療薬の導入を目指した薬剤師外来の開設と有用性考察(外来薬剤師業務,ポスター発表,一般演題,医療薬学の進歩と未来-次の四半世紀に向けて-)
    家永 嘉子, 萱野 勇一郎, 杉本 充弘, 吉田 優子, 山本 崇, 野口 葉子, 今井 哲司, 深津 祥央, 石塚 良子, 矢野 育子, 上田 佳秀, 丸澤 宏之, 松原 和夫
    日本医療薬学会, 23 Oct. 2015, 日本医療薬学会年会講演要旨集, 25, 296 - 296, Japanese

  • 小児におけるバンコマイシン血中濃度と治療効果の関連
    KONDO MIKI, NAKAGAWA SHUNSAKU, YONEZAWA ATSUSHI, YANO IKUKO, NAKAGAWA TAKAYUKI, MATSUBARA KAZUO
    日本医療薬学会, 23 Oct. 2015, 日本医療薬学会年会講演要旨集, 25th, 330 - 330, Japanese

  • 生体肝移植術後のタクロリムス静脈内導入における点滴速度の適正化
    都築 徹教, 矢野 育子, 中川 俊作, 津田 真弘, 上杉 美和, 杉本 充弘, 岡島 英明, 海道 利実, 上本 伸二, 松原 和夫
    (一社)日本移植学会, Sep. 2015, 移植, 50(総会臨時) (総会臨時), 336 - 336, Japanese

  • 血液・リンパ リンパ腫治療の将来展望 生体内におけるリツキシマブの経時的構造変化の解析
    大谷 祐基, 米澤 淳, 今井 哲司, 津田 真弘, 兼吉 真千子, 池見 泰明, 大村 友博, 中川 俊作, 矢野 育子, 北野 俊行, 高折 晃史, 松原 和夫
    (一社)日本癌治療学会, Sep. 2015, 日本癌治療学会誌, 50(3) (3), 2082 - 2082, Japanese

  • プロトコルに基づいた薬物治療管理の臨床アウトカム:心臓血管外科におけるワルファリンプロトコル
    KATADA YOSHIKI, TAGAMI YUMI, NAKAGAWA SHUNSAKU, ODAKA MIZUHO, YONEZAWA ATSUSHI, KAYANO YUICHIRO, YANO IKUKO, MINAKATA KENJI, SAKATA RYUZO, MATSUBARA KAZUO
    Jun. 2015, 医療薬学フォーラム講演要旨集, 23rd, 283, Japanese

  • 新規抗てんかん薬の使用状況と血中濃度モニタリングの実際
    SATO AYUKO, TSUDA MASAHIRO, TSUZUKI TETSUNORI, SUGIMOTO MITSUHIRO, YANO IKUKO, NAKAGAWA TAKAYUKI, MATSUBARA KAZUO
    日本TDM学会, 15 May 2015, TDM研究, 32(2) (2), 141 - 141, Japanese

  • 生体肝移植術後のタクロリムス静脈内導入における血中濃度の評価
    TSUZUKI TETSUNORI, YANO IKUKO, NAKAGAWA SHUNSAKU, TSUDA MASAHIRO, UESUGI MIWA, SUGIMOTO MITSUHIRO, KAIDO TOSHIMI, UEMOTO SHINJI, MATSUBARA KAZUO
    日本TDM学会, 15 May 2015, TDM研究, 32(2) (2), 136 - 136, Japanese

  • 糸原 光太郎, 矢野 育子, 井上 美帆, 松原 和夫
    (一社)日本TDM学会, May 2015, TDM研究, 32(2) (2), 193 - 193, Japanese

  • プロトコルに基づいた薬物治療管理が臨床アウトカムに与える影響:TDMオーダを含めた処方設計支援
    KATADA YOSHIKI, NAKAGAWA SHUNSAKU, TAGAMI YUMI, TSUDA MASAHIRO, TSUZUKI TETSUNORI, ODAKA MIZUHO, YONEZAWA ATSUSHI, KAYANO YUICHIRO, YANO IKUKO, MINAKATA KENJI, SAKATA RYUZO, MATSUBARA KAZUO
    (公社)日本薬学会, Mar. 2015, 日本薬学会年会要旨集(CD-ROM), 135th(4) (4), ROMBUNNO.27G-PM08 - 56, Japanese

  • 生体肝移植後C型肝炎再燃に対するシメプレビル+ペグインターフェロン+リバビリン療法の治療効果とタクロリムス血中濃度への影響
    TSUZUKI TETSUNORI, NAKAGAWA SHUNSAKU, TSUDA MASAHIRO, UESUGI MIWA, YANO IKUKO, MATSUBARA KAZUO, UEDA YOSHIHIDE, CHIBA TSUTOMU, KAIDO TOSHIMI, UEMOTO SHINJI
    (公社)日本薬学会, Mar. 2015, 日本薬学会年会要旨集(CD-ROM), 135th(4) (4), ROMBUNNO.27G-PM06 - 55, Japanese

  • テモゾロミド長期服用患者の実態調査
    川田将義, 中川俊作, 山際岳朗, 矢野育子, 中川貴之, 荒川芳輝, 宮本享, 松原和夫
    2015, 日本脳腫瘍学会プログラム・抄録集, 33rd, 198, Japanese

  • 乳癌患者におけるドセタキセルの母集団薬物動態解析とファーマコゲノミクス
    尾上 晴香, 矢野 育子, 田中 惇子, 本橋 秀之, 中川 俊作, 米澤 淳, 石黒 洋, 松原 和夫
    (一社)日本臨床薬理学会, Nov. 2014, 臨床薬理, 45(Suppl.) (Suppl.), S236 - S236, Japanese

  • 薬剤師による処方設計 外来がん化学療法におけるトレーシングレポートを活用した病診薬連携の取り組み
    津田真弘, 礒本唯, 萱野勇一郎, Yano Ikuko, 松原和夫
    Nov. 2014, 医薬ジャーナル, 50(11号) (11号), 2685 - 2691, Japanese
    Introduction commerce magazine

  • 27-O1PM-04 クロザピンによる副作用の実態調査と薬剤師による介入の効果(副作用(実態調査と対策),優秀演題候補セッション1,新時代を拓く医療薬学フロンティア)
    八田 眞菜美, 重面 雄紀, 山本 将太, 萱野 勇一郎, 大村 友博, 矢野 育子, 諏訪 太朗, 村井 俊哉, 松原 和夫
    日本医療薬学会, 25 Aug. 2014, 日本医療薬学会年会講演要旨集, 24, 175 - 175, Japanese

  • 28-WS-6 薬物療法専門薬剤師の認定申請のための症例サマリーの書き方 : 感染症領域(薬物療法専門薬剤師による薬物治療介入の実際と症例サマリーの纏め方,薬物療法専門薬剤師認定制度委員会企画ワークショップ,新時代を拓く医療薬学フロンティア)
    吉田 優子, 矢野 育子, 松原 和夫
    日本医療薬学会, 25 Aug. 2014, 日本医療薬学会年会講演要旨集, 24, 168 - 168, Japanese

  • 27-O3PM-16 転倒・転落事故減少を目指した薬剤師による睡眠薬適正使用への介入(医療安全2,一般演題(口頭),新時代を拓く医療薬学フロンティア)
    重面 雄紀, 八田 眞菜美, 山本 将太, 山縣 有子, 萱野 勇一郎, 石塚 良子, 中川 貴之, 矢野 育子, 杉原 玄一, 村井 俊哉, 松原 和夫
    日本医療薬学会, 25 Aug. 2014, 日本医療薬学会年会講演要旨集, 24, 216 - 216, Japanese

  • 27-P3PM-010 授乳婦に対する母乳移行性情報情報データベースの作成(妊婦・授乳婦,一般演題(ポスター),新時代を拓く医療薬学フロンティア)
    木下 里紗, 森田 真樹子, 萱野 勇一郎, 矢野 育子, 小林 政彦, 松原 和夫
    日本医療薬学会, 25 Aug. 2014, 日本医療薬学会年会講演要旨集, 24, 320 - 320, Japanese

  • 保険薬局と協働で行う吸入指導外来の取り組みとその評価
    TERAO MAKOTO, SUGIMOTO MITSUHIRO, KAYANO YUICHIRO, TADEHARA MASAMI, KIMURA YOSHIHIKO, OGATA AKIRA, TSUZUKI TETSUNORI, YAMAGIWA TAKEO, YOSHIDA YUKO, IMAI TETSUJI, YANO IKUKO, SATO SUSUMU, MATSUMOTO HISAKO, MURO SHIGEO, MATSUBARA KAZUO
    日本医療薬学会, 25 Aug. 2014, 日本医療薬学会年会講演要旨集, 24th, 189 - 189, Japanese

  • がん領域におけるプレガバリン使用実態に基づく効果と副作用に関する調査
    IWAI CHIKAKO, YANO IKUKO, TSUDA MASAHIRO, NAKAGAWA TAKAYUKI, MATSUBARA KAZUO
    (一社)日本癌治療学会, Jun. 2014, 日本癌治療学会学術集会(CD-ROM), 52nd(3) (3), ROMBUNNO.P82-3 - 2331, Japanese

  • 小児及び成人てんかん患者の日常診療におけるレベチラセタム血中濃度データの評価と母集団薬物動態解析
    伊藤聡子, 矢野育子, 端幸代, 米澤淳, 池田昭夫, 松原和夫
    (一社)日本TDM学会, 15 May 2014, TDM研究, 31(3) (3), 107 - 107, Japanese

  • ヨード造影剤におけるアレルギー発現率の検討 水分摂取効果及び先発品・後発品間の比較
    元井 玲子, 尾崎 淳子, 矢野 育子, 深津 祥央, 石塚 良子, 松村 由美, 東村 享治, 松原 和夫
    (公社)日本薬学会, Mar. 2014, 日本薬学会年会要旨集, 134年会(4) (4), 62 - 62, Japanese

  • 病院薬剤師を対象としたフィジカルアセスメント講習会の実施とその評価
    杉本 充弘, 矢野 育子, 吉田 優子, 山際 岳朗, 河合 知喜, 萱野 勇一郎, 内藤 知佐子, 南 麻弥, 大鶴 繁, 小池 薫, 松原 和夫
    (公社)日本薬学会, Mar. 2014, 日本薬学会年会要旨集, 134年会(4) (4), 230 - 230, Japanese

  • 神経膠腫患者における抗てんかん薬の血中濃度とてんかん発作出現との関連
    西岡由貴, 萱野勇一郎, 西脇布貴, 中石真由美, 山際岳朗, 矢野育子, 荒川芳輝, 宮本享
    2014, 日本脳腫瘍学会プログラム・抄録集, 32nd, 75, Japanese

  • 【薬学教育モデル・コアカリキュラム改訂の目指すもの】 薬剤師教育の充実とは 病院薬剤師の立場から
    松原和夫, 米澤淳, 中川貴之, Yano Ikuko
    医薬ジャーナル社, Jan. 2014, 医薬ジャーナル, 50(1号) (1号), 77 - 81, Japanese
    [Invited]
    Introduction scientific journal

  • K. Kawaguchi, H. Ishiguro, I. Yano, H. Yamashiro, M. Toi
    Nov. 2013, ANNALS OF ONCOLOGY, 24, English
    Summary international conference

  • Impact of P-Glycoprotein and Breast Cancer Resistance Protein on the Brain Distribution of Antiepileptic Drugs
    Yano, I, H. Nakanishi, A. Yonezawa, K. Matsubara
    Oct. 2013, THERAPEUTIC DRUG MONITORING, 35(5) (5), 693 - 693, English
    Summary international conference

  • 土-P3-476 胆道がんに対するゲムシタビン+シスプラチン療法の有害反応解析と治療継続に関する影響因子の検討(がん薬物療法(その他),ポスター発表,一般演題,再興、再考、創ろう最高の医療の未来)
    高橋 克之, 尾上 雅英, 福土 将秀, 池見 泰明, 小林 政彦, 深津 祥央, 矢野 育子, 永山 勝也, 松原 和夫
    日本医療薬学会, 28 Aug. 2013, 日本医療薬学会年会講演要旨集, 23, 331 - 331, Japanese

  • リファンピシンの薬物相互作用に対する薬学的介入を指標とした病棟薬剤業務の質的評価
    吉田優子, 米澤淳, 河合知喜, 杉本充弘, 山際岳朗, 土生康司, 矢野育子, 松原和夫
    日本医療薬学会, 28 Aug. 2013, 日本医療薬学会年会講演要旨集, 23rd, 427 - 427, Japanese

  • 腎がん患者におけるエベロリムスの使用実態に関する調査
    NIISAKO KEIKO, YANO IKUKO, TANAKA ATSUKO, FUKUDO MASAHIDE, TSUDA MASAHIRO, KATADA YOSHIKI, NAKAISHI MAYUMI, KOBAYASHI YASUSHI, OKUBO KAZUTOSHI, KAMBA TOMOMI, YOSHIMURA KOJI, OGAWA OSAMU, MATSUBARA KAZUO
    日本医療薬学会, 28 Aug. 2013, 日本医療薬学会年会講演要旨集, 23rd, 330 - 330, Japanese

  • 電子カルテ端末から利用可能な注射薬配合変化情報検索システムの構築と評価
    佐藤 栄里子, 尾崎 淳子, 志田 あゆみ, 土生 康司, 矢野 育子, 深津 祥央, 松原 和夫
    (一社)日本医薬品情報学会, Aug. 2013, 日本医薬品情報学会総会・学術大会講演要旨集, 16回, 68 - 68, Japanese

  • 抗てんかん薬TDMガイドライン
    猪爪信夫, 今村知世, 末丸克矢, 鈴木小夜, 戸田貴大, Yano Ikuko, 湯川栄二, 中村秀文
    Apr. 2013, TDM研究, 30(2号) (2号), 53 - 108, Japanese
    [Invited]
    Introduction scientific journal

  • 抗てんかん薬クロバザムの臨床効果に対するCYP2C19遺伝子多型の重要性
    端 幸代, 柴田 茉衣, 増田 智先, 大村 友博, 松原 和夫, 木下 真幸子, 松本 理器, 池田 昭夫, 高橋 良輔, 矢野 育子
    (公社)日本薬学会, Mar. 2013, 日本薬学会年会要旨集, 133年会(4) (4), 69 - 69, Japanese
    [Refereed]

  • 病棟専任薬剤師が参画したチーム医療による持参薬管理の実践~安全性向上と業務負担軽減~
    杉本充弘, 米澤淳, 蓼原昌美, 吉田優子, 丸山志穂子, 谷口理沙, 松田裕也, 森田洋亮, 尾上雅英, 深津祥央, 矢野育子, 園田ゆい, 塚本優子, 合野由香, 佐藤晋, 平井豊博, 松原和夫
    (公社)日本薬学会, Mar. 2013, 日本薬学会年会要旨集(CD-ROM), 133rd(4) (4), ROMBUNNO.30PMF-716 - 208, Japanese

  • BLOOD CONCENTRATION MONITORING OF EVEROLIMUS IN JAPANESE PATIENTS WITH RENAL CELL CARCINOMA
    I. Yano, A. Tanaka, K. Shinsako, E. Sato, M. Fukudo, S. Masuda, K. Matsubara, T. Kamba, T. Yamasaki, O. Ogawa
    Feb. 2013, CLINICAL PHARMACOLOGY & THERAPEUTICS, 93, S114 - S115, English
    Summary international conference

  • 右股関節離断術後のプレガバリン無効の幻肢痛・幻肢覚に対してデュロキセチンが奏効した症例~がんサポートチームの介入~
    祝千佳子, 祝千佳子, 蓮池史画, 土生康司, 土生康司, 吉野秀紀, 矢野育子, 岡本健, 林晶子, 松原和夫
    2013, 日本緩和医療薬学会年会プログラム・要旨集, 7th

  • P1-018 ベルテポルフィン使用後におけるLED照射の安全性に関する検討(薬剤管理指導・病棟薬剤業務,ポスター,一般演題,岐路に立つ医療〜千年紀の目覚め〜よみがえれ!ニッポン!薬の改革は我らが手で!)
    佐藤 裕紀, 矢野 育子, 中西 晴香, 土生 康司, 祝 千佳子, 米澤 淳, 深津 祥央, 松原 和夫
    日本医療薬学会, 10 Oct. 2012, 日本医療薬学会年会講演要旨集, 22, 269 - 269, Japanese

  • 新規抗凝固薬ダビガトランの出血性副作用発現因子の探索
    KIMURA YOSHIHIKO, ONOUE MASAHIDE, KAWADA MASAYOSHI, HASHIMOTO EMINA, OGATA AKIRA, TSUDA MASAHIRO, YOSHINO HIDEKI, SAZAWA MIZUHO, MORITA YOSUKE, MASUDA SATOHIRO, YANO IKUKO, MATSUBARA KAZUO
    日本医療薬学会, 10 Oct. 2012, 日本医療薬学会年会講演要旨集, 22nd, 346 - 346, Japanese

  • 炭酸リチウム及びアデニンの投与によってクロザピン治療を継続できた治療抵抗性統合失調症の2症例
    八田 眞菜美, 諏訪 太朗, 権道 直人, 深津 祥央, 矢野 育子, 村井 俊哉, 松原 和夫
    日本臨床精神神経薬理学会・日本神経精神薬理学会, Oct. 2012, 日本臨床精神神経薬理学会・日本神経精神薬理学会合同年会プログラム・抄録集, 22回・42回, 174 - 174, Japanese

  • 慢性拒絶反応を呈した肝移植患者におけるシロリムスの臨床効果
    杉本 充弘, 増田 智先, 河合 知喜, 端 幸代, 矢野 育子, 桂 敏也, 秦 浩一郎, 岡本 晋弥, 海道 利実, 上本 伸二
    (公社)日本薬学会, Mar. 2012, 日本薬学会年会要旨集, 132年会(4) (4), 196 - 196, Japanese

  • メトホルミンのPK/PDにおけるMATEの役割
    遠山佳奈, 米澤淳, 増田智先, 矢野育子, 大澤理代, 細川雅也, 藤本新平, 稲垣暢也, 乾賢一, 桂敏也
    24 Nov. 2011, 生体膜と薬物の相互作用シンポジウム講演要旨集, 33rd, 76 - 77, Japanese

  • 難治性潰瘍性大腸炎のタクロリムス治療における大腸粘膜のMDR1発現量とCYP3A5遺伝子多型の影響
    西岡 由貴, 増田 智先, 丸山 志穂子, 河合 知喜, 端 幸代, 矢野 育子, 桂 敏也, 松浦 稔, 仲瀬 裕志, 千葉 勉
    Oct. 2011, 臨床薬理, 42(Suppl.) (Suppl.)

  • ビノレルビン/シスプラチン併用療法中の嘔吐に対するアプレピタントの効果に関する検討(一般演題(口頭)1,がん薬物療法(副作用対策)(1),Enjoy Pharmacists' Lifestyles)
    中村 光, 山田 智沙佳, 本橋 秀之, 祝 千佳子, 矢野 育子, 園部 誠, 伊達 洋至, 桂 敏也
    日本医療薬学会, 09 Sep. 2011, 日本医療薬学会年会講演要旨集, 21, 132 - 132, Japanese

  • P-0226 進行肝細胞がん患者におけるソラフェニブの服薬継続並びに有害事象発現に及ぼす影響因子の検討(一般演題 ポスター発表,がん薬物療法(外来化学療法),Enjoy Pharmacists' Lifestyles)
    下雅意 彩, 福士 将秀, 深津 祥央, 矢野 育子, 桂 敏也
    日本医療薬学会, 09 Sep. 2011, 日本医療薬学会年会講演要旨集, 21, 219 - 219, Japanese

  • P-0181 ドセタキセル、シスプラチン併用療法時の感染対策に関する調査(一般演題 ポスター発表,がん薬物療法(副作用対策),Enjoy Pharmacists' Lifestyles)
    土生 康司, 鬼塚 文子, 深津 祥央, 矢野 育子, 楯谷 一郎, 伊藤 壽一, 桂 敏也
    日本医療薬学会, 09 Sep. 2011, 日本医療薬学会年会講演要旨集, 21, 212 - 212, Japanese

  • P-0485 新規疑義照会データベースの構築とその評価(一般演題 ポスター発表,調剤・処方鑑査・リスクマネジメント,Enjoy Pharmacists' Lifestyles)
    小形 瑛, 尾上 雅英, 古俵 孝明, 佐藤 裕紀, 吉野 秀紀, 影山 由佳, 深津 祥央, 矢野 育子, 桂 敏也
    日本医療薬学会, 09 Sep. 2011, 日本医療薬学会年会講演要旨集, 21, 262 - 262, Japanese

  • P-1001 HIV感染妊婦の受け入れに対する薬剤部の取り組み(一般演題 ポスター発表,HIV,Enjoy Pharmacists' Lifestyles)
    尾崎 淳子, 山本 崇, 古俵 孝明, 上杉 美和, 矢野 育子, 桂 敏也
    日本医療薬学会, 09 Sep. 2011, 日本医療薬学会年会講演要旨集, 21, 348 - 348, Japanese

  • Association between biliary concentration of 13-O-demethylated tacrolimus and clinical course in liver transplant patients
    M. Uesugi, S. Masuda, M. Hosokawa, H. Shinke, T. Kawai, Yano, I, K. Hata, Y. Ogura, T. Kaido, S. Uemoto
    Aug. 2011, THERAPEUTIC DRUG MONITORING, 33(4) (4), 494 - 495, English
    Summary international conference

  • Significance of trough monitoring of tacrolimus blood concentration and calcineurin activity in living-donor liver transplant patients
    Yano, I, S. Masuda, H. Egawa, Y. Sugimoto, M. Fukudo, Y. Yoshida, S. Yasuda, T. Kaido, S. Uemoto, K. Inui
    Aug. 2011, THERAPEUTIC DRUG MONITORING, 33(4) (4), 529 - 530, English
    Summary international conference

  • タクロリムス血中濃度管理における脳死全肝移植と生体肝移植との比較
    河合 知喜, 増田 智先, 西岡 由貴, 端 幸代, 杉本 充弘, 矢野 育子, 桂 敏也, 秦 浩一郎, 小倉 靖弘, 海道 利実, 上本 伸二
    (一社)日本TDM学会, Jun. 2011, TDM研究, 28(3) (3), s182 - s182, Japanese

  • 薬学6年制における病院実務実習の評価:学生に対するアンケート調査及び実習記録から
    細川実緒, 矢野育子, 土生康司, 深津祥央, 小林政彦, 山田和司, 増田智先, 桂敏也
    2011, 医療薬学フォーラム講演要旨集, 19th

  • H+/有機カチオンアンチポータMATEの遺伝子多型によるメトホルミンの体内動態変化
    TOOYAMA KANA, YONEZAWA ATSUSHI, TSUDA MASAHIRO, MASUDA SATOHIRO, YANO IKUKO, OSAWA RIYO, HOSOKAWA MASAYA, FUJIMOTO SHIMPEI, INAGAKI NOBUYA, KATSURA TOSHIYA, INUI KEN'ICHI
    10 Nov. 2010, 臨床薬理, 41(Supplement) (Supplement), S204, Japanese

  • 生体肝移植患者の術後経過に及ぼす遺伝的背景の影響
    河合知喜, 増田智先, 米澤淳, 杉本充弘, 深津祥央, 矢野育子, 桂敏也, 秦浩一郎, 小倉靖弘, 海道利実, 上本伸二
    (一社)日本臨床薬理学会, Nov. 2010, 臨床薬理, 41(Suppl.) (Suppl.), S312 - S312, Japanese

  • 生体肝移植後のタクロリムス関連腎障害の発症におけるCYP3A5遺伝子多型の影響
    上杉美和, 増田智先, 米澤淳, 杉本充弘, 深津祥央, 矢野育子, 桂敏也, 秦浩一郎, 小倉靖弘, 海道利実, 上本伸二
    (一社)日本臨床薬理学会, Nov. 2010, 臨床薬理, 41(Suppl.) (Suppl.), S205 - S205, Japanese

  • P2-583 薬学実務実習における調剤室の取り組みとその評価(一般演題 ポスター発表,薬学教育(実務実習),臨床から学び臨床へと還元する医療薬学)
    河崎 育代, 古俵 孝明, 尾崎 淳子, 丸山 志穂子, 橋田 妙子, 佐藤 麻由子, 河合 知喜, 蓼原 昌美, 中野 典昭, 影山 由佳, 矢野 育子, 桂 敏也
    日本医療薬学会, 25 Oct. 2010, 日本医療薬学会年会講演要旨集, 20, 487 - 487, Japanese

  • O8-04 パクリタキセル・カルボプラチン併用療法の副作用発現に関連する因子の検討(一般演題 口頭発表,がん薬物療法(副作用対策),臨床から学び臨床へと還元する医療薬学)
    土生 康司, 木村 嘉彦, 矢野 育子, 桂 敏也, 乾 賢一
    日本医療薬学会, 25 Oct. 2010, 日本医療薬学会年会講演要旨集, 20, 273 - 273, Japanese

  • P1-170 進行非小細胞肺がんに対するエルロチニブの肝障害発症に関する検討(一般演題 ポスター発表,有害事象・副作用,臨床から学び臨床へと還元する医療薬学)
    祝 千佳子, 矢野 育子, 宮原 亮, 伊達 洋至, 桂 敏也
    日本医療薬学会, 25 Oct. 2010, 日本医療薬学会年会講演要旨集, 20, 315 - 315, Japanese

  • P2-357 質量分析法を用いた経口チロシンキナーゼ阻害薬6種の一斉定量法の確立(一般演題 ポスター発表,癌薬物療法(その他),臨床から学び臨床へと還元する医療薬学)
    水野 知行, 増田 智先, 石橋 直哉, 福土 将秀, 矢野 育子, 桂 敏也
    日本医療薬学会, 25 Oct. 2010, 日本医療薬学会年会講演要旨集, 20, 449 - 449, Japanese

  • P1-032 NICUにおける薬剤師の新しい業務展開とその評価(一般演題 ポスター発表,薬剤管理指導・情報提供,臨床から学び臨床へと還元する医療薬学)
    田上 裕美, 池見 泰明, 深津 祥央, 矢野 育子, 河井 昌彦, 桂 敏也, 乾 賢一
    日本医療薬学会, 25 Oct. 2010, 日本医療薬学会年会講演要旨集, 20, 292 - 292, Japanese

  • ワルファリン服用患者においてオキシコドン併用がプロトロンビン時間に及ぼす影響
    土生康司, 細川実緒, 深津祥央, 矢野育子, 岸本寛史, 桂敏也
    2010, 日本緩和医療薬学会年会プログラム・要旨集, 4th

  • 免疫抑制薬とアゾール系抗真菌薬の薬物動態学的相互作用
    Yano Ikuko, 乾賢一
    Dec. 2009, 治療学, 43(12号) (12号), 1351 - 1355, Japanese
    [Invited]
    Introduction scientific journal

  • 小細胞肺がん治療におけるシスプラチンとカルボプラチンの副作用比較及びその危険因子の抽出
    KITAMURA MIHO, KITAMURA MIHO, IKEMI YASUAKI, YANO IKUKO, NAKATA TETSUO, MIO TADASHI, KANENAGA MANABU, MISHIMA MICHIAKI, INUI KEN'ICHI
    Jul. 2009, 医療薬学フォーラム講演要旨集, 17th, 212, Japanese

  • 脳神経外科大量化学療法レジメンにおける薬剤師の関わり
    石橋直哉, 古俵孝明, 山際岳朗, 小林政彦, 荒川芳輝, 西村真樹, 岸陽, 三國信啓, 矢野育子, 乾賢一
    Jul. 2009, 医療薬学フォーラム講演要旨集, 17th, 222, Japanese

  • 腎排泄型カチオン性薬物メトホルミンのクリアランス予測因子の探索
    遠山佳奈, 米澤淳, 増田智先, 矢野育子, 大澤理代, 木村尚子, 谷原悠子, 桂敏也, 細川雅也, 藤本新平, 稲垣暢也, 乾賢一
    (公社)日本薬剤学会, 30 Apr. 2009, 薬剤学, 69(Supplement) (Supplement), 111 - 111, Japanese

  • イトラコナゾール内用液の小児患者における有用性に関する検討
    甲野 貴久, 田上 裕美, 増田 智先, 矢野 育子, 桂 敏也, 加藤 格, 松原 央, 渡邉 健一郎, 足立 壮一, 中畑 龍俊, 乾 賢一
    (公社)日本薬学会, Mar. 2009, 日本薬学会年会要旨集, 129年会(4) (4), 206 - 206, Japanese

  • 免疫抑制剤の体内動態と薬効の速度論的解析に基づく個別化投与設計システムの開発
    Yano Ikuko
    Dec. 2008, 上原記念生命科学財団研究報告集, 22, 1 - 4, Japanese
    [Invited]
    Introduction scientific journal

  • 癌化学療法における骨髄抑制作用の経時的変化に関する速度論的解析
    矢野 義孝, 古俵 孝明, 本郷 春幸, 矢野 育子, 岸 陽, 高橋 潤, 乾 賢一
    (一社)日本臨床薬理学会, Nov. 2008, 臨床薬理, 39(Suppl.) (Suppl.), S189 - S189, Japanese

  • 21-P1-042 注射薬調剤における疑義照会データベースの構築と照会内容の解析(データベース,来るべき時代への道を拓く)
    松田 裕也, 古俵 孝明, 池見 泰明, 内堀 聡子, 土生 康司, 長谷川 真理, 尾上 雅英, 高橋 一栄, 寺田 智祐, 矢野 育子, 乾 賢一
    日本医療薬学会, 01 Sep. 2008, 日本医療薬学会年会講演要旨集, 18, 381 - 381, Japanese

  • 20H-05 病院実習における9年間のアンケート結果からみた治験教育の状況と今後の課題(薬学教育(モデル・コアカリキュラム)・卒後研修・研修制度,来るべき時代への道を拓く)
    猪熊 容子, 老本 名津子, 泉福 愛美, 松山 倫子, 志田 あゆみ, 佐藤 栄里子, 橋田 妙子, 松井 あや, 石塚 良子, 矢野 育子, 乾 賢一
    日本医療薬学会, 01 Sep. 2008, 日本医療薬学会年会講演要旨集, 18, 258 - 258, Japanese

  • 20-P1-010 調剤業務と薬剤管理指導業務における薬学的介入の比較(調剤・処方鑑査(内用薬),来るべき時代への道を拓く)
    新迫 恵子, 若杉 博子, 河崎 育代, 安田 幸代, 平塚 理恵, 足達 尚美, 矢野 育子, 乾 賢一
    日本医療薬学会, 01 Sep. 2008, 日本医療薬学会年会講演要旨集, 18, 284 - 284, Japanese

  • 20-P2-260 腎機能低下時の大腸がん患者に対するOxaliplatinの使用調査(がん薬物療法(その他),来るべき時代への道を拓く)
    福本 郁子, 寺田 智祐, 橋田 亨, 矢野 育子, 乾 賢一
    日本医療薬学会, 01 Sep. 2008, 日本医療薬学会年会講演要旨集, 18, 326 - 326, Japanese

  • 21-P2-213 進行膵がんに対するTS-1とGemcitabine併用療法時の骨髄抑制に関する調査(がん薬物療法(外来化学療法),来るべき時代への道を拓く)
    祝 千佳子, 小林 政彦, 寺田 智祐, 矢野 育子, 金井 雅史, 西村 貴文, 松本 繁己, 柳原 一広, 福島 雅典, 乾 賢一
    日本医療薬学会, 01 Sep. 2008, 日本医療薬学会年会講演要旨集, 18, 410 - 410, Japanese

  • 温度変化に対するビンカアルカロイド系抗がん剤の物理化学的特性の検討
    KOJIMA KAZUAKI, TERADA TOMOHIRO, TSUDA MASAHIRO, HASHIDA TOORU, YANO IKUKO, INUI KEN'ICHI
    日本医療薬学会, 01 Sep. 2008, 日本医療薬学会年会講演要旨集, 18th, 250 - 250, Japanese

  • 脳神経外科病棟でのテモゾロミド・放射線併用療法における薬剤師の関わり
    山際岳朗, 古俵孝明, 矢野育子, 荒川芳輝, 西村真樹, 岸陽, 三國信啓, 乾賢一
    日本医療薬学会, 01 Sep. 2008, 日本医療薬学会年会講演要旨集, 18th, 423 - 423, Japanese

  • カルシニューリン阻害剤の体内動態と薬効の速度論的解析に基づく個別化投与設計法
    Yano Ikuko, 福士将秀, 増田智先, 小倉靖弘, 尾池文隆, 田中紘一, 乾賢一
    Jul. 2008, 臨床薬理の進歩, (29号) (29号), 113 - 119, Japanese
    [Invited]
    Introduction scientific journal

  • 成人肝移植患者におけるジピリダモール、アシクロビル、ST合剤の予防的投与に関する検討
    志水陽一, 杉本充弘, 矢野育子, 橋田 亨, 江川裕人, 上本伸二, 乾 賢一
    Mar. 2008, 第128回日本薬学会
    Summary national conference

  • タクロリムス血中濃度の調整メカニズム
    Yano Ikuko, 乾賢一
    Jan. 2008, 今日の移植, 21(1号) (1号), 17 - 23, Japanese
    [Invited]
    Introduction scientific journal

  • これからの臨床薬剤師のあり方 薬剤師が変える薬物治療
    Yano Ikuko
    Dec. 2007, 日本医療薬学会会報, 11(4号) (4号), 24 - 29, Japanese
    [Invited]
    Report scientific journal

  • P2-62 Pharmacokinetic analysis of antiepileptic drug clobazam and its active metabolite(The 41^ Congress of the Japan Epilepsy Society)
    安田 幸代, 北村 朋子, 矢野 育子, 橋田 亨, 木下 真幸子, 池田 昭夫, 高橋 良輔, 乾 賢一
    Japan Epilepsy Society, 30 Sep. 2007, Journal of the Japan Epilepsy Society, 25(3) (3), 377 - 377, Japanese

  • 29-S4-3 臓器移植に生かす免疫抑制剤のPK/PD(シンポジウム29-S4 一歩進んだ「がん薬物業務」,社会の期待に応える医療薬学を)
    矢野 育子, 乾 賢一
    日本医療薬学会, 01 Sep. 2007, 日本医療薬学会年会講演要旨集, 17, 152 - 152, Japanese

  • 30-C1-09-2 小児脳腫瘍患者のコンプライアンス向上を目指したテモゾロミドの投与方法に関する検討(がん薬物療法,社会の期待に応える医療薬学を)
    水野 知行, 古俵 孝明, 田上 裕美, 橋田 亨, 矢野 育子, 乾 賢一
    日本医療薬学会, 01 Sep. 2007, 日本医療薬学会年会講演要旨集, 17, 211 - 211, Japanese

  • 29-C1-14-1 外来患者に対する安全ながん薬物療法に向けたTS-1服薬指導の取り組み(がん薬物療法,社会の期待に応える医療薬学を)
    田上 裕美, 祝 千佳子, 家永 嘉子, 慈幸 麻里, 小林 政彦, 高橋 一栄, 寺田 智祐, 橋田 亨, 矢野 育子, 乾 賢一
    日本医療薬学会, 01 Sep. 2007, 日本医療薬学会年会講演要旨集, 17, 197 - 197, Japanese

  • 29-B4-13-5 がん化学療法における医療経済学的視点に基づく薬剤使用評価(がん薬物療法,社会の期待に応える医療薬学を)
    池見 泰明, 橋田 亨, 深津 祥央, 矢野 育子, 石津 雅弘, 桂 敏也, 乾 賢一
    日本医療薬学会, 01 Sep. 2007, 日本医療薬学会年会講演要旨集, 17, 195 - 195, Japanese

  • 【薬学的視点から薬をみる力 薬物動態パラメータをどう読むか?】 薬物動態パラメータを活用した臨床事例 カルシニューリン阻害剤について
    Yano Ikuko, 乾賢一
    じほう, Sep. 2007, 薬事, 49(9号) (9号), 1359 - 1364, Japanese
    Introduction commerce magazine

  • Intestinal CYP3A5 genotype and MDR1 expression influence apparent clearance of tacrolimus in adult living-donor liver transplant recipients
    Masahide Fukudo, Atsushi Yoshimura, Ikuko Yano, Satohiro Masuda, Miwa Uesugi, Keiko Hosohata, Toshiya Katsura, Yasutsugu Takada, Shinji Uemoto, Ken-ichi Inui
    Aug. 2007, THERAPEUTIC DRUG MONITORING, 29(4) (4), 484 - 484, English
    Summary international conference

  • Neoral once daily dosing utilizing trough and C2 monitoring in de novo living donor liver transplant recipients.
    Yasuhiro Ogura, Fumitaka Oike, Yasutsugu Takada, Koichi Tanaka, Satohiro Masuda, Ikuko Yano, Ken-ichi Inui, Shinji Uemoto
    May 2007, AMERICAN JOURNAL OF TRANSPLANTATION, 7, 551 - 551, English
    Summary international conference

  • 電子カルテを活用したオピオイド鎮痛薬に関する薬剤管理指導の標準化
    土生 康司, 野田 晋司, 橋田 亨, 矢野 育子, 桂 敏也, 乾 賢一
    (公社)日本薬学会, Mar. 2007, 日本薬学会年会要旨集, 127年会(3) (3), 199 - 199, Japanese

  • 外来がん化学療法における性差に基づく副作用解析
    赤澤 麻衣子, 橋田 亨, 寺田 智祐, 矢野 育子, 桂 敏也, 手良向 聡, 松本 繁巳, 柳原 一広, 福島 雅典, 乾 賢一
    (公社)日本薬学会, Mar. 2007, 日本薬学会年会要旨集, 127年会(3) (3), 189 - 189, Japanese

  • P-134 ゲフィチニブの臨床効果と副作用の背景因子に関する解析(分子標的治療2, 第47回日本肺癌学会総会)
    祝 千佳子, 田中 文啓, 矢野 育子, 桂 敏也, 園部 誠, 阪井 宏彰, 宮原 亮, 板東 徹, 和田 洋巳, 乾 賢一
    日本肺癌学会, 05 Nov. 2006, 肺癌, 46(5) (5), 559 - 559, Japanese

  • 【Ciclosporin Pharmaco-Clinical Forum 2006】 TDMによる臨床成績向上への更なる挑戦 カルシニューリン阻害剤のpharmacodynamicsと至適投与設計
    福土将秀, Yano Ikuko, 増田智先, 桂敏也, 小倉靖弘, 尾池文隆, 高田泰次, 上本伸二, 田中紘一, 乾賢一
    Nov. 2006, 今日の移植, 19(6号) (6号), 658 - 660, Japanese
    [Invited]
    Introduction commerce magazine

  • 01-H-08 mTOR阻害薬をシロリムスからエベロリムスに変更した膵島移植患者における血中濃度モニタリング(薬物動態(TDM・投与設計等),医療薬学の扉は開かれた)
    佐藤 栄里子, 下村 昌寛, 増田 智先, 矢野 育子, 桂 敏也, 興津 輝, 岩永 康裕, 松本 慎一
    日本医療薬学会, 01 Sep. 2006, 日本医療薬学会年会講演要旨集, 16, 347 - 347, Japanese

  • 30P2-150 膵島移植患者におけるミコフェノール酸の薬物動態学/薬力学的解析(薬物動態(TDM・投与設計等),医療薬学の扉は開かれた)
    古俵 孝明, 田中 健太, 増田 智先, 矢野 育子, 興津 輝, 岩永 康裕, 松本 慎一, 乾 賢一
    日本医療薬学会, 01 Sep. 2006, 日本医療薬学会年会講演要旨集, 16, 429 - 429, Japanese

  • 01P1-109 手術前の適切な休薬期間設定への取り組み(医薬品適正使用,医療薬学の扉は開かれた)
    尾上 雅英, 谿 有紀, 寺田 智祐, 橋田 亨, 矢野 育子, 乾 賢一
    日本医療薬学会, 01 Sep. 2006, 日本医療薬学会年会講演要旨集, 16, 506 - 506, Japanese

  • Prescription survey of schizophrenia in the psychiatric outpatient unit of a university hospital (I): comparison between prescriptions before and after the introduction of novel antipsychotics
    Mika Takeda, Takashi Okada, Masahiko Kobayashi, Ikuyo Kawasaki, Yoshihisa Awano, Hiroko Wakasugi, Akihiro Ono, Ikuko Yano, Takuji Hayashi, Ken'ichi Inui
    Jul. 2006, INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 21(4) (4), A25 - A26, English
    [Refereed]
    Summary international conference

  • Major factors inhibiting spread of novel antipsychotic monotherapy for schizophrenia: prescription survey in the psychiatric outpatient unit of Kyoto University Hospital
    Takashi Okada, Mika Takeda, Masahiko Kobayashi, Ikuyo Kawasaki, Yoshihisa Awano, Hiroko Wakasugi, Akihiro Ono, Ikuko Yano, Ken'ichi Inui, Takuji Hayashi
    Jul. 2006, INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 21(4) (4), A11 - A11, English
    [Refereed]
    Summary international conference

  • 【薬剤師による臨床研究の進め方 日常業務から医療薬学研究のシーズを育てる】 臨床研究の実例と進め方のポイント 緑内障治療薬アセタゾラミドの体内動態と薬効の速度論的解析 着眼点と進め方のポイント
    Yano Ikuko
    じほう, Jul. 2006, 薬事, 48(8号) (8号), 1289 - 1293, Japanese
    [Invited]
    Introduction commerce magazine

  • Improved cyclosporine absorption and immunosuppression by a once daily dosing in living-donor liver transplant patients.
    Yano, I, M Fukudo, S Masuda, T Katsura, Y Ogura, F Oike, Y Takada, K Tanaka, K Inui
    May 2006, LIVER TRANSPLANTATION, 12(5) (5), C5 - C5, English
    Summary international conference

  • 膵島移植患者におけるラパマイシンの体内動態と薬効・副作用に関する検討
    佐藤 栄里子, 下村 昌寛, 増田 智先, 矢野 育子, 土生 康司, 桂 敏也, 松本 慎一, 興津 輝, 岩永 康裕, 野口 洋文, 永田 英生, 米川 幸秀, 田中 紘一, 乾 賢一
    (一社)日本TDM学会, Apr. 2006, TDM研究, 23(2) (2), 85 - 86, Japanese

  • 小児造血幹細胞移植におけるシクロスポリン間歇点滴法の血中濃度モニタリング
    澤田 京子, 小谷 敦子, 増田 智先, 桂 敏也, 矢野 育子, 松原 央, 平松 英文, 小林 道弘, 足立 壯一, 中畑 龍俊, 乾 賢一
    (一社)日本TDM学会, Apr. 2006, TDM研究, 23(2) (2), 87 - 88, Japanese

  • 薬剤師が変える薬物治療 生体肝移植症例におけるカルシニューリン活性の測定に基づく薬効評価と個別化投与設計
    Yano Ikuko, 乾賢一
    じほう, Feb. 2006, 薬事, 48(2号) (2号), 269 - 275, Japanese
    [Invited]
    Introduction commerce magazine

  • 平成17年度日本薬物動態学会奨励賞を受賞して
    矢野 育子
    27 Dec. 2005, Drug metabolism and pharmacokinetics, 20(6) (6), 1 - 2, Japanese

  • 【CPCF2005】 肝臓移植患者の小腸・肝組織を用いた遺伝子解析に基づく免疫抑制剤の投与設計
    増田智先, 上杉美和, Yano Ikuko, 尾池文隆, 高田泰次, 乾賢一
    Nov. 2005, 今日の移植, 18(6号) (6号), 721 - 724, Japanese
    [Invited]
    Introduction commerce magazine

  • 薬物血中濃度モニタリングの現状と課題 免疫抑制剤の適正使用
    Yano Ikuko
    Oct. 2005, Drug Metabolism and Pharmacokinetics, 20(5号) (5号), 25 - 28, Japanese
    [Invited]
    Introduction scientific journal

  • P-643 バンコマイシンの目標血中濃度と副作用発現に関する検討 : ICTとの連携による取り組み(9.薬物動態(TDM・投与設計等)3,医療薬学の未来へ翔(はばた)く-薬剤師の薬剤業務・教育・研究への能動的関わり-)
    三宅 麻文, 澤田 京子, 古俵 孝明, 増田 智先, 矢野 育子, 高倉 俊二, 飯沼 由嗣, 一山 智, 乾 賢一
    日本医療薬学会, 01 Sep. 2005, 日本医療薬学会年会講演要旨集, 15, 389 - 389, Japanese

  • P-618 薬剤溶出ステント留置患者における抗血小板薬の適正使用について(8.有害事象・副作用(基礎と臨床)1,医療薬学の未来へ翔(はばた)く-薬剤師の薬剤業務・教育・研究への能動的関わり-)
    大谷 佳代子, 伊田 厚輝, 河崎 育代, 平塚 理恵, 若杉 博子, 矢野 育子, 木村 剛, 乾 賢一
    日本医療薬学会, 01 Sep. 2005, 日本医療薬学会年会講演要旨集, 15, 383 - 383, Japanese

  • P-161 京大病院薬剤部における膵島移植に対する取り組み(6.服薬指導(入院・外来)3,医療薬学の未来へ翔(はばた)く-薬剤師の薬剤業務・教育・研究への能動的関わり-)
    大澤 理代, 佐藤 栄里子, 増田 智先, 若杉 博子, 矢野 育子, 松本 慎一, 福田 一仁, 山田 祐一郎, 稲垣 暢也, 乾 賢一
    日本医療薬学会, 01 Sep. 2005, 日本医療薬学会年会講演要旨集, 15, 269 - 269, Japanese

  • P-465 癌化学療法の質的向上を目指した薬剤師の取り組み : 副作用結果に基づく危険因子の解析(2.癌薬物療法(外来化学療法、緩和ケア等)7,医療薬学の未来へ翔(はばた)く-薬剤師の薬剤業務・教育・研究への能動的関わり-)
    古俵 孝明, 高柳 和伸, 矢野 育子, 桂 敏也, 片岡 大治, 北条 雅人, 高木 康志, 高橋 潤, 橋本 信夫, 乾 賢一
    日本医療薬学会, 01 Sep. 2005, 日本医療薬学会年会講演要旨集, 15, 345 - 345, Japanese

  • P-461 外来化学療法におけるレジメン登録と注射オーダー支援機能の導入(2.癌薬物療法(外来化学療法、緩和ケア等)7,医療薬学の未来へ翔(はばた)く-薬剤師の薬剤業務・教育・研究への能動的関わり-)
    老本名 津子, 橋田 亨, 慈幸 麻里, 谷口 理沙, 家永 嘉子, 赤澤 麻衣子, 長谷川 真理, 田上 裕美, 上井 優一, 矢野 育子, 柳原 一広, 福島 雅典, 乾 賢一
    日本医療薬学会, 01 Sep. 2005, 日本医療薬学会年会講演要旨集, 15, 344 - 344, Japanese

  • P-558 ゲフィチニブ内服患者に対する服薬指導と副作用モニタリング(6.服薬指導(入院・外来)5,医療薬学の未来へ翔(はばた)く-薬剤師の薬剤業務・教育・研究への能動的関わり-)
    祝 千佳子, 矢野 育子, 桂 敏也, 園部 誠, 田中 文啓, 和田 洋巳, 乾 賢一
    日本医療薬学会, 01 Sep. 2005, 日本医療薬学会年会講演要旨集, 15, 368 - 368, Japanese

  • SP11-1 膵島移植患者における免疫抑制剤のTDM(SP11「移植医療とTDM」,医療薬学の未来へ翔(はばた)く-薬剤師の薬剤業務・教育・研究への能動的関わり-)
    増田 智先, 矢野 育子, 乾 賢一
    日本医療薬学会, 01 Sep. 2005, 日本医療薬学会年会講演要旨集, 15, 199 - 199, Japanese

  • rOCT2(Slc22a2)に焦点を合わせたシスプラチンの腎毒性(Nephrotoxicity of cisplatin focusing on rOCT2 (Slc22a2))
    米澤 淳, 増田 智先, 西原 久美子, 矢野 育子, 桂 敏也, 乾 賢一
    (一社)日本腎臓学会, May 2005, 日本腎臓学会誌, 47(3) (3), 298 - 298, English

  • 泌尿器系癌患者におけるパクリタキセルの体内動態と薬効・副作用に関する解析
    慈幸 麻里, 矢野 育子, 高橋 一栄, 本橋 秀之, 増田 智先, 奥田 真弘, 伊藤 哲之, 木下 秀文, 山本 新吾, 賀本 敏行, 小川 修, 乾 賢一
    (一社)日本TDM学会, Apr. 2005, TDM研究, 22(2) (2), 105 - 106, Japanese

  • 前立腺癌患者におけるカルボプラチン体内動態と副作用の解析
    佐藤 栄里子, 矢野 育子, 慈幸 麻里, 高橋 一栄, 本橋 秀之, 増田 智先, 伊藤 哲之, 山本 新吾, 賀本 敏行, 小川 修, 乾 賢一
    (公社)日本薬学会, Mar. 2005, 日本薬学会年会要旨集, 125年会(2) (2), 180 - 180, Japanese

  • 新規抗精神病薬の普及と単剤化を阻害する要因 大学病院精神科外来における処方調査から
    武田 光加, 小林 政彦, 河崎 育代, 淡野 芳久, 若杉 博子, 大野 明洋, 矢野 育子, 岡田 俊, 林 拓二, 乾 賢一
    (公社)日本薬学会, Mar. 2005, 日本薬学会年会要旨集, 125年会(2) (2), 214 - 214, Japanese

  • Yano Ikuko, 乾賢一
    The Japanese Society of Clinical Pharmacology and Therapeutics, Mar. 2005, 臨床薬理, 36(2号) (2号), 58 - 62, Japanese
    [Invited]
    Introduction scientific journal

  • 【臨床に活かすPK/PD 薬物の体内動態と薬効・毒性】 免疫抑制剤のPK/PD
    Yano Ikuko, 乾賢一
    医薬ジャ-ナル社, Jan. 2005, 医薬ジャーナル, 41(1号) (1号), 75 - 80, Japanese
    [Invited]
    Introduction commerce magazine

  • カルシニューリン阻害剤の薬効測定に基づく個別化投与設計
    Yano Ikuko, 福土将秀, 増田智先, 深津祥央, 奥田真弘, 小倉靖弘, 高田泰次, 田中紘一, 乾賢一
    Nov. 2004, 今日の移植, 17(6号) (6号), 801 - 803, Japanese
    [Invited]
    Introduction commerce magazine

  • 【Q and Aで学ぶTDM活用ガイド】 TDM 実践Q and A 免疫抑制剤 免疫抑制剤のTDMを実施することによってどのようなメリットがあるのでしょうか?
    Yano Ikuko, 乾賢一
    Oct. 2004, 薬局, 55(10月臨増) (10月臨増), 173 - 175, Japanese
    [Invited]
    Introduction commerce magazine

  • 【Q and Aで学ぶTDM活用ガイド】 TDM 実践Q and A 免疫抑制剤 今まではシクロスポリンはトラフ値を測定していましたが,最近ピーク値も有用になってきたと聞きました.これについて教えてください
    Yano Ikuko, 乾賢一
    Oct. 2004, 薬局, 55(10月臨増) (10月臨増), 184 - 185, Japanese
    [Invited]
    Introduction commerce magazine

  • 【Q and Aで学ぶTDM活用ガイド】 TDM 実践Q and A 免疫抑制剤 シクロスポリンの有効治療域は疾患によって異なるのでしょうか?
    Yano Ikuko, 乾賢一
    Oct. 2004, 薬局, 55(10月臨増) (10月臨増), 186 - 187, Japanese
    [Invited]
    Introduction commerce magazine

  • 【Q and Aで学ぶTDM活用ガイド】 TDM 実践Q and A 遺伝子情報をTDMに活かすことはできますか?また逆にTDMで得られた情報を遺伝子多型に活かすことはできますか?
    Yano Ikuko, 乾賢一
    Oct. 2004, 薬局, 55(10月臨増) (10月臨増), 291 - 292, Japanese
    [Invited]
    Introduction commerce magazine

  • S7-4 生体腎移植患者におけるカルシニューリン阻害剤の体内動態と薬効の解析(一般講演,薬物治療に薬物動態情報を活かすには,(7)薬物動態情報の活用1:PK/PD,2.最近研究情報の現状と適用,"薬剤師がつくる薬物治療"-薬・薬・学の連携-)
    福土 将秀, 矢野 育子, 高橋 一栄, 本橋 秀之, 増田 智先, 奥田 真弘, 伊藤 哲之, 山本 新吾, 賀本 敏行, 小川 修, 乾 賢一
    日本医療薬学会, 01 Sep. 2004, 日本医療薬学会年会講演要旨集, 14, 161 - 161, Japanese

  • P-13 パクリタキセルとカルボプラチンの少量分割投与による骨髄抑制の軽減 : 非小細胞肺癌を中心として(1.薬物療法(基礎と臨床),"薬剤師がつくる薬物治療"-薬・薬・学の連携-)
    祝 千佳子, 橋田 亨, 矢野 育子, 柳原 一広, 田中 文啓, 和田 洋巳, 乾 賢一
    日本医療薬学会, 01 Sep. 2004, 日本医療薬学会年会講演要旨集, 14, 220 - 220, Japanese

  • P-212 京大病院における外来化学療法レジメンの登録とその評価(14.調剤・処方管理・オーダリング(注射剤含む),"薬剤師がつくる薬物治療"-薬・薬・学の連携-)
    赤澤 麻衣子, 橋田 亨, 家永 嘉子, 大谷 佳代子, 上井 優一, 長谷川 真理, 大塚 哉, 田上 裕美, 矢野 育子, 福島 雅典, 乾 賢一
    日本医療薬学会, 01 Sep. 2004, 日本医療薬学会年会講演要旨集, 14, 269 - 269, Japanese

  • P-107 開心術後肺高血圧症に対する経口シルデナフィル使用の薬学的検討(5.薬剤服用歴管理・服薬指導(入院患者服薬指導),"薬剤師がつくる薬物治療"-薬・薬・学の連携-)
    横山 純子, 高柳 和伸, 若杉 博子, 矢野 育子, 梅原 英太郎, 根本 慎太郎, 池田 義, 米田 正始, 乾 賢一
    日本医療薬学会, 01 Sep. 2004, 日本医療薬学会年会講演要旨集, 14, 243 - 243, Japanese

  • 【移植医療】 臓器移植に活かす薬剤師の専門性
    Yano Ikuko, 乾賢一
    じほう, Sep. 2004, 薬事, 46(10号) (10号), 1745 - 1749, Japanese
    [Invited]
    Introduction commerce magazine

  • 福土 将秀, 矢野 育子, 深津 祥央, 増田 智先, 奥田 真弘, 高田 泰次, 田中 紘一, 乾 賢一
    一般社団法人 日本臨床薬理学会, 31 Jan. 2004, 臨床薬理 = JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 35(1) (1), 86S, Japanese

  • 臨床薬剤業務と連携した薬物動態と薬効の母集団解析
    Yano Ikuko
    Jan. 2004, 薬剤学: 生命とくすり, 64(1号) (1号), 32 - 35, Japanese
    [Invited]
    Introduction scientific journal

  • 28-02-15 高カロリー輸液 (TPN) の無菌調製完全実施と適応に関する検討
    家永 嘉子, 橋田 亨, 小林 政彦, 大塚 哉, 上井 優一, 矢野 育子, 石津 雅弘, 乾 賢一
    日本医療薬学会, 01 Sep. 2003, 日本医療薬学会年会講演要旨集, 13, 146 - 146, Japanese

  • 27-03-02 3 年次学生を対象とした医療薬学実習(1 ヶ月)の取り組みとその評価
    矢野 育子, 若杉 博子, 高柳 和伸, 深津 祥央, 大野 明洋, 石津 雅弘, 奥田 真弘, 乾 賢一
    日本医療薬学会, 01 Sep. 2003, 日本医療薬学会年会講演要旨集, 13, 135 - 135, Japanese

  • ランソプラゾール併用がタクロリムス血中濃度に影響したと考えられた症例
    米澤 淳, 高橋 一栄, 本橋 秀之, 矢野 育子, 奥田 真弘, 吉田 浩士, 伊藤 哲之, 山本 新吾, 小川 修, 乾 賢一
    (公社)日本薬学会, Mar. 2003, 日本薬学会年会要旨集, 123年会(4) (4), 179 - 179, Japanese

  • 【女性診療科医のための薬物療法マニュアル】 薬物動態を考慮した処方計画
    Yano Ikuko, 乾賢一
    Mar. 2003, 産婦人科治療, 86(増刊) (増刊), 377 - 384, Japanese
    [Invited]
    Introduction commerce magazine

  • 福土 将秀, 矢野 育子, 新迫 恵子, 齋藤 秀之, 木内 哲也, 田中 紘一, 乾 賢一
    The Japanese Society of Clinical Pharmacology and Therapeutics, 31 Jan. 2003, 臨床薬理, 34(1) (1), 25S - 26S, Japanese

  • P-335 生体肝移植後に発生した全身性皮膚掻痒感に対する薬剤管理指導
    倉本 健史, 増田 智先, 新迫 恵子, 矢野 育子, 木内 哲也, 田中 紘一, 乾 賢一
    日本医療薬学会, 24 Sep. 2002, 日本医療薬学会年会講演要旨集, 12, 228 - 228, Japanese

  • P-302 薬剤管理指導における医薬品情報のニーズと提供内容の解析
    若杉 博子, 高橋 一栄, 中桐 真樹子, 石井 淳子, 金子 育代, 矢野 育子, 乾 賢一
    日本医療薬学会, 24 Sep. 2002, 日本医療薬学会年会講演要旨集, 12, 220 - 220, Japanese

  • P-408 シクロスポリンとプロブコールの相互作用機序に関する検討
    慈幸 麻里, 矢野 育子, 若杉 博子, 齋藤 秀之, 乾 賢一
    日本医療薬学会, 24 Sep. 2002, 日本医療薬学会年会講演要旨集, 12, 246 - 246, Japanese

  • P-275 抗悪性腫瘍剤無菌調製のシステム化
    奥山 雅子, 小林 政彦, 大塚 哉, 尾崎 淳子, 橋田 亨, 高柳 和伸, 矢野 育子, 乾 賢一
    日本医療薬学会, 24 Sep. 2002, 日本医療薬学会年会講演要旨集, 12, 213 - 213, Japanese

  • グレパフロキサシンのバイオアベイラビリティにおける P-糖蛋白質の役割
    山口 浩明, 矢野 育子, 斉藤 秀之, 乾 賢一
    05 Mar. 2002, 薬剤学, 62, 104 - 104, Japanese

  • 高尿酸血症モデルラットにおける腎尿細管薬物輸送活性と有機イオントランスポーターの発現量変動
    土生 康司, 矢野 育子, 竹内 綾子, 齋藤 秀之, 乾 賢一
    (公社)日本薬学会, Mar. 2002, 日本薬学会年会要旨集, 122年会(4) (4), 57 - 57, Japanese

  • 福土 将秀, 矢野 育子, 深津 祥央, 斎藤 秀之, 乾 賢一, 上本 仲二, 木内 哲也, 田中 紘一
    The Japanese Society of Clinical Pharmacology and Therapeutics, 31 Jan. 2002, 臨床薬理, 33(1) (1), 127S - 128S, Japanese

  • キノロン系抗菌薬の消化管分泌に及ぼす腎障害の影響
    山口 浩明, 矢野 育子, 齋藤 秀之, 乾 賢一
    17 Sep. 2001, 薬物動態 = Xenobiotic metabolism and disposition, 16, S207, Japanese

  • O-98 腎障害時におけるシクロスポリン体内動態の解析
    五十嵐 敏明, 矢野 育子, 齋藤 秀之, 乾 賢一
    日本医療薬学会, 01 Sep. 2001, 日本医療薬学会年会講演要旨集, 11, 103 - 103, Japanese

  • Caco-2細胞におけるグレパフロキサシン及びレボフロキサシンの取り込み特性
    山口 浩明, 矢野 育子, 齋藤 秀之, 乾 賢一
    05 Mar. 2001, 薬剤学 = Journal of Pharmaceutical Science and Technology, Japan, 61, 195 - 195, Japanese

  • 高尿酸血症モデルラットにおける有機イオン輸送系の活性と発現量変動
    土生 康司, 矢野 育子, 齋藤 秀之, 乾 賢一
    (公社)日本薬学会, Mar. 2001, 日本薬学会年会要旨集, 121年会(3) (3), 82 - 82, Japanese

  • P-196 うっ血性心不全患者のジゴキシンクリアランスに及ぼすイトラコナゾール併用の影響
    若杉 博子, 石塚 良子, 是枝 範子, 矢野 育子, 二見 高弘, 乾 賢一, 野原 隆司, 篠山 重威
    日本医療薬学会, 01 Sep. 2000, 日本病院薬学会年会講演要旨集, 10, 252 - 252, Japanese

  • O-119 タクロリムスの体内動態に及ぼす腎障害の影響
    岡部 裕美, 矢野 育子, 橋本 征也, 乾 賢一
    日本医療薬学会, 01 Sep. 2000, 日本病院薬学会年会講演要旨集, 10, 142 - 142, Japanese

  • 腎障害ラットにおける有機イオントランスポータの輸送活性とその発現変動
    伊藤 達也, 森田 真也, 矢野 育子, 土生 康司, 橋本 征也, 乾 賢一
    (一社)日本薬物動態学会, Sep. 2000, 薬物動態, 15(Suppl.) (Suppl.), S215 - S215, Japanese

  • 薬物相互作用の臨床薬理 薬物トランスポータ群の構造・機能解析に基づく薬物相互作用の評価
    乾賢一, 橋本征也, 斎藤秀之, 矢野育子, 奥田真弘
    29 May 2000, 臨床薬理の進歩, (21) (21), 1 - 11, Japanese

  • 培養腎上皮細胞OKの頂側膜におけるPAH輸送
    土生 康司, 矢野 育子, 橋本 征也, 乾 賢一
    (公社)日本薬学会, Mar. 2000, 日本薬学会年会要旨集, 120年会(4) (4), 57 - 57, Japanese

  • 培養腎上皮細胞OKにおける有機アニオン輸送 アデノシンA1レセプターアンタゴニストKW-3902の影響
    土生 康司, 永井 純也, 矢野 育子, 桂 敏也, 橋本 征也, 乾 賢一
    (一社)日本薬物動態学会, Sep. 1999, 薬物動態, 14(Suppl.) (Suppl.), S166 - S166, Japanese

  • 培養腎上皮細胞OKの有機アニオン輸送に及ぼすキノロン系抗菌薬の影響
    松尾 裕美子, 土生 康司, 矢野 育子, 桂 敏也, 橋本 征也, 乾 賢一
    (一社)日本薬物動態学会, Oct. 1998, 薬物動態, 13(Suppl.) (Suppl.), S178 - S178, Japanese

  • キノロン系抗菌薬の腎移行特性
    伊藤 達也, 矢野 育子, 橋本 征也, 乾 賢一
    09 Oct. 1997, 薬物動態 = Xenobiotic metabolism and disposition, 12, 193 - 193, Japanese

  • 培養腎上皮細胞 LLC-PK_1におけるレボフロキサシンの輸送特性
    松尾 裕美子, 伊藤 達也, 矢野 育子, 橋本 征也, 乾 賢一
    09 Oct. 1997, 薬物動態 = Xenobiotic metabolism and disposition, 12, 193 - 193, Japanese

  • 28 Population Pharmacokinetics によるテォフィリン体内動態の変動要因解析
    矢野 育子, 谷川原 祐介, 安原 眞人, 堀 了平, 川勝 一雄, 西村 浩一
    日本医療薬学会, 25 Jun. 1991, 日本病院薬学会年会講演要旨集, 1, 108 - 109, Japanese

  • 安原 眞人, 矢野 育子, 谷川原 祐介, 堀 了平, 伊藤 正利, 奥野 武彦, 三河 春樹
    The Japanese Society of Clinical Pharmacology and Therapeutics, 1991, Jpn. J. Clin. Pharmacol. Ther., 22(1) (1), 193 - 194, Japanese

  • 2B3-14 ACTH療法によるバルプロ酸血中濃度の変動について
    伊藤 正利, 奥野 武彦, 三河 春樹, 安原 真人, 矢野 育子, 谷川原 祐介, 堀 了平
    日本てんかん学会, 1990, 日本てんかん学会プログラム・抄録集, (24) (24), 214 - 214, Japanese

■ Books And Other Publications
  • 薬剤業務補助者育成ガイドブック : 実践!タスクシフト
    松原, 和夫, 矢野, 育子, 大村, 友博, 米澤, 淳
    Joint editor, 1 薬剤業務の補助業務. 3 基本的な補助業務, 薬事日報社, Nov. 2024, Japanese, ISBN: 9784840816472

  • 生物薬剤学
    谷川原, 祐介, 井上, 勝央
    Contributor, 薬物代謝能の変動要因, 南江堂, Mar. 2024, Japanese, ISBN: 9784524403813

  • これだけは気をつけたい!高齢者への薬剤処方
    今井, 博久
    α1遮断薬−ループ利尿薬, フェニトイン−ST合剤（スルファメトキサゾール−トリメトプリム）, ワルファリン−アミオダロン、ワルファリン−シプロフロキサシン、ワルファリン−マクロライド系抗菌薬、ワルファリン−ST合剤（スルファメトキサゾール−トリメトプリム）, 医学書院, Feb. 2024, Japanese, ISBN: 9784260052733

  • ケーススタディで学ぶ処方提案：これが決め手！同効薬の使いどころ
    矢野育子
    Editor, 月刊薬事（10月臨時増刊号）, Oct. 2023

  • 調剤指針
    日本薬剤師会
    Contributor, 経皮吸収型製剤, 薬事日報社, Aug. 2022, Japanese, ISBN: 9784840815963

  • できる薬剤師とよばれるために上手に使いたい薬学ナレッジ101
    北河, 修治, 清水, 忠, 中川, 素子, 中村, 任, 土生, 康司, 矢野, 育子
    Joint editor, Q56薬物の胎盤透過性はどのように予測する？Q57薬物の母乳移行性はどのように予測する？Q58薬剤の催奇性はどのように予測する？Q59更年期障害時に注意すべき薬剤は？, じほう, Dec. 2021, Japanese, ISBN: 9784840754019

  • 臨床薬学テキストシリーズ. 〔薬理・病態・薬物治療〕消化器/感覚器・皮膚/生殖器・産婦人科
    安原, 眞人, 木内, 祐二, 服部, 尚樹, 乾, 賢一
    Contributor, 第5章生殖器・婦人科疾患．A総論．1. 修得すべき知識の概要．2. 生殖器系の構造と機能．3. 妊娠・分娩・避妊に関する薬物．B疾患各論．1. 月経異常．2. 不妊症．3. 更年期障害．4．子宮内膜症．5. 子宮筋腫．6.異常妊娠．7.異常分娩．8. 性感染症．9．母子感染症．, 中山書店, May 2020, Japanese, ISBN: 9784521744544

  • 抗てんかん薬TDM標準化ガイドライン
    日本TDM学会
    Joint editor, 金原出版, Nov. 2018, Japanese, ISBN: 9784307470483

  • 臨床薬学テキストシリーズ．薬物治療総論/症候・臨床検査/個別化医療 / 薬物の副作用
    Yano Ikuko, 内藤俊夫, 鈴木麻衣
    Others, 中山書店, 2018, Japanese
    Textbook

  • 臨床薬学テキストシリーズ．薬物治療総論/症候・臨床検査/個別化医療 / 薬害，薬物乱用と健康リスク
    Yano Ikuko, 内藤俊夫, 鈴木麻衣
    Others, 中山書店, 2018, Japanese
    Textbook

  • 第十四改訂調剤指針 / 経皮吸収型製剤
    Yano Ikuko
    Others, 薬事日報社, 2018, Japanese
    Dictionary or encycropedia

  • 抗てんかん薬TDM標準化ガイドライン2018 / 抗てんかん薬TDM標準化ガイドライン2018
    Yano Ikuko
    Others, 金原出版株式会社, 2018, Japanese
    Others

  • ポリファーマシー見直しのための医師・薬剤師連携ガイド / ポリファーマシー見直しのための医師・薬剤師連携ガイド
    Yano Ikuko, 木村丈司, 宇田篤史, 小倉史愛
    Others, 南山堂, 2018, Japanese
    Others

  • スタンダード薬学シリーズII 7. 臨床薬学III.チーム医療および地域の保健・医療・福祉への参画 / 第2章チーム医療と薬剤師2-1病院内のチームと構成員の役割
    Yano Ikuko, 松原和夫
    Others, 東京化学同人, 2018, Japanese
    Textbook

  • スタンダード薬学シリーズII 7. 臨床薬学III.チーム医療および地域の保健・医療・福祉への参画 / 第1章医療機関におけるチーム医療 1-1 チーム医療の基本的事項
    Yano Ikuko, 松原和夫
    Others, 東京化学同人, 2018, Japanese
    Textbook

  • 医療薬学第6版
    矢野 育子
    Joint work, 第2章 医療と薬剤師．第4章 処方せんと調剤．第10章10.5 臓器移植時の薬物療法と処方, 廣川書店, Mar. 2014

  • 医療薬学第6版 / 第4章 処方せんと調剤
    Yano Ikuko, 乾賢一
    Others, 廣川書店, 2014, Japanese
    Textbook

  • 医療薬学第6版 / 第2章 医療と薬剤師
    Yano Ikuko, 乾賢一
    Others, 廣川書店, 2014, Japanese
    Textbook

  • 医療薬学第6版 / 10.5 臓器移植時の薬物療法と処方
    乾賢一, 尾崎淳子, Yano Ikuko
    Others, 廣川書店, 2014, Japanese
    Textbook

  • 薬学用語辞典 / ?
    Yano Ikuko
    Others, 東京化学同人, 2012, Japanese
    Textbook

  • 疾患からみた臨床薬理学第3版 / 臓器移植と免疫抑制療法
    Yano Ikuko
    Others, じほう, 2012, Japanese
    Textbook

  • 疾患からみた臨床薬理学第3版
    矢野 育子
    Joint work, 14. 臓器移植と免疫抑制療法, じほう, 2012

  • 最新薬剤学第10版 / 第 5 章 医療薬剤学 5.1 医療と薬剤師．5.2医薬品の有効性と安全性.
    Yano Ikuko, 乾賢一
    Others, 廣川書店, 2012, Japanese
    Textbook

  • 最新薬剤学第10版
    矢野 育子
    Joint work, 第 5 章 医療薬剤学 5.1 医療と薬剤師, 廣川書店, 2012

  • カラー版内科学
    矢野 育子
    Joint work, 第5章 １．pharmacokineticsとpharmacodynamics, 西村書店, 2012

  • 第十三改訂調剤指針 / 経皮吸収型製剤
    Yano Ikuko
    薬事日報社, 2011, Japanese
    Dictionary or encycropedia

  • 第十三改訂調剤指針
    矢野 育子
    Others, 経皮吸収型製剤, 薬事日報社, 2011

  • 薬物トランスポーター活用ライブラリー 機能・輸送基質から創薬・臨床応用まで / ジゴキシンの薬物相互作用に関わるトランスポーター
    Yano Ikuko
    Others, 羊土社, 2009, Japanese
    Scholarly book

  • 医療薬学第5版 / 第4章 処方せんと調剤
    Yano Ikuko
    Others, 廣川書店, 2009, Japanese
    Textbook

  • 医療薬学第5版 / 第2章 医療と薬剤師
    Yano Ikuko
    Others, 廣川書店, 2009, Japanese
    Textbook

  • 医療薬学第5版 / 10.5 臓器移植時の薬物療法と処方
    Yano Ikuko
    Others, 廣川書店, 2009, Japanese
    Textbook

  • Frontiers in drug design and discovery vol. 4 / Pharmacogenomic considerations in breast cancer management.
    Ishiguro, H, Yano Ikuko, I, dToi, M
    Others, Bentham Science Publishers Ltd., 2009, English
    Scholarly book

  • Frontiers in drug design and discovery vol. 4 / Important drug interactions for clinical oncologists.
    Ishiguro, H, Yano Ikuko, I, dToi, M
    Others, Bentham Science Publishers Ltd., 2009, English
    Scholarly book

  • Evolution of living-donor liver transplantation / Therapeutic drug monitoring and individualized therapy with tacrolimus in recipients of living-donor liver transplantation.
    Yano Ikuko, I, Masuda, S, dInui, K
    Others, Thomson Reuters, 2008, English
    Scholarly book

  • 薬剤師が変える薬物治療２−安全ながん治療とテーラーメイド医療に向けて− / バルビツレート療法時のチオペンタール体内動態と脳死判定時における体制整備
    Yano Ikuko
    Others, じほう, 2007, Japanese
    Scholarly book

  • 薬剤師が変える薬物治療２−安全ながん治療とテーラーメイド医療に向けて− / カルシニューリン活性に基づく薬効評価と個別化投与設計
    Yano Ikuko
    Others, じほう, 2007, Japanese
    Scholarly book

  • 最新薬剤学第9版 / 5.1 医療と薬剤師．5.2医薬品の有効性と安全性
    Yano Ikuko, 乾賢一
    Others, 廣川書店, 2006, Japanese
    Textbook

  • ハーバード大学テキスト 病態生理に基づく臨床薬理学 / 薬力学
    Yano Ikuko
    Joint translation, メディカル・サイエンス・インターナショナル, 2006, Japanese
    Textbook

  • スタンダード薬学シリーズ10. 実務実習事前学習：病院・薬局実習に行く前に / 第2章 チーム医療に注目するSBO4-6
    Yano Ikuko, 乾賢一
    Others, 東京化学同人, 2006, Japanese
    Textbook

  • 薬剤師・薬学生のための実践TDMマニュアル / 喘息治療薬(テオフィリン)
    Yano Ikuko, 乾賢一
    Others, じほう, 2004, Japanese
    Scholarly book

  • 薬剤師・薬学生のための実践TDMマニュアル / タクロリムス
    橋田亨, Yano Ikuko, 増田智先, 乾賢一
    Others, じほう, 2004, Japanese
    Scholarly book

  • 眼科薬物治療ガイド / 第 3 章 胃腸障害を避けるには, 併用薬・食事との折り合いと問題点
    Yano Ikuko, 乾賢一
    Others, 文光堂, 2004, Japanese
    Scholarly book

  • スタンダード薬学シリーズ9. 薬学と社会2 / 医療の担い手としての使命
    Yano Ikuko, 乾賢一
    Others, 東京化学同人, 2004, Japanese
    Textbook

■ Lectures, oral presentations, etc.
  • ニルマトレルビル/リトナビル適正使用に向けた体制の構築とその評価
    松本由季, 木村丈司, 冨田猛, 宇田篤史, 山本和宏, 大村友博, 矢野育子
    日本薬学会第144回年会, Mar. 2024
    Oral presentation

  • ECU栄養プロトコール
    岡崎裕太朗, 山西美沙, 阿保惠美, 高橋路子, 大村友博, 矢野育子, 小谷穣治
    第51回日本集中治療医学会学術集会, Mar. 2024
    Poster presentation

  • ブレクスピプラゾール，クエチアピンおよびリスペリドンを服用中の妊婦とその児における薬物動態の評価
    小西徹, 北廣優実, 藤原尚子, 山本和宏, 糸原光太郎, 大村友博, 矢野育子
    第45回日本病院薬剤師会近畿学術大会, Jan. 2024
    Oral presentation

  • 薬剤師の職能と生涯研鑽
    矢野育子
    全国自治体病院協議会 2023年度薬剤管理研修会プログラム, Dec. 2023
    Public discourse

  • 妊婦および新生児におけるリスペリドンと活性代謝物パリペリドンの生理学的薬物動態モデル解析
    矢野育子
    第97回日本薬理学会年会, Dec. 2023
    [Invited]
    Public symposium

  • Impact of ALBI grade on lenvatinib treatment discontinuation due to adverse events in hepatocellular carcinoma patients
    Enomoto D., Yamamoto K., Matsumoto Y., Morioka A., Omura T., Komatsu S., Yano Y., Fukumoto T., Takara K., Yano I.
    第33回日本医療薬学会年会, Nov. 2023
    Oral presentation

  • Effect of early dose reduction of osimertinib on efficacy in the first-line treatment for EGFR-positive non-small cell lung cancer
    Hori T., Yamamoto K., Ito T., Ikushima S., Itohara K., Kitahiro Y., Omura T., Yano I.
    第33回日本医療薬学会年会, Nov. 2023
    Oral presentation

  • 先天性サイトメガロウイルス感染症患者におけるガンシクロビルのPK/PD解析
    糸原光太郎, 藤中俊輔, 山本和宏, 橋本真梨, 田村直暉, 北廣優実, 大村友博, 藤岡一路, 矢野育子
    第33回日本医療薬学会年会, Nov. 2023
    Oral presentation

  • 薬剤師外来が抗血栓薬服用患者の長期臨床アウトカムに与える影響
    栗村朋子, 山本和宏, 田中秀和, 鳥羽敬義, 木村丈司, 土生康司, 糸原光太郎, 北廣優実, 大村友博, 矢野育子
    第33回日本医療薬学会年会, Nov. 2023
    Oral presentation

  • A model-based pharmacokinetic analysis of drug-drug interaction between nirmatrelvir/ritonavir and tacrolimus
    Itohara K., Tomida T., Yamamoto K., Kimura T., Fujita K., Uda A., Kitahiro Y., Yokoyama N., Hyodo Y., Omura T., Yano I.
    The 21st International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT 2023), Nov. 2023
    Poster presentation

  • 薬剤師の職能と生涯研鑽〜プロフェッショナリズムを考える〜
    矢野育子
    令和5年度 兵庫県病院薬剤師会 新入局者研修会, Oct. 2023
    [Invited]
    Public discourse

  • 食道癌FP 療法施行患者における術後回復期以降のプラチナ血中濃度推移と臨床検査値との連関解析
    吉岡佐恵, 山下和彦, 岩永一範, 山本和宏, 矢野育子, 中村 任
    第73回日本薬学会関西支部大会・総会, Oct. 2023
    Poster presentation

  • PBPMを活用したチーム医療の推進と 薬物療法の質向上
    矢野育子
    第28回観三薬剤師会, Sep. 2023
    [Invited]
    Public discourse

  • Physiologically-based pharmacokinetic modeling and simulation of fentanyl for treatment optimization in neonates
    Yamamoto K., Mahdy WYB, Hashimoto M., Hasegawa M., Nakasone R., Fujioka K., Itohara K., Kitahiro Y., Omura T., Yano I.
    The 21st International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT 2023), Sep. 2023
    Oral presentation

  • TDM-QC実施報告（抗てんかん薬）
    山本和宏, 矢野育子
    第8回TDM-QC研究会, Aug. 2023
    Oral presentation

  • 神戸大学における 薬剤部の取り組みについて
    矢野育子
    トーアエイヨー株式会社 社内研修会, Aug. 2023
    [Invited]
    Public discourse

  • 薬剤師の専門性と職能将来像〜バイオシミラーを通じた病院経営への関わりを含めて〜
    矢野育子
    第65回秋田県臨床薬学研究会, Jul. 2023
    Public discourse

  • シンポジウム19「薬剤師のための臨床研究入門」趣旨説明
    矢野育子
    第6回日本病院薬剤師会Future Pharmacist Forum, Jul. 2023
    Public discourse

  • 薬剤師の専門性と研究について考える
    矢野育子
    第24回青森県臨床薬学研究会, Jul. 2023
    [Invited]
    Public discourse

  • microRNAを介した小胞体ストレス関連分子SEL1L/HRD1の機能解析とパーキンソン病治療への応用
    矢野育子, 坂根稔康, 大村友博, 古林呂之, 田中晶子
    2022年度神戸薬科大学学長裁量経費に基づく共同研究プログラム 公開報告会, Jul. 2023
    Others

  • パーキンソン病発症に関連する小胞体ストレス関連分子SEL1Lを制御するmicroRNAの探索と血漿中microRNA発現量の検討
    西口大生, 大村友博, 野村月渚, 渡邉蘭, 北廣優実, 糸原光太郎, 山本和宏, 國正淳一, 松原和夫, 矢野育子
    医療薬学フォーラム2023／第31回クリニカルファーマシーシンポジウム, Jul. 2023
    Poster presentation

  • ニルマトレルビル/リトナビル併用時にタクロリムス濃度の異常高値を認めた腎移植症例
    冨田猛, 木村丈司, 山本和宏, 宇田篤史, 藤田浩平, 荻原孝史, 糸原光太郎, 北廣優実, 大村友博, 矢野育子
    第25回日本医薬品情報学会総会・学術大会, Jun. 2023
    Oral presentation

  • 高度腎機能障害患者におけるバンコマイシンAUC-guided TDMの安全性に関する検討
    藤田浩平, 山本和宏, 宇田篤史, 荻原孝史, 阪上倫行, 田村直暉, 木村丈司, 糸原光太郎, 北廣優実, 大村友博, 矢野育子
    第39回日本TDM学会・学術大会, Jun. 2023
    Oral presentation

  • マルチキナーゼ阻害薬による手足皮膚反応の予防軽減を目指した製剤開発
    石田喬裕, 山本和宏, 植田笙, 吉岡正人, 矢野育子, 野上紀子, 山原年
    第8回日本がんサポーティブケア学会学術集会, Jun. 2023
    Poster presentation

  • 肺胞上皮細胞におけるエベロリムスの上皮間葉転換誘導とシグナル伝達因子の関連
    高橋大, 山本和宏, 西口大生, 糸原光太郎, 北廣優実, 大村友博, 國正淳一, 矢野育子
    日本医療薬学会 第6回 フレッシャーズ・カンファランス, Jun. 2023
    Oral presentation

  • 1%クロルヘキシジングルコン酸エタノールの使用促進による血液培養汚染率への影響
    田村直暉, 宇田篤史, 木村丈司, 糸原光太郎, 大村友博, 楠木まり, 出田理恵, 八幡眞理子, 宮良高維, 矢野育子
    日本医療薬学会 第6回 フレッシャーズ・カンファランス, Jun. 2023
    Oral presentation

  • 卒前・卒後における臨床薬学教育を考える
    矢野育子
    第3回兵庫県薬剤師会・病院薬剤師会・薬系5大学連携学術大会, Jun. 2023
    [Invited]
    Nominated symposium

  • 神戸大学における 薬剤部の取り組みについて
    矢野育子
    大塚製薬工場 社内研修会, May 2023
    [Invited]
    Public discourse

  • 非がん性疼痛に対して使用されるオピオイド性鎮痛薬の薬剤師による使用状況モニタリングとその効果
    飯田真之, 志田有里, 番匠咲帆, 大本暢子, 山下和彦, 槇本博雄, 山本和宏, 大村友博, 矢野育子
    第16回日本緩和医療薬学会年会, May 2023
    Oral presentation

  • 抗てんかん薬の薬物動態と投与設計 up-to-date
    矢野育子
    第6回Kinki Epilepsy Summit -てんかんの新知見とパラダイムシフト-, Apr. 2023
    [Invited]
    Invited oral presentation

  • ユビキチンリガーゼHRD1を誘導する化合物の探索と神経細胞死抑制効果の検討
    西口大生, 大村友博, 佐登礼佳, 北廣優実, 山本和宏, 國正淳一, 矢野育子
    日本薬学会第143年会, Mar. 2023

  • 非小細胞肺がん患者におけるオシメルチニブの有害事象に関する薬理遺伝学的解析
    丹田雅明, 山本和宏, 堀智貴, 西口大生, 八木美樹, 清水倫子, 小西徹, 尾崎智規, 吉岡奈津恵, 立原素子, 伊藤武文, 生島繁樹, 大村友博, 矢野育子
    Mar. 2023

  • 免疫チェックポイント阻害薬投与患者の好中球リンパ球比による層別化とプロトンポンプ阻害薬の併用による生命予後への影響
    堀智貴, 山本和宏, 伊藤武文, 生島繁樹, 大村友博, 矢野育子
    日本臨床腫瘍薬学会学術大会2023, Mar. 2023

  • 兵庫県下の病院施設における新人薬剤師の卒後研修に関する現状調査
    槇本博雄, 矢野育子, 小野聡, 柿木博士, 岸本修一, 志方敏幸, 濱宏仁, 福井由美子, 室井延之
    近畿薬剤師合同学術大会2023（第25回近畿薬剤師学術大会・第44回日本病院薬剤師会近畿学術大会）, Mar. 2023

  • 薬剤師の専門性のあり方について： 研究班からの提案
    矢野育子
    公開シンポジウム：令和4年度厚生労働科学研究費補助金 （医薬品・医療機器等レギュラトリーサイエンス政策研究事業） 国民のニーズに応える薬剤師の 専門性のあり方に関する調査研究, Feb. 2023
    Public discourse

  • 潜在的不適切処方の中止維持における退院時薬剤情報提供の有用性
    古江由依, 山本和宏, 木村丈司, 高橋知子, 大本暢子, 槇本博雄, 大村友博, 坂根稔康, 國正淳一, 矢野育子
    第44日本病院薬剤師会近畿学術大会, Feb. 2023

  • 薬と上手に付き合うために
    矢野育子
    神戸大学第18回 附属学校連携授業, Dec. 2022
    Public discourse

  • がん薬物療法におけるポリファーマシー対策
    矢野育子
    “がん”に関わる薬剤師の為のWebセミナー Vol.1, Dec. 2022

  • 抗てんかん薬のTDMと薬局との連携
    矢野育子
    ユーシービージャパンオンライン特別セミナー, Nov. 2022

  • 成人肝移植患者におけるエベロリムスの母集団薬物動態解析および小児肝移植患者への外挿
    糸原光太郎, 矢野育子, 中川俊作, 杉本充弘, 平井真智子, 米澤淳, 平大樹, 伊藤孝司, 秦浩一郎, 波多野悦朗, 寺田智祐, 松原和夫
    第43回日本臨床薬理学会学術総会, Nov. 2022

  • Association of ACTN3 polymorphism with Sarcopenia in Kidney Transplant Recipients
    Fujimoto T., Ishimura T., Tashiro Y., Endo T., Nisioka S., Yokoyama N., Hyodo Y., Yamamoto K., Yano I., Fujisawa M.
    Transplantation Science Symposium Asian Regional Meeting 2022, Nov. 2022

  • Mir-101 regulates neuronal cell death by targeting suppressor/enhancer lin-12-like (SEL1L) in a cellular model of Parkinson’s disease using 6-hydorxydopamine
    Omura T., Nomura L., Nishiguchi H., Yamamoto K., Imai S., Nakagawa S., Itohara K., Yonezawa A., Nakagawa T., Yano I., Matsubara K.
    Neuroscience 2022, Nov. 2022
    Poster presentation

  • 分子標的型抗がん薬による間質性肺疾患発症の分子機構に基づく予測法の開発 -mTOR阻害薬による間質性肺疾患とSTAT3の関連-
    山本和宏, 吉田彩夏, 大村友博, 矢野育子
    第72回日本薬学会関西支部総会・大会, Oct. 2022

  • クリニカルファーマコメトリクス概論：個別化投与設計の変遷
    矢野育子
    日本医療薬学会 第86回医療薬学公開シンポジウム, Oct. 2022
    [Invited]
    Keynote oral presentation

  • 医療現場で35年：「薬剤師が変われば医療が変わる」と言われたい
    矢野育子
    第16回京都大学薬学部生涯教育講演会, Sep. 2022
    [Invited]
    Public discourse

  • Effects of long-term multiple immunosuppressants on everolimus pharmacokinetics in patients after renal transplantation
    Tomoyuki Sakaue, Kazuhiro Yamamoto, Takahito Endo, Takeshi Ishimura, Masato Fujisawa, Tomohiro Omura, Ikuko Yano
    第32回医療薬学会年会, Sep. 2022

  • ニルマトレルビル/リトナビルの適正使用に向けた予備的検討
    冨田猛, 木村丈司, 山本和宏, 野崎晃, 田村直暉, 藤田浩平, 飯田真之, 大村友博, 矢野育子
    第32回日本医療薬学会年会, Sep. 2022

  • 薬剤師が変わると医療が変わる ～輝ける未来に向かって～
    矢野育子
    第32回日本医療薬学会年会, Sep. 2022
    Public symposium

  • Effects of pregnancy and renal ontogeny on risperidone/paliperidone pharmacokinetics predicted by physiologically based pharmacokinetic model
    Yamamoto K., Mahdy WYB, Ito T., Fujiwara N., Fujioka K., Horai T., Otsuka I., Imafuku H., Omura T., Iijima K., Yano I.
    The 20th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT 2022), Sep. 2022
    Poster presentation

  • TDM-QC実施報告（抗てんかん薬）
    山本和宏, 矢野育子
    第7回TDM-QC研究会, Aug. 2022

  • 薬剤師が変わると医療が変わる：リサーチマインドを持とう！
    矢野育子
    Inovative Pharmacist Seminar in Yamagata 2022, Jul. 2022
    [Invited]
    Public discourse

  • 神戸大学医学部附属病院 薬剤部・薬剤師の業務について
    矢野育子
    旭化成ファーマ社内教育講演会, Jul. 2022

  • ユビキチンリガーゼHRD1を制御するマイクロRNAの探索とパーキンソン病との関連
    西口大生, 大村友博, 山本和宏, 矢野育子
    医療薬学フォーラム2022・第30回クリニカルファーマシーシンポジウム, Jul. 2022
    Poster presentation

  • スニチニブ投与ラットを用いた手足皮膚反応の原因角化因子の探索とヒト表皮角化細胞株による検証
    中嶋木の実, 山本和宏, 坂根稔康, 藤川実加, 大村友博, 矢野育子
    医療薬学フォーラム2022・第30回クリニカルファーマシーシンポジウム, Jul. 2022

  • 「薬剤師の臨床研究計画から公表に至るまでのピットフォール」 クロージング
    矢野育子
    第5回 日本病院薬剤師会 Future Pharmacist Forum, Jul. 2022
    Others

  • 薬の倫理とプロフェショナルオートノミー
    矢野育子
    沖縄県病院薬剤師会講演会, Jun. 2022

  • スニチニブによる手足皮膚反応の予防に対するAmitose-DGA含有クリームの第1/2相試験
    山本和宏, 西山智司, 国定充, 五百蔵武士, 飯田真之, 伊藤雄大, 槇本博雄, 大村友博, 原田健一, 藤澤正人, 錦織千佳子, 矢野育子
    第121回日本皮膚科学会, Jun. 2022

  • 抗菌薬のTDMにおけるプレアボイド事例と入院期間に及ぼす影響
    田村直暉, 山本和宏, 阪上倫行, 木村丈司, 大村友博, 矢野育子
    第38回日本TDM学会学術大会, May 2022
    Oral presentation

  • 国民のニーズに応える専門薬剤師のあり方について
    矢野育子
    第25回日本臨床救急医学会総会・学術集会, May 2022
    [Invited]
    Nominated symposium

  • 日本の病院薬剤師の業務とがん薬物療法への関わり
    矢野育子
    北京華通国康公益基金会セミナー, Apr. 2022
    [Invited]
    Public discourse

  • 消化管上皮細胞モデルにおけるABCB1発現・機能に及ぼすエベロリムス長期曝露の影響
    中山優子, 高良恒史, 山本和宏, 大村友博, 矢野育子
    日本薬学会第141年会, Mar. 2021, Japanese, WEB開催, Domestic conference
    Poster presentation

  • セルトラリンに起因するセロトニン症候群関連症状のリスク因子の探索
    山本和宏, 松山夏実, 國正淳一, 大村友博, 矢野育子
    日本薬学会第141年会, Mar. 2021, Japanese, Domestic conference
    Poster presentation

  • 粘度可変型流動食マーメッド®と胃酸分泌抑制薬の併用による下痢発現のリスクに関する検討
    平島七海, 森尾佳代子, 住吉霞美, 山本和宏, 大村友博, 矢野育子
    第10回日本薬剤師レジデントフォーラム, Mar. 2021, Japanese, 日本薬剤師レジデント制度研究会, WEB開催, Japan, Domestic conference
    Poster presentation

  • 一包化錠剤仕分け装置TABSORT®の効率的かつ安全性の高い運用方法の検討
    藤澤諒子, 山下和彦, 岡崎裕太朗, 山本和宏, 大村友博, 矢野育子
    第10回日本薬剤師レジデントフォーラム, Mar. 2021, Japanese, 日本薬剤師レジデント制度研究会, WEB開催, Japan, Domestic conference
    Poster presentation

  • 病院 - 保険薬局間のシームレスな吸入指導体制の構築に向けたツールの作成とその評価
    高橋慶, 清水倫子, 大本暢子, 山本和宏, 大村友博, 矢野育子
    第10回日本薬剤師レジデントフォーラム, Mar. 2021, Japanese, 日本薬剤師レジデント制度研究会, WEB開催, Japan, Domestic conference
    Poster presentation

  • 薬剤師によるTDM関連オーダリング補助業務の有用性の検討
    村川亜光, 山本和宏, 石井順子, 阪上倫行, 高木妙子, 清水倫子, 大村友博, 坂根稔康, 國正淳一, 宮田興子, 矢野育子
    第10回日本薬剤師レジデントフォーラム, Mar. 2021, Japanese, 日本薬剤師レジデント制度研究会, WEB開催, Japan, Domestic conference
    Poster presentation

  • 若年の腎機能正常患者におけるVCM有効血中濃度への到達に影響する因子の調査
    岡誠吾, 阪上倫行, 山本和宏, 大村友博, 坂根稔康, 國正淳一, 宮田興子, 矢野育子
    第10回日本薬剤師レジデントフォーラム, Mar. 2021, Japanese, 日本薬剤師レジデント制度研究会, WEB開催, Japan, Domestic conference
    Poster presentation

  • 院外処方箋への臨床検査値印字が保険薬局の処方介入に与える影響
    益成宏美, 冨田猛, 木村丈司, 髙木妙子, 野﨑晃, 山本和宏, 大村友博, 坂根稔康, 國正淳一, 宮田興子, 矢野育子
    第10回日本薬剤師レジデントフォーラム, Mar. 2021, Japanese, 日本薬剤師レジデント制度研究会, WEB開催, Japan, Domestic conference
    Poster presentation

  • セロトニン受容体拮抗型制吐薬投与患者における便秘発現の実態調査
    津田瑞季, 伊藤雄大, 丹田雅明, 山本和宏, 大村友博, 坂根稔康, 國正淳一, 宮田興子, 矢野育子
    第10回日本薬剤師レジデントフォーラム, Mar. 2021, Japanese, 日本薬剤師レジデント制度研究会, WEB開催, Japan, Domestic conference
    Poster presentation

  • 病院と保険薬局の連携強化を目的とした研修会（Team Based Learning）による人材育成
    植田梨沙, 丹田雅明, 伊藤雄大, 榎本彩花, 飯田真之, 水田直美, 山本和宏, 槇本博雄, 大村友博, 矢野育子
    日本臨床腫瘍薬学会学術大会2021, Mar. 2021, Japanese, Domestic conference
    Nominated symposium

  • 持続可能な医療に向けて 〜薬剤師が変われば医療が変わる！〜
    矢野育子
    第7回兵庫県薬剤師会・兵庫県病院薬剤師会共催講演会, Feb. 2021, Japanese, Domestic conference
    [Invited]
    Public discourse

  • 抗がん薬調製ロボット導入前後における抗がん薬関連業務の比較
    伊藤雄大, 丹田雅明, 水田直美, 丸上奈穂, 山口由加里, 植田梨沙, 山本和宏, 槇本博雄, 大村友博, 矢野育子
    第27 回日本がんチーム医療研究会, Feb. 2021, Japanese, Domestic conference
    Oral presentation

  • 医薬品適正使用を目指した薬物動態研究の実践〜これまでのキャリアを振り返って〜
    矢野育子
    文部科学省科学技術人材育成費補助事業「ダイバーシティ研究環境実現イニシアティブ（連携型）清流の国輝くギフジョ支援プロジェクト」「キャリパス支援講演会」, Feb. 2021, Japanese, Domestic conference
    [Invited]
    Public discourse

  • Impact of sunitinib on the expression of cornifying factors in human epidermal 3D skin models
    Yoshida A, Yamamoto K, Ishida T, Omura T, Itoh T, Nishigori C, Sakane T, Yano I
    The 4th International Cancer Research Symposium of Training Plan for Oncology Professionals, Feb. 2021, English, International conference
    Poster presentation

  • 進行固形がん患者を対象とした心血管疾患予防のための降圧薬の使用実態に関する調査
    丹田雅明, 塩見真由, 山本和宏, 國正淳一, 槇本博雄, 大村友博, 矢野育子
    第42回日本病院薬剤師会近畿学術大会, Jan. 2021, Japanese, Domestic conference
    Poster presentation

  • 薬剤師が変われば医療が変わる 〜ハートフルに洞察しスキルで対応する〜
    矢野育子
    Next Generation Leader Conference, Jan. 2021, Japanese, Domestic conference
    [Invited]
    Public discourse

  • 腎移植患者におけるタクロリムスPBPKモデル構築と肝移植患者の薬物動態との比較
    糸原光太郎, 矢野育子, 中川俊作, 米澤淳, 中川貴之, 今井哲司, 小川修, 小林恭, 坂井薫, 松原和夫
    第41回日本臨床薬理学会学術総会, Dec. 2020, Japanese, Domestic conference
    Poster presentation

  • 腎細胞癌患者を対象とした2週投与1週休薬スケジュール下におけるスニチニブ至適血中濃度に関する検討
    伊藤雄大, 山本和宏, 北村匠, 古川順也, 原田健一, 藤澤正人, 大村友博, 矢野育子
    第41回日本臨床薬理学会学術総会, Dec. 2020, Japanese, Domestic conference
    Poster presentation

  • 薬剤師による抗菌薬血中濃度測定オーダー登録と注射薬仮登録がもたらす実践的有用性の評価
    村川亜光, 山本和宏, 石井順子, 阪上倫行, 清水倫子, 槇本博雄, 大村友博, 坂根稔康, 國正淳一, 宮田興子, 矢野育子
    第30回日本医療薬学会年会, Oct. 2020, Japanese, WEB開催, Domestic conference
    Poster presentation

  • レンバチニブによる有害事象の発生予測に対するALBI Gradeの有用性の検討
    松本由季, 榎本大智, 山本和宏, 大村友博, 小松昇平, 矢野嘉彦, 矢野育子
    第30回日本医療薬学会年会, Oct. 2020, Japanese, WEB開催, Domestic conference
    Poster presentation

  • 人工弁置換術後のワルファリン導入下におけるPT-INR値に関する解析
    森岡朝美, 清水倫子, 山本和宏, 大村友博, 井上武, 岡田健次, 矢野育子
    第30回日本医療薬学会年会, Oct. 2020, Japanese, WEB開催, Domestic conference
    Poster presentation

  • 病棟薬剤師に対する手指衛生の教育効果と評価者としての薬学部実務実習生への波及効果
    柴田京香, 飯田真之, 宇田篤史, 出田理恵, 八幡眞理子, 大本暢子, 山本和宏, 大村友博, 矢野育子
    第30回日本医療薬学会年会, Oct. 2020, Japanese, 日本医療薬学会, WEB開催, Domestic conference
    Oral presentation

  • Reinforced collaboration between community pharmacies and hospital for the management of oral anti-cancer therapy using information sharing tools and team-based learning
    Ueda R, Tanda M, Ito T, Enomoto A, Iida M, Mizuta N, Yamamoto K, Makimoto H, Omura T, Yano I
    第30回日本医療薬学会年会, Oct. 2020, English, 一般社団法人日本医療薬学会, WEB開催, Japan, Domestic conference
    Poster presentation

  • Effects of pharmacist-led antimicrobial stewardship programme in urological patients
    Uda A, Shigemura K, Kitagawa K, Osawa K, Onuma K, Inoue S, Kotani J, Yan Y, Nakano Y, Nishioka T, Miyara T, Fujisawa M, Yano I
    第30回日本医療薬学会年会, Oct. 2020, English, WEB開催, Domestic conference
    Poster presentation

  • 薬物動態モデル解析の変遷と薬剤師として想うこと
    矢野育子
    第23回千葉TDMセミナー, Oct. 2020, Japanese
    [Invited]
    Public discourse

  • 全病棟を対象としたボリファーマシー対策の実践
    飯田真之, 木村丈司, 松本久美子, 栗村朋子, 山本和宏, 矢野育子
    第4回日本老年薬学会学術大会, Jun. 2020, Japanese, 日本老年薬学会, WEB開催, Japan, Domestic conference
    Oral presentation

  • 薬剤師による転院時の診療情報提供書作成支援
    大本暢子, 飯田真之, 田中響子, 竹中かおり, 久米学, 矢野育子
    第4回日本老年薬学会学術大会, Jun. 2020, Japanese, WEB開催, Domestic conference
    Oral presentation

  • ポリファーマシーに対する薬剤師介入の取り組み
    大村友博, 木村丈司, 山本和宏, 矢野育子
    日本病院薬剤師会 東北ブロック第10回学術大会, Jun. 2020, Japanese, Domestic conference
    Nominated symposium

  • 腎移植後にスニチニブ治療を開始した腎癌患者におけるタクロリムス・エベロリムスの薬物動態モデル解析
    伊藤 雄大, 山本 和宏, 小川 悟史, 古川 順也, 原田 健一, 藤澤 正人, 大村 友博, 矢野 育子
    日本薬学会第140年会, Mar. 2020, Japanese, 京都, Domestic conference
    Poster presentation

  • 人工弁置換術後のワルファリン導入におけるプロトロンビン時間国際標準比推移の現状と課題
    森岡 朝美, 清水 倫子, 山本 和宏, 大村 友博, 井上 武, 坂根 稔康, 國正 淳一, 宮田 興子, 矢野 育子
    第9回日本薬剤師レジデントフォーラム, Mar. 2020, Japanese, 東京, Domestic conference
    Poster presentation

  • 薬剤師によるTDMオーダーと注射仮登録の有用性評価
    村川 亜光, 山本 和宏, 石井 順子, 阪上 倫行, 大村 友博, 坂根 稔康, 國正 淳一, 宮田 興子, 矢野 育子
    第9回日本薬剤師レジデントフォーラム, Mar. 2020, Japanese, 東京, Domestic conference
    Poster presentation

  • レンバチニブによる有害事象の発生予測に対するALBIスコアの有用性の検討
    松本 由季, 榎本 大智, 山本 和宏, 大村 友博, 小松 昇平, 矢野 嘉彦, 矢野 育子
    第9回日本薬剤師レジデントフォーラム, Mar. 2020, Japanese, 東京, Domestic conference
    Poster presentation

  • 神戸大学・神戸薬科大学薬剤師レジデントにおける教育関連業務
    穐原 裕奈, 山本 和宏, 坂根 稔康, 國正 淳一, 宮田 興子, 大村 友博, 矢野 育子
    第9回日本薬剤師レジデントフォーラム, Mar. 2020, Japanese, 東京, Domestic conference
    Poster presentation

  • マウス血清中バイオメタル濃度に及ぼすシスプラチン、オキサリプラチンおよびデキサメタゾンの影響
    石崎 裕馬, 荻原 孝史, 林 真穂, 中川 貴之, 山下 和彦, 久米 学, 矢野 育子, 平岡 純, 安井 裕之, 中村 任
    日本薬学会第140年会, Mar. 2020, Japanese, 京都, Domestic conference
    Poster presentation

  • がん悪液質に対する補中益気湯による改善効果に関する調査
    北廣 優実, 山本 和宏, 大本 暢子, 久米 学, 芝野 真喜雄, 大村 友博, 矢野 育子
    日本薬学会第140年会, Mar. 2020, Japanese, 京都, Domestic conference
    Poster presentation

  • Physiologically-based pharmacokinetic modeling and simulation of serum risperidone and paliperidone concentrations in pregnant woman taking risperidone and in her baby
    Walaa Mahdy, Kazuhiro Yamamoto, Takahiro Ito, Kazumichi Fujioka, Tadasu Horai, Ikuo Otsuka, Hitomi Imafuku, Tomohiro Omura, Kazumoto Iijima, Ikuko Yano
    日本薬学会第140年会, Mar. 2020, Japanese, 京都, Domestic conference
    Poster presentation

  • スニチニブによる表皮角化細胞のkeratin 6AおよびSERPINB1発現変動
    吉田 彩夏, 山本 和宏, 石田 喬裕, 伊藤 智雄, 大村 友博, 矢野 育子
    日本薬学会第140年会, Mar. 2020, Japanese, 京都, Domestic conference
    Poster presentation

  • 生下時より経時的に薬物血中濃度を測定し得たリスペリドン内服母体児の１例
    永井 貞之, 伊藤 雄大, 藤岡 一路, 蓬莱 政, 大塚 郁夫, 藤原 尚子, 山本 和宏, 矢野 育子, 飯島 一誠
    第33回近畿小児科学会, Mar. 2020, Japanese, 大阪, Domestic conference
    Oral presentation

  • Monitoring of concentrations of sunitinib, tacrolimus, and everolimus in the patient with metastatic renal cell carcinoma after renal transplantation
    Takahiro Ito, Kazuhiro Yamamoto, Satoshi Ogawa, Junya Furukawa, Kenichi Harada, Masato Fujisawa, Ikuko Yano
    The 3rd International Cancer Research Symposium of Training Plan for Oncology Professionals, Feb. 2020, English, 大阪, International conference
    Poster presentation

  • 抗がん薬混合調製ロボットの導入と稼働状況
    伊藤 恵, 丸上 奈穂, 丹田 雅明, 山口 由加里, 野崎 晃, 山本 和宏, 槇本 博雄, 大村 友博, 矢野 育子
    第41回日本病院薬剤師会近畿学術大会, Feb. 2020, Japanese, 神戸, Domestic conference
    Poster presentation

  • 乳児におけるテイコプラニン血中濃度の評価
    石井 順子, 山本 和宏, 阪上 倫行, 西岡 達也, 大村 友博, 矢野 育子
    第41回日本病院薬剤師会近畿学術大会, Feb. 2020, Japanese, 神戸, Domestic conference
    Poster presentation

  • 薬と上手に付き合うために
    矢野 育子
    兵庫県予防協会・神戸市主催：2019年度後期土曜健康科学セミナー, Jan. 2020, Japanese, 神戸, Domestic conference
    Public discourse

  • 新生児の先天性サイトメガロウイルス感染症患者におけるガンシクロビル血中濃度測定と生理学的薬物動態モデルを用いたシミュレーション
    山本 和宏, 大山 正平, 福嶋 祥代, 橋本 真梨, 山川 恵, 藤原 尚子, 藤岡 一路, 飯島 一誠, 大村 友博, 矢野 育子
    第40回日本臨床薬理学会学術総会, Dec. 2019, Japanese, 東京, Domestic conference
    Poster presentation

  • Population pharmacokinetic modeling of everolimus in renal transplant patients with multiple immunosuppressive therapy.
    Tomoyuki Sakaue, Kazuhiro Yamamoto, Takahito Endo, Takeshi Ishimura, Tomohiro Omura, Ikuko Yano
    日本薬物動態学会第34回年会, Dec. 2019, English, つくば, Domestic conference
    Poster presentation

  • 免疫抑制薬のファーマコメトリクス
    矢野 育子
    第22回宝ヶ池セミナー, Nov. 2019, Japanese, 京都, Domestic conference
    Public discourse

  • 医薬品開発及び個別化治療におけるファーマコメトリクス
    矢野 育子
    三重大学大学院医科学専攻修士課程, Nov. 2019, Japanese, 津, Domestic conference
    Public discourse

  • 医薬品不適切使用症例検出システムの構築
    熊岡 穣, 山本 和宏, 大田 美香, 高岡 裕, 矢野 育子, 前田 英一
    第39回医療情報学連合大会・第20回日本医療情報学会学術大会, Nov. 2019, Japanese, 千葉, Domestic conference
    Oral presentation

  • クロザピン及び活性代謝物の母集団薬物動態解析：入院・外来の影響
    小岸 かれん, 大村 友博, 山本 将太, 中川 俊作, 米澤 淳, 糸原 光太郎, 竹内 理人, 松尾 研志, 橋本 凱朝, 諏訪 太朗, 佐藤 夕紀, 今井 哲司, 中川 貴之, 村井 俊哉, 矢野 育子, 松原 和夫
    第29回日本医療薬学会年会, Nov. 2019, Japanese, 福岡, Domestic conference
    Poster presentation

  • 再発・難治性悪性リンパ腫患者におけるフィルグラスチムバイオ後続品の有効性と安全性に関する検討
    奥野 護, 関 菜摘子, 五百蔵 武士, 丹田 雅明, 西岡 達也, 久米 学, 槇本 博雄, 矢野 育子
    第29回日本医療薬学会年会, Nov. 2019, Japanese, 福岡, Domestic conference
    Oral presentation

  • プロトコルおよび 薬剤部門システムを活用した DOACの薬物相互作用マネジメント
    平山陽奈、木村丈司、高橋知子、冨田猛、野崎晃、山本和宏、大本暢子、大村友博、矢野育子
    第29回日本医療薬学会年会, Nov. 2019, Japanese, 福岡, Domestic conference
    Oral presentation

  • プロトンポンプ阻害薬の院内フォーミュラリー策定による後発医薬品の使用促進と薬剤費の削減効果
    高橋 知子, 木村 丈司, 冨田 猛, 野崎 晃, 平山 陽奈, 山本 和宏, 槇本 博雄, 大村 友博, 矢野 育子
    第29回日本医療薬学会年会, Nov. 2019, Japanese, 福岡, Domestic conference
    Oral presentation

  • SGLT2阻害剤の皮膚障害に関する研究―ラット体内動態データの薬物動態学的解析とマイクロアレイ解析―
    豊田 凌大, 片山 英人, 鈴木 悠実, 松尾 直弥, 河渕 真治, 山本 和宏, 伊藤 由佳子, 矢野 育子, 栄田 敏之
    第69回日本薬学会関西支部総会・大会, Oct. 2019, Japanese, 神戸, Domestic conference
    Oral presentation

  • Oxicam-derived non-steroidal anti-inflammatory drugs protect against 1-methyl-4-phenyl pyridinium-induced cell death by suppressing of endoplasmic reticulum stress response and mitochondrial dysfunction
    Omura T, Sasaoka M, Hashimoto G, Imai S, Yamamoto J, Sato Y, Nakagawa S, Yonezawa A, Nakagawa T, Tasaki Y, Yano I, Matsubara K
    Neuroscience2019, Oct. 2019, English, Chicago, International conference
    Poster presentation

  • 薬物動態を理解し、処方設計に活かす
    矢野 育子
    神戸薬科大学第91回リカレントセミナー, Sep. 2019, Japanese, 神戸, Domestic conference
    Public discourse

  • PHARMACOKINETIC ASSESSMENT FOR A CASE OF ALPRAZOLAM-INDUCED NEONATAL ABSTINENCE SYNDROME USING PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL
    Kazuhiro Yamamoto, Sachiyo Fukushima, Yui Mishima, Mari Hashimoto, Kei Yamakawa, Kazumichi Fujioka, Kazumoto Iijima, Ikuko Yano
    The 17th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT 2019), Sep. 2019, English, Iguazu, International conference
    Poster presentation

  • Use of PBPK model simulator for the individualized therapy
    Ikuko Yano
    The 17th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT 2019), Sep. 2019, English, Iguazu, International conference
    Nominated symposium

  • 認定・専門薬剤師制度のあり方
    矢野 育子
    日本学術会議、日本薬学会共催公開シンポジウム：薬剤師が担う日本の医療と薬学教育, Aug. 2019, Japanese, 東京, Domestic conference
    Public discourse

  • ポリファーマシーにおける薬剤師の取り組み〜病診薬連携の強化を目指して〜
    矢野 育子
    広島大学薬学部主催：令和元年度ヒロシマ薬剤師研修会, Jul. 2019, Japanese, 広島, Domestic conference
    Public discourse

  • 通院治療室における急変時対応システムの構築と職員教育
    木下 実里, 土井 久容, 清田 尚臣, 久傳 真由美, 丹田 雅明, 矢野 育子, 後藤 秀彰, 崔 諭司, 吉次 育子, 小谷 穣治, 重村 克巳, 立原 素子, 西野 聖子, 南 博信
    第17回日本臨床腫瘍学会学術集会, Jul. 2019, Japanese, 京都, Domestic conference
    Poster presentation

  • 血清クレアチニン低値の患者におけるバンコマイシン母集団薬物動態解析
    大野 由花, 阪上 倫行, 山本 和宏, 平 大樹, 上島 智, 角本 幹夫, 矢野 育子
    医療薬学フォーラム2019 第27回 クリニカルファーマシーシンポジウム, Jul. 2019, Japanese, 広島, Domestic conference
    Poster presentation

  • 肺由来細胞のエベロリムス反応性におけるSTAT3遺伝子多型の影響
    浜崎 美月, 山本 和宏, 濵口 常男, 國正 淳一, 矢野 育子
    医療薬学フォーラム2019 第27回 クリニカルファーマシーシンポジウム, Jul. 2019, Japanese, 広島, Domestic conference
    Poster presentation

  • ICU入室患者における睡眠薬使用後のせん妄発現に対するリスク因子の探索
    藤田 浩平, 菅生 有夏, 山本 和宏, 大本 暢子, 西岡 達也, 久米 学, 槇本 博雄, 矢野 育子
    医療薬学フォーラム2019 第27回 クリニカルファーマシーシンポジウム, Jul. 2019, Japanese, 広島, Domestic conference
    Poster presentation

  • 処方オーダリングシステムにおける検査値に対応した処方禁忌チェック機能の導入と評価
    冨田 猛, 山本 和宏, 熊岡 穣, 木村 丈司, 北島 美有, 北村 直子, 大本 暢子, 矢野 育子
    第22回日本医薬品情報学会総会・学術大会, Jun. 2019, Japanese, 札幌, Domestic conference
    Oral presentation

  • 新規抗てんかん薬の薬物動態とTDMの有用性
    矢野 育子
    第81回大阪薬科大学公開教育講座, May 2019, Japanese, 大阪, Domestic conference
    Public discourse

  • ポリファーマシーに対する薬剤師の取り組み
    矢野 育子
    病院薬剤師セミナー in OSAKA, May 2019, Japanese, 大阪, Domestic conference
    Public discourse

  • ラモトリギンTDMの現状と血中濃度の変動因子に関する調査
    松田 美玖, 山本 和宏, 阪上 倫行, 高橋 知子, 矢野 育子
    第36回日本TDM学会・学術大会, May 2019, Japanese, 東京, Domestic conference
    Poster presentation

  • 抗てんかん薬TDMガイドライン
    矢野 育子
    第36回日本TDM学会・学術大会, May 2019, Japanese, 東京, Domestic conference
    Nominated symposium

  • 薬剤師のポリファーマシーに対する取り組みについて〜抗不安薬・睡眠薬・NSAIDsを中心に〜
    矢野 育子
    医薬品情報研修会, Apr. 2019, Japanese, 京都, Domestic conference
    Public discourse

  • 薬剤業務を科学する
    YANO IKUKO
    第7回つるまい医療薬学シンポジウム, Mar. 2019, Japanese, 名古屋, Domestic conference
    [Invited]
    Nominated symposium

  • 明日からの薬物治療を変える
    YANO IKUKO
    第2回神戸臨床薬学研究会, Mar. 2019, Japanese, 神戸, Domestic conference
    Public discourse

  • 睡眠薬使用後にせん妄が出現した患者のICU入室中におけるリスク因子の探索
    菅生 有夏, 藤田 浩平, YAMAMOTO KAZUHIRO, 大本 暢子, 西岡 達也, 久米 学, 槇本 博雄, 坂根 稔康, 國正 淳一, 濱口 常男, 北河 修治, YANO IKUKO
    第8回日本薬剤師レジデントフォーラム, Mar. 2019, Japanese, 福岡, Domestic conference
    Poster presentation

  • 新規Bcl-2選択的阻害剤の長期間曝露がヒト白血病細胞株に及ぼす影響
    中山 優子, 高良 恒史, 峯垣 哲也, YAMAMOTO KAZUHIRO, YANO IKUKO
    日本薬学会第139年会, Mar. 2019, Japanese, 日本薬学会, 千葉, Domestic conference
    Poster presentation

  • 高度催吐性リスクの化学療法に伴う悪心・嘔吐に対するオランザピン投与量の検討
    穐原 裕奈, YAMAMOTO KAZUHIRO, 水田 直美, 丹田 雅明, 伊藤 雄大, 坂根 稔康, 國正 淳一, 濵口 常男, 北河 修治, YANO IKUKO
    第8回日本薬剤師レジデントフォーラム, Mar. 2019, Japanese, 福岡, Domestic conference
    Poster presentation

  • 抗がん薬の副作用マネジメントにおける地域薬局との連携
    YANO IKUKO
    神戸大学医学部・近畿大学薬学部合同セミナー, Mar. 2019, Japanese, 大阪, Domestic conference
    [Invited]
    Nominated symposium

  • 経口抗がん薬を含む術後補助化学療法における薬薬協働支援の有用性
    榎本 彩花, 丹田 雅明, 植田 梨沙, 水田 直美, YAMAMOTO KAZUHIRO, 西岡 達也, 槇本 博雄, 坂根 稔康, 國正 淳一, 濱口 常男, 北河 修治, YANO IKUKO
    第8回日本薬剤師レジデントフォーラム, Mar. 2019, Japanese, 福岡, Domestic conference
    Poster presentation

  • 経口抗がん薬を含む術後補助化学療法における病院および保険薬局薬剤師との協働支援の有用性評価
    榎本 彩花, 丹田 雅明, 植田 梨沙, 水田 直美, YAMAMOTO KAZUHIRO, 西岡 達也, 槇本 博雄, 坂根 稔康, 國正 淳一, 濱口 常男, 北河 修治, YANO IKUKO
    日本臨床腫瘍薬学会学術大会2019, Mar. 2019, Japanese, 日本臨床腫瘍薬学会, 札幌, Domestic conference
    Poster presentation

  • 化学療法誘発性の悪心・嘔吐予防目的のオランザピン投与量に関する検討
    穐原 裕奈, YAMAMOTO KAZUHIRO, 水田 直美, 丹田 雅明, 伊藤 雄大, 坂根 稔康, 國正 淳一, 濵口 常男, 北河 修治, YANO IKUKO
    日本薬学会第139年会, Mar. 2019, Japanese, 日本薬学会, 千葉, Domestic conference
    Poster presentation

  • 医薬品適正使用のためのクリニカルファーマコメトリクス※佐藤記念国内賞受賞講演
    YANO IKUKO
    日本薬学会第139年会, Mar. 2019, Japanese, 日本薬学会, 千葉, Domestic conference
    [Invited]
    Invited oral presentation

  • チーム基盤型学習を用いた経口抗がん薬に関する勉強会の有用性の検討
    植田 梨沙, 伊藤 雄大, 丹田 雅明, 飯田 真之, YAMAMOTO KAZUHIRO, 槇本 博雄, YANO IKUKO
    日本臨床腫瘍薬学会学術大会2019, Mar. 2019, Japanese, 日本臨床腫瘍薬学会, 札幌, Domestic conference
    Oral presentation

  • 薬物治療の質的向上を目指して〜薬剤師に研究が必要な理由〜
    YANO IKUKO
    京都薬科大学キャリアパスセミナー, Feb. 2019, Japanese, 京都, Domestic conference
    Public discourse

  • 低アルブミン血症の原因がPPIによるcollagenous colitisと考えられた1例
    清水 倫子, 村前 直和, 脇田 久美子, 秋山 恵里, 曽我 昭宏, 生田 智子, 北秋 翔子, 山本 麻里, 上岡 美和, 野口 まどか, 松田 佳子, YANO IKUKO, 髙橋 路子, OGAWA WATARU
    第34回日本静脈経腸栄養学会学術集会, Feb. 2019, Japanese, 日本静脈経腸栄養学会, 東京, Domestic conference
    Poster presentation

  • 低Mg血症による副甲状腺機能低下症を呈した2症例
    秋山 恵里, 村前 直和, 田渕 聡子, 脇田 久美子, 中谷 早希, 生田 智子, 曽我 昭宏, 清水 倫子, 上岡 美和, 野口 まどか, 北秋 翔子, 松田 佳子, YANO IKUKO, 髙橋 路子, OGAWA WATARU
    第34回日本静脈経腸栄養学会学術集会, Feb. 2019, Japanese, 日本静脈経腸栄養学会, 東京, Domestic conference
    Poster presentation

  • 神戸大学病院の現状分析とこれから
    YANO IKUKO
    第4回Hyogo Pharmacy Director Conference, Feb. 2019, Japanese, 神戸, Domestic conference
    Public discourse

  • 神戸大学・神戸薬科大学連携事業における薬剤部の役割
    YANO IKUKO
    神戸大学・神戸薬科大学合同シンポジウム, Feb. 2019, Japanese, 神戸, Domestic conference
    [Invited]
    Nominated symposium

  • ポリファーマシー見直しのための多職種協働〜高齢者の安全な薬物療法への取り組み〜
    YANO IKUKO
    第214回大阪薬品適正使用研究会, Feb. 2019, Japanese, 大阪, Domestic conference
    Public discourse

  • Molecular characteristics of human leukemia cell line after the long-term exposure to the Bcl-2 inhibitor ABT-199
    Nakayama Y, Takara K, Minegaki T, Yamamoto K, Yano I
    The 2nd International Cancer Research Symposium of Training Plan for Oncology Professionals, Feb. 2019, Japanese, Osaka, International conference
    Poster presentation

  • 免疫関連有害事象防止のための診療連携体制構築により有害事象の重症化を回避できた2症例
    石井 順子, 丹田 雅明, 奥野 護, 髙田 麻季, 槇本 博雄, YANO IKUKO
    第40回日本病院薬剤師会近畿学術大会, Jan. 2019, Japanese, 日本病院薬剤師会, 奈良, Domestic conference
    Oral presentation

  • 個別化投与設計のためのファーマコメトリクス
    YANO IKUKO
    神戸薬科大学大学院薬剤学特論, Jan. 2019, Japanese, 神戸, Domestic conference
    Public discourse

  • 検査値連動型の処方チェックシステムを用いた疑義照会の有用性
    冨田 猛, YAMAMOTO KAZUHIRO, 野﨑 晃, 高橋 知子, 木村 丈司, 大本 暢子, 西岡 達也, 久米 学, 槇本 博雄, YANO IKUKO
    平成30年度大学病院情報マネジメント部門連絡会議, Jan. 2019, Japanese, 大学病院情報マネジメント部門連絡会議, 熊本, Domestic conference
    Public symposium

  • 改訂薬学教育モデルコア・カリキュラムに準拠した病院実務実習のプログラムの作成と評価
    YAMAMOTO KAZUHIRO, 藤田 浩平, 秋山 恵里, 清水 倫子, 久保 萌子, 松本 久美子, 谷藤 亜希子, 大本 暢子, YANO IKUKO
    第40回日本病院薬剤師会近畿学術大会, Jan. 2019, Japanese, 日本病院薬剤師会, 奈良, Domestic conference
    Poster presentation

  • 薬物動態学（PK）の観点から見る免疫抑制剤
    YANO IKUKO
    第45回日本臓器保存生物医学会学術集会, Nov. 2018, Japanese, 日本臓器保存生物医学会, 名古屋, Domestic conference
    [Invited]
    Nominated symposium

  • 薬剤部における業務・教育・研究
    YANO IKUKO
    協和発酵キリン株式会社社内研修会, Nov. 2018, Japanese, 神戸, Domestic conference
    Public discourse

  • 抗がん薬の薬物動態と薬効解析
    YANO IKUKO
    平成30年度大学院特別講義がんプロフェショナル養成特論, Nov. 2018, Japanese, 神戸, Domestic conference
    Public discourse

  • ポリファーマシー対策のための医薬連携合同勉強会の開催とアンケートによる現状調査
    秋山 恵里, 木村 丈司, YAMAMOTO KAZUHIRO, 飯田 真之, 藤田 弥佐, 清水 倫子, 久保 萌子, 住吉 霞美, 番匠 咲帆, 三島 唯, 戸田 飛鳥, 宇田 篤史, YANO IKUKO
    第28回日本医療薬学会年会, Nov. 2018, Japanese, 日本医療薬学会, 神戸, Domestic conference
    Poster presentation

  • ポリファーマシーの効率的な検出と保険薬局との連携を目指したwebシステムの構築
    野﨑 晃, YAMAMOTO KAZUHIRO, 木村 丈司, 松田 美玖, 高橋 知子, 小倉 史愛, YANO IKUKO
    第28回日本医療薬学会年会, Nov. 2018, Japanese, 日本医療薬学会, 神戸, Domestic conference
    Poster presentation

  • シクロスポリン内服中に母乳育児を行なった２症例
    山川 恵, 三島 唯, 北島 美有, 藤原 尚子, 橋本 真梨, 松本 久美子, 大本 暢子, 久米 学, 森實 真由美, YANO IKUKO
    第28回日本医療薬学会年会, Nov. 2018, Japanese, 日本医療薬学会, 神戸, Domestic conference
    Poster presentation

  • STOPP criteria version 2と高齢者の安全な薬物療法ガイドライン2015を組み合わせた不適切処方への介入
    藤田 弥佐, 木村 丈司, 清水 倫子, 久保 萌子, 住吉 霞美, 番匠 咲帆, 三島 唯, 戸田 飛鳥, 松本 久美子, 大本 暢子, 西岡 達也, YANO IKUKO
    第28回日本医療薬学会年会, Nov. 2018, Japanese, 日本医療薬学会, 神戸, Domestic conference
    Oral presentation

  • Improvement of Patient Care Quality through Pharmacist Intervention as A Member of Multidisciplinary Team Creates New Roles in Japan
    Matsubara K, Yonezawa A, Nakagawa T, Imai S, Omura T, Nakagawa S, Sato Y, Yano I
    Taiwan Society of Health-System Pharmacist (TSHP) Annual Conference, Nov. 2018, English, 高雄, International conference
    [Invited]
    Invited oral presentation

  • 薬学部実務実習生へのチーム医療「糖尿病」に関する教育課題について
    松本 久美子, 谷藤 亜希子, 秋山 恵里, 大本 暢子, OGAWA WATARU, YANO IKUKO
    第55回日本糖尿病学会近畿地方会, Oct. 2018, Japanese, 日本糖尿病学会, 神戸, Domestic conference
    Oral presentation

  • Up-to-date 抗てんかん薬のTDM
    YANO IKUKO
    第68回日本薬学会近畿支部総会・大会, Oct. 2018, Japanese, 姫路, Domestic conference
    Public symposium

  • Physiologically based pharmacokinetic model for tacrolimus in living-donor liver transplantation considering liver regeneration and CYP3A5 genotype
    Itohara K, Yano I, Tsuzuki T, Uesugi M, Nakagawa S, Yonezawa A, Okajima H, Kaido T, Uemoto S, Matsubara K
    2018 International Meeting on 22nd MDO and 33rd JSSX, Oct. 2018, English, 日本薬物動態学会, Kanazawa, International conference
    Oral presentation

  • Drug metabolism in pediatric populations-Prediction of hepatic clearance-
    Ikuko Yano
    2018 International Meeting on 22nd MDO and 33rd JSSX, Oct. 2018, English, 日本薬物動態学会, Kanazawa, International conference
    [Invited]
    Nominated symposium

  • Influence of CYP2C19 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in the combination therapy with lansoprazole in Japanese renal transplant recipients
    Kazuhiro Yamamoto, Masashi Iida, Ayaka Yoshida, Takahiro Ito, Naoki Yokoyama, Takeshi Ishimura, Masato Fujisawa, Ikuko Yano
    The 16th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT 2018), Sep. 2018, English, International Association of Therapeutic Drug Monitoring & Clinical Toxicology, Brisbene, International conference
    Poster presentation

  • Association of pharmacokinetic and pharmacodynamic markers of mycophenolic acid and clinical outcomes in cord blood transplant patients
    Ikuko Yano, K. Yoshimura, T. Yamamoto, T. Kondo, M. Kawanishi, Y. Isomoto, A. Yonezawa, A. Takaori-Kondo, K. Matsubara
    The 16th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT 2018), Sep. 2018, English, International Association of Therapeutic Drug Monitoring & Clinical Toxicology, Brisbene, International conference
    Public symposium

  • 冷却療法は凍傷予防の手足カバー使用下においても化学療法誘発性末梢神経障害を予防する
    華井 明子, 石黒 洋, 寒水 孝司, 津田 萌, YANO IKUKO, 中川 貴之, 今井 哲司, 浜辺 陽子, 戸井 雅和, 新井 秀典, 坪山 直生
    第16回日本臨床腫瘍学会学術集会, Jul. 2018, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • リスペリドンによる錐体外路症状とCYP2D6遺伝子多型の関連
    伊藤 雄大, YAMAMOTO KAZUHIRO, 大澤 史宜, 大塚 郁夫, 菱本 明豊, 曽良 一郎, 平井 みどり, YANO IKUKO
    第2回フレッシャーズ・カンファランス, Jul. 2018, Japanese, 一般社団法人 日本医療薬学会, 京都, Domestic conference
    Oral presentation

  • ポリファーマシーと薬剤師の役割
    YANO IKUKO
    大阪府下市立病院薬剤部長会学術講演会, Jul. 2018, Japanese, 大阪, Domestic conference
    [Invited]
    Nominated symposium

  • Effects of sunitinib on the expression of keratin 9 in human keratinocyte cell lines and a 3D skin model
    Ayaka Yoshida, Kazuhiro Yamamoto, Akane Murakawa, Takahiro Ishida, Tsutomu Nakagawa, Tomoo Itoh, Ikuko Yano
    18th World Congress of Basic and Clinical Pharmacology, Jul. 2018, English, International Union of Basic and Clinical Pharmacology, Kyoto, International conference
    Poster presentation

  • 新規抗てんかん薬のTDMは必要か？〜ラコサミドを含めて〜
    YANO IKUKO
    第32回島根てんかん研究会, Jun. 2018, Japanese, 島根, Domestic conference
    Public discourse

  • ケラチン9の発現に及ぼす皮膚高次構造とスニチニブの影響
    村川 亜光, YAMAMOTO KAZUHIRO, 吉田 彩夏, 濵口 常男, NAKAGAWA TSUTOMU, YANO IKUKO
    医療薬学フォーラム2018 第26回クリニカルファーマーシーシンポジウム, Jun. 2018, Japanese, 日本薬学会, 東京, Domestic conference
    Poster presentation

  • エベロリムス長期曝露肺胞上皮細胞の上皮間葉転換に寄与するケモカインの探索
    岩間 弓奈, YAMAMOTO KAZUHIRO, 濵口 常男, NAKAGAWA TSUTOMU, YANO IKUKO
    医療薬学フォーラム2018 第26回クリニカルファーマーシーシンポジウム, Jun. 2018, Japanese, 日本薬学会, 東京, Domestic conference
    Poster presentation

  • Development of a pediatric dosing regimen of trichlofos and chloral hydrate based on population pharmacokinetics and pharmacodynamics in pediatric intensive care patients
    Inoue M, Itohara K, Sato H, Kato Y, Ishii S, Yano I, Yonezawa A, Matsubara K, Ito Y, Kamijima M, Nasu T, Yamagishi M, Sawa T, Hashimoto S
    9 th Congress of World Federation of Pediatric Intensive and Critical Care Societies, Jun. 2018, English, World Federation of Pediatric Intensive and Critical Care, Singapore, International conference
    Oral presentation

  • ベンゾジアゼピン系薬剤（クロバザム）レベチラセタム
    YANO IKUKO
    第35回日本ＴＤＭ学会・学術大会, May 2018, Japanese, 日本ＴＤＭ学会, 福岡, Domestic conference
    [Invited]
    Nominated symposium

  • アルプラゾラム服用妊婦から出生した児の薬物血中濃度測定を行った一症例
    三島 唯, YAMAMOTO KAZUHIRO, 橋本 真梨, 福嶋 祥代, 藤岡 一路, YANO IKUKO
    第35回日本TDM学会・学術大会, May 2018, Japanese, 日本ＴＤＭ学会, 福岡, Domestic conference
    Poster presentation

  • 薬剤師教育におけるチーム基盤型学習 (TBL) の導入とその有用性の検討
    髙田 麻季, 伊藤 雄大, 飯田 真之, 秋山 恵里, 住吉 霞美, 木村 丈司, 西岡 達也, 久米 学, 槇本 博雄, Yano Ikuko
    日本薬学会第138年会, Mar. 2018, Japanese, 日本薬学会, 金沢, Domestic conference
    Oral presentation

  • 薬剤師レジデントの学生教育機会に関する報告
    石川 愛子, Nakagawa Tsutomu, 西岡 達也, 久米 学, 槇本 博雄, 濱口 常男, 岩川 精吾, 北河 修治, Yano Ikuko
    第7回日本薬剤師レジデントフォーラム, Mar. 2018, Japanese, 日本薬剤師レジデント研究会, 神戸, Domestic conference
    Poster presentation

  • 造血器腫瘍の化学療法におけるフィルグラスチム先行品とバイオ後続品の有効性と安全性の比較
    関 菜摘子, 奥野 護, 西岡 達也, 久米 学, 槇本 博雄, 濱口 常男, 岩川 精吾, 北河 修治, Yano Ikuko
    第7回日本薬剤師レジデントフォーラム, Mar. 2018, Japanese, 日本薬剤師レジデント研究会, 神戸, Domestic conference
    Poster presentation

  • 持参薬確認業務における危険予知トレーニングツールの開発とその評価
    谷藤 亜希子, 山本 和宏, 木村 丈司, 五百蔵 武士, 西岡 達也, 久米 学, 槇本 博雄, Yano Ikuko
    日本薬学会第138年会, Mar. 2018, Japanese, 日本薬学会, 金沢, Domestic conference
    Oral presentation

  • ポリファーマシーに対する介入の長期的な評価
    高橋 知子, 小倉 史愛, 木村 丈司, 清水 倫子, 西岡 達也, 久米 学, 槇本 博雄, Yano Ikuko
    日本薬学会第138年会, Mar. 2018, Japanese, 日本薬学会, 金沢, Domestic conference
    Oral presentation

  • グアーガム分解物含有経腸栄養剤使用患者に対する整腸剤の相加効果の検討
    八木 美樹, 曽我 昭宏, 西岡 達也, 久米 学, 槇本 博雄, 濱口 常男, 岩川 精吾, 北河 修治, Yano Ikuko
    第7回日本薬剤師レジデントフォーラム, Mar. 2018, Japanese, 日本薬剤師レジデント研究会, 神戸, Domestic conference
    Poster presentation

  • Nab-Paclitaxelと併用薬混合時の安定性に関する検討
    水田 直美, Nakagawa Tsutomu, 山本 和宏, 西岡 達也, 久米 学, 槇本 博雄, Yano Ikuko, Minami Hironobu, Hirai Midori
    日本臨床腫瘍薬学会学術大会2018, Mar. 2018, Japanese, 日本臨床腫瘍薬学会, 横浜, Domestic conference
    Poster presentation

  • 統合失調症治療における頓用薬の使用に関する評価
    中谷 優花, 大瀧 隆介, 西岡 達也, 久米 学, 槇本 博雄, Yano Ikuko
    近畿薬剤師合同学術大会2018, Feb. 2018, Japanese, 京都府薬剤師会, 京都, Domestic conference
    Poster presentation

  • 造血器腫瘍の化学療法におけるフィルグラスチム先行品とバイオ後続品の有効性と安全性の検討
    関 菜摘子, 奥野 護, 西岡 達也, 久米 学, 槇本 博雄, 濱口 常男, 岩川 精吾, 北河 修治, Yano Ikuko
    近畿薬剤師合同学術大会2018, Feb. 2018, Japanese, 京都府薬剤師会, 京都, Domestic conference
    Poster presentation

  • 小児用量鑑査システム導入のための処方状況調査
    北島 美有, 野﨑 晃, 西岡 達也, 久米 学, 槇本 博雄, Yano Ikuko
    近畿薬剤師合同学術大会2018, Feb. 2018, Japanese, 川勝一雄, 京都府, Domestic conference
    Poster presentation

  • オピオイド服用患者における酸化マグネシウムの緩下作用に対してプロトンポンプ阻害薬併用が与える影響
    岡田 美咲, 飯田 真之, 五百蔵 武士, 西岡 達也, 久米 学, 槇本 博雄, Yano Ikuko
    近畿薬剤師合同学術大会2018, Feb. 2018, Japanese, 京都府薬剤師会, 京都, Domestic conference
    Poster presentation

  • 病院薬剤部からのメッセージ
    Yano Ikuko
    メディショナルナノテク研究会, Dec. 2017, Japanese, テクノグローバルウェイブ, 神戸, Domestic conference
    [Invited]
    Nominated symposium

  • 小児におけるトリクロロエタノールの薬物動態・薬力学の発達・成長に伴う変化の解析
    井上 美帆, 糸原 光太郎, 佐藤 博貴, 加藤 祐子, 石井 祥代, 伊藤 由起, 中平 有紀, 那須 民江, 上島 通浩, Yano Ikuko, 松原 和夫, 佐和 貞治, 橋本 悟
    第38回日本臨床薬理学会学術集会, Dec. 2017, Japanese, 日本臨床薬理学会, 横浜, Domestic conference
    Oral presentation

  • 実臨床データを用いたファーマコメトリクス による個体間変動予測
    Yano Ikuko
    第38回日本臨床薬理学会学術集会, Dec. 2017, Japanese, 日本臨床薬理学会, 横浜, Domestic conference
    Public symposium

  • 外国人患者受入れ医療機関認証制度と患者用クリニカルパス
    Takaoka Yutaka, Yano Ikuko, 中町 祐司, 日下 亜紀子, 山本 育子, ウィリアムソン 彰子, 輪野 透, Kakeji Yoshihiro, Nishi Shinichi, Itoh Tomoo
    第17回日本クリニカルパス学会, Dec. 2017, Japanese, 日本クリニカルパス学会, 大阪, Domestic conference
    Poster presentation

  • 外国人患者受入れ医療機関認証制度と患者用クリニカルパス
    Takaoka Yutaka, Yano Ikuko, 中町 祐司, 日下 亜紀子, 山本 育子, ウィリアムソン 彰子, 輪野 透, Kakeji Yoshihiro, Nishi Shinichi, Itoh Tomoo
    第18回日本クリニカルパス学会学術集会, Dec. 2017, Japanese, 日本クリニカルパス学会, 大阪, Domestic conference
    Oral presentation

  • B細胞リンパ腫患者における，リツキシマブのPK/PD解析
    森 万優子, 米澤 淳, 大谷 祐基, 礒本 唯, 津田 真弘, 池見 泰明, 今井 哲司, 大村 友博, 北野 俊行, 高折 晃史, Yano Ikuko, 松原 和夫
    第38回日本臨床薬理学会学術集会, Dec. 2017, Japanese, 日本臨床薬理学会, 横浜, Domestic conference
    Oral presentation

  • 麻酔科術前外来患者を対象とした薬剤師の介入効果
    岡崎 裕太朗, 木村 丈司, 戸田 飛鳥, 阪上 倫行, 江口 舞, 西岡 達也, 久米 学, 槇本 博雄, Hirai Midori, Yano Ikuko
    第27回日本医療薬学会年会, Nov. 2017, Japanese, 日本医療薬学会, 千葉, Domestic conference
    Poster presentation

  • 統合失調症患者における錐体外路症状発現に及ぼすCYP2D6遺伝子多型の影響
    伊藤 雄大, 山本 和宏, 西岡 達也, 久米 学, 槇本 博雄, Otsuka Ikuo, Hishimoto Akitoyo, Ichiro Sora, Hirai Midori, Yano Ikuko
    第27回日本医療薬学会年会, Nov. 2017, Japanese, 日本医療薬学会, 千葉, Domestic conference
    Oral presentation

  • 検査値連動型の処方チェックシステムを用いた疑義照会の有用性
    冨田 猛, 山本 和宏, 野﨑 晃, 宇田 篤史, 阪上 倫行, 西岡 達也, 久米 学, 槇本 博雄, Hirai Midori, Yano Ikuko
    第27回日本医療薬学会年会, Nov. 2017, Japanese, 日本医療薬学会, 千葉, Domestic conference
    Poster presentation

  • 院内製剤レボチロキシンナトリウム坐剤の至適投与量の探索と安定性の検討
    南 いく子, 志田 あゆみ, 山際 岳朗, 大村 友博, 中川 貴之, 中川 俊作, Yano Ikuko, 松原 和夫
    第27回日本医療薬学会年会, Nov. 2017, Japanese, 日本医療薬学会, 千葉, Domestic conference
    Oral presentation

  • Population pharmacokinetics and pharmacodynamics of trichloroethanol in pediatric patients
    Kotaro Itohara, Miho Inoue, Yano Ikuko, Hirotaka Sato, Yuko Kato, Sachiyo Ishii, Atsushi Yonezawa, Yuki Ito, Michihiro Kamijima, Teiji Sawa, Satoru Hashimoto, Kazuo Matsubara
    日本薬物動態学会第32年会, Nov. 2017, Japanese, 日本薬物動態学会, 東京, Domestic conference
    Oral presentation

  • PK/PD analysis of rituximab in the patient with non-Hodgkin’s lymphoma
    Atsushi Yonezawa, Mayuko Mori, Yuki Otani, Yui Isomoto, Masahiro Tsuda, Yasuaki Ikemi, Satoshi Imai, Tomohiro Omura, Yano Ikuko, Toshiyuki Kitano, Akifumi Takaori, Kazuo Matsubara
    日本薬物動態学会第32年会, Nov. 2017, Japanese, 日本薬物動態学会, 東京, Domestic conference
    Oral presentation

  • 腎移植患者における術後早期のタクロリムス血中濃度の評価
    飯田 真之, 山本 和宏, 伊藤 雄大, 大澤 史宜, 西岡 達也, 久米 学, 槇本 博雄, 横山 直己, Ishimura Takeshi, Fujisawa Masato, Yano Ikuko
    第34回日本TDM学会・学術大会, Sep. 2017, Japanese, 日本TDM学会, 京都, Domestic conference
    Poster presentation

  • TDM for a new class of anti-epileptic drugs, S-12 TDM for central nervous system drugs.
    Yano Ikuko
    the 15th Congress of the International Association of Therapeutic Drug Monitoring & Clinical Toxicology, Sep. 2017, English, the International Association of Therapeutic Drug Monitoring & Clinical Toxicology, Kyoto, Japan, International conference
    [Invited]
    Nominated symposium

  • Population pharmacokinetic modeling and simulation of topiramate using the routinely monitored data for the individualized dosage adjustment
    Masato Takeuchi, Yano Ikuko, Satoko Ito, Mitsuhiro Sugimoto, Shota Yamamoto, Atsushi Yonezawa, Akiko Ikeda, Kazuo Matsubara
    the 15th Congress of the International Association of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT), Sep. 2017, English, the International Association of Therapeutic Drug Monitoring & Clinical Toxicology, Kyoto, Japan, International conference
    Poster presentation

  • Molecular cornifying mechanisms of multi-targeted tyrosine kinase inhibitors-induced hand-foot skin reaction based on genetic differences of STAT3
    Kazuhiro Yamamoto, Takahiro Ishida, Nakagawa Tsutomu, Tatsuya Nishioka, Manabu Kume, Hiroo Makimoto, Hideaki Miyake, Fujisawa Masato, Nishigori Chikako, Yano Ikuko, Hirai Midori
    the 15th Congress of the International Association of Therapeutic Drug Monitoring & Clinical Toxicology, Sep. 2017, English, the International Association of Therapeutic Drug Monitoring & Clinical Toxicology, Kyoto, Japan, International conference
    Poster presentation

  • Impact of STAT3 genetic polymorphism on sunitinib-induced stomatitis in Japanese renal cell carcinoma patients
    Aimi Watanabe, Kazuhiro Yamamoto, Takeshi Ioroi, Sachi Hirata, Harada Kenichi, Hideaki Miyake, Fujisawa Masato, Nakagawa Tsutomu, Yano Ikuko, Hirai Midori
    the 15th Congress of the International Association of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT), Sep. 2017, English, the International Association of Therapeutic Drug Monitoring & Clinical Toxicology, Kyoto, Japan, International conference
    Poster presentation

  • CYP2C19 polymorphism affects the efficacy but not drowsiness in the low dose clobazam therapy
    Sachiyo Hashi, Yano Ikuko, Mai Shibata, Ryosuke Matsumoto, Akiko Ikeda, Atsushi Yonezawa, Ryosuke Takahashi, Kazuo Matsubara
    the 15th Congress of the International Association of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT), Sep. 2017, English, the International Association of Therapeutic Drug Monitoring & Clinical Toxicology, Kyoto, Japan, International conference
    Oral presentation

  • 冷却手袋靴下によるパクリタキセル起因性末梢神経障害の予防：乳癌化学療法患者に対する個体内比較試験
    華井 明子, 石黒 洋, 寒水 孝司, 津田 萌, Yano Ikuko, 中川 貴之, 今井 哲司, 戸井 雅和, 新井 秀典, 坪山 直生
    第15回日本臨床腫瘍学会学術集会, Jul. 2017, Japanese, 日本臨床腫瘍学会, 神戸, Domestic conference
    Oral presentation

  • 病棟薬剤師によるベンゾジアゼピン系薬剤の適正使用についての取り組みとその評価
    山岡 慶子, 木村 丈司, 宇田 篤史, 秋山 恵里, 大瀧 隆介, 小出 慶子, 國光 葉子, 住吉 霞美, 田中 雄大, 布目 春乃, 野間 千尋, 藤田 浩平, 山崎 直樹, 西岡 達也, 久米 学, 槇本 博雄, Yano Ikuko, Hirai Midori
    医療薬学フォーラム2017 第25回クリニカルファーマシーシンポジウム, Jul. 2017, Japanese, 日本薬学会医療薬科学部会, 鹿児島, Domestic conference
    Poster presentation

  • リツキシマブの体内動態とその変動因子の考察
    大谷 祐基, 米澤 淳, 礒本 唯, 津田 真弘, 池見 泰明, 今井 哲司, 大村 友博, 中川 俊作, 中川 貴之, Yano Ikuko, 北野 俊行, 高折 晃史, 松原 和夫
    医療薬学フォーラム2017 第25回クリニカルファーマシーシンポジウム, Jul. 2017, Japanese, 日本薬学会医療薬科学部会, 鹿児島, Domestic conference
    Poster presentation

  • 薬剤師主導のオピオイド使用全入院患者を対象としたカルテ回診の評価と課題
    志田 有里, 奥野 護, 打保 裕子, 西岡 達也, 久米 学, 槇本 博雄, Yano Ikuko, Hirai Midori
    第11回日本緩和医療薬学会年会, Jun. 2017, Japanese, 日本緩和医療薬学会, 札幌, Domestic conference
    Poster presentation

  • 生理学的薬物動態モデルを用いた生体肝移植患者におけるタクロリムスのモデリング&シミュレーション
    Yano Ikuko
    第11回日本薬物動態学会ショートコース, May 2017, Japanese, 日本薬物動態学会, 東京, Domestic conference
    Public discourse

  • 高齢者の安全な薬物療法ガイドライン2015を 用いた高齢者のポリファーマシーに対する 薬剤師による介入とその評価 − STOPP criteria ver.2との比較−
    小倉 史愛, 木村 丈司, 久木田 礼子, 高橋 知子, 西岡 達也, 久米 学, 槇本 博雄, Yano Ikuko, Hirai Midori
    第1回日本老年薬学会学術大会, May 2017, Japanese, 日本老年薬学会, 東京, Domestic conference
    Oral presentation

  • ChREBPのグルコース濃度依存的なDNA結合はO-GlcNAc修飾により制御される
    Nakagawa Tsutomu, 吉村 友希, 崎山 晴彦, 中川 孝俊, 山本 和宏, Yano Ikuko, 藤原 範子, 朝日 通雄, 鈴木 敬一郎, Hirai Midori
    第64回日本生化学会近畿支部例会, May 2017, Japanese, 日本生化学会, 大阪, Domestic conference
    Oral presentation

  • 頭頸部がん患者におけるcisplatinと強度変調放射線同時併用療法の完遂率を低下させる因子の検討
    伊藤 雄大, 志田 有里, 西岡 達也, 久米 学, 槇本 博雄, Yano Ikuko, Hirai Midori
    日本薬学会第137年会, Mar. 2017, Japanese, 日本薬学会, 仙台, Domestic conference
    Poster presentation

  • 腎細胞癌患者のスニチニブ治療効果に及ぼす組織STAT3発現の影響
    山本 和宏, 劉 兵, 原 琢人, 渡邊 愛未, 西岡 達也, 久米 学, 槇本 博雄, Nakagawa Tsutomu, Yano Ikuko, 三宅 秀明, Fujisawa Masato, Hirai Midori
    日本薬学会第137年会, Mar. 2017, Japanese, 日本薬学会, 仙台, Domestic conference
    Poster presentation

  • 小児におけるテイコプラニンの薬物動態解析
    松尾 研志, 近藤 美貴, 吉村 一晃, 中川 俊作, 米澤 淳, 中川 貴之, Yano Ikuko, 松原和夫
    日本薬学会第137年会, Mar. 2017, Japanese, 日本薬学会, 仙台, Domestic conference
    Oral presentation

  • 後方視的解析に基づくバンコマイシン初回投与ノモグラムの検討
    住吉 霞美, 山本 和宏, 田中 雄大, 久木田 礼子, 阪上 倫行, 木村 丈司, 西岡 達也, 久米 学, 槇本 博雄, Yano Ikuko, Hirai Midori
    日本薬学会第137年会, Mar. 2017, Japanese, 日本薬学会, 仙台, Domestic conference
    Poster presentation

  • 経口抗がん薬処方に対する保険薬局との連携強化のためのツールの評価と今後の課題
    植田 梨沙, 丹田 雅明, 槇本 博雄, 西岡 達也, 久米 学, 濱口 常男, 岩川 精吾, 北河 修治, Yano Ikuko, Hirai Midori
    第6回日本薬剤師レジデントフォーラム, Mar. 2017, Japanese, 日本薬剤師レジデント制度研究会, 東京, Domestic conference
    Poster presentation

  • 経口抗がん薬処方に対する地域保険薬局との連携強化に向けた保険薬局薬剤師の意識調査と連携ツールの作成
    植田 梨沙, 丹田 雅明, 槇本 博雄, 西岡 達也, 久米 学, 濱口常男, 岩川 精吾, 北河 修治, Yano Ikuko, Hirai Midori
    日本臨床腫瘍薬学会学術大会2017, Mar. 2017, Japanese, 日本臨床腫瘍薬学会, 新潟, Domestic conference
    Poster presentation

  • 吸入指導外来の立ち上げとその評価について
    小澤 拓, 大本 暢子, 桒原 晶子, 久米 学, 西岡 達也, 槇本 博雄, Yano Ikuko, 濱口 常男, 岩川 精吾, 北河 修治, Hirai Midori
    第6回日本薬剤師レジデントフォーラム, Mar. 2017, Japanese, 日本薬剤師レジデント制度研究会, 東京, Domestic conference
    Poster presentation

  • 院外処方箋における疑義照会簡素化プロトコールの運用とその評価
    石川 愛子, 宇田 篤史, Yano Ikuko, 冨田 猛, 阪上 倫行, 野崎 晃, 西岡 達也, 久米 学, 槇本 博雄, 濱口 常男, 岩川 精吾, 北河 修治, Hirai Midori
    第6回日本薬剤師レジデントフォーラム, Mar. 2017, Japanese, 日本薬剤師レジデント制度研究会, 東京, Domestic conference
    Poster presentation

  • 院外処方箋における疑義照会簡素化プロトコールの運用とその効果
    石川 愛子, 宇田 篤史, Yano Ikuko, 冨田 猛, 阪上 倫行, 野崎 晃, 西岡 達也, 久米 学, 槇本 博雄, 濱口 常男, 岩川 精吾, 北河 修治, Hirai Midori
    日本薬学会第137年会, Mar. 2017, Japanese, 日本薬学会, 仙台, Domestic conference
    Oral presentation

  • エルロチニブによる皮膚障害におけるアクアポリン3の発現変動
    小野 ひとみ, 山本 和宏, 七里 博章, 渡邉 愛未, Nakagawa Tsutomu, 濱口 常男, Yano Ikuko, 尾藤 利憲, Nishigori Chikako, Hirai Midori
    日本薬学会第137年会, Mar. 2017, Japanese, 日本薬学会, 仙台, Domestic conference
    Poster presentation

  • エベロリムスによる間質性肺疾患発症メカニズムにおけるTGF-βの関与
    穐原 裕奈, 山本 和宏, 渡邉 愛未, 七里 博章, Nakagawa Tsutomu, 濱口 常男, Yano Ikuko, Hirai Midori
    日本薬学会第137年会, Mar. 2017, Japanese, 日本薬学会, 仙台, Domestic conference
    Poster presentation

  • mTOR阻害薬によるトリグリセリド合成亢進作用におけるACAA2の役割
    渡邉 愛未, 山本 和宏, Nakagawa Tsutomu, Yano Ikuko, Hirai Midori
    日本薬学会第137年会, Mar. 2017, Japanese, 日本薬学会, 仙台, Domestic conference
    Poster presentation

  • Effects of Topical Cryotherapy on Chemotherapy-induced Peripheral Neuropathy among Breast Cancer Patients: A Self Controlled Clinical Trial.
    Akiko Hanai, Hiroshi Ishiguro, Takashi Sozu, Moe Tsuda, Yano Ikuko, Takayuki Nakagawa, Satoshi Imai, Yoko Hamabe, Masakazu Toi, Hidenori Arai, Tadao Tsuboyama
    The 5th International Symposium of Training Plan for Oncology Professionals, Mar. 2017, English, Training Plan for Oncology Professionals, Osaka, Japan, International conference
    Poster presentation

  • Association of Single Nucleotide Polymorphisms in STAT3, ABCB1, and ABCG2 with Stomatitis in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib: A Retrospective Analysis in Japanese Patients
    Watanabe Aimi, Yamamoto Kazuhiro, Ioroi Takeshi, Hirata Sachi, Harada Kenichi, Miyake Hideaki, Fujisawa Masato, Nakagawa Tsutomu, Yano Ikuko, Hirai Midori
    The 5th International Symposium of Training Plan for Oncology Professionals, Mar. 2017, English, Training Plan for Oncology Professionals, Osaka, Japan, International conference
    Poster presentation

  • 脳神経外科領域CARE療法におけるカルボプラチン推定AUCと抗腫瘍効果ならびに血液毒性の関連について
    國光 葉子, 山下 和彦, Sasayama Takashi, 西岡 達也, 久米 学, 槇本 博雄, 中村 任, Yano Ikuko, Hirai Midori
    第38回日本病院薬剤師会近畿学術大会, Feb. 2017, Japanese, 日本病院薬剤師会, 大阪, Domestic conference
    Oral presentation

  • 参加型を意識した糖尿病教室用ツール・薬物療法かるたとカードの開発
    谷藤 亜希子, 山崎 直樹, 岡崎 裕太朗, 松本 久美子, 小澤 拓, 松田 季代子, 芝 唯, Ono Kumiko, 高田 綾子, Okada Yuko, Hirota Yushi, 西岡 達也, 久米 学, 槇本 博雄, Yano Ikuko, Hirai Midori
    第38回日本病院薬剤師会近畿学術大会, Feb. 2017, Japanese, 日本病院薬剤師会, 大阪, Domestic conference
    Oral presentation

  • 抗てんかん薬のTDMとファーマコゲノミクス
    Yano Ikuko
    平成28年度北海道薬科大学生涯学習センター：病態・薬物治療フォローアップ講座, Feb. 2017, Japanese, 北海道薬科大学, 札幌, Domestic conference
    Public discourse

  • 院外処方箋における疑義照会簡素化について
    Yano Ikuko
    Kobe Pharmacist Seminar, Feb. 2017, Japanese, 兵庫県病院薬剤師会, 神戸, Domestic conference
    Public discourse

  • ファーマコメトリクスを活用した医薬品開発と個別投与設計
    Yano Ikuko
    平成28年度熊本薬学教育部大学院「先端医療学特論」, Jan. 2017, Japanese, 熊本薬学教育部大学院, 熊本, Domestic conference
    Public discourse

  • 臍帯血移植患者におけるミコフェノール酸血中濃度と急性GVHD発症との関連
    吉村 和晃, Yano Ikuko, 山本 崇, 川西 美咲, 磯本 唯, 米澤 淳, 近藤 忠一, 高折 晃史, 松原 和夫
    第37回日本臨床薬理学会, Dec. 2016, Japanese, 日本臨床薬理学会, 米子, Domestic conference
    Poster presentation

  • 生体肝移植術後における1日1回製剤のタクロリムス薬物動態と薬効
    岩崎 真実, Yano Ikuko, 端 幸代, 山本 由貴, 杉本 充弘, 福土 将秀, 増田 智先, 中川 俊作, 米澤 淳, 海道 利実, 上本 伸二, 松原 和夫
    第37回日本臨床薬理学会, Dec. 2016, Japanese, 日本臨床薬理学会, 米子, Domestic conference
    Oral presentation

  • Effects of pharmacists' assessment and intervention based on screening tool of older persons' potentially inappropriate prescriptions criteria version 2
    Kimura Takeshi, Ogura Fumie, Nishioka Tatsuya, Yano Ikuko, Hirai Midori
    2016 ASHP Midyear Clinical Meeting and Exhibitions, Dec. 2016, English, ASHP, Las Vegas, USA, International conference
    Poster presentation

  • 薬物療法の適正化：クリニカルクエスチョンから臨床研究へ、そして再び臨床へ
    Yano Ikuko
    信州病棟薬剤師セミナー, Nov. 2016, Japanese, 長野県病院薬剤師会, 松本, Domestic conference
    Public discourse

  • 貧血時におけるタクロリムスの体内動態
    赤田 菜々, 中川 俊作, 大村 友博, 今井 哲, 米澤 淳, 中川 貴之, Yano Ikuko, 松原 和夫
    第66回日本薬学会近畿支部総会・大会, Oct. 2016, Japanese, 日本薬学会, 大阪, Domestic conference
    Poster presentation

  • Physiologically-based pharmacokinetic modeling and simulation of tacrolimus in living-donor liver transplantation: Effects of liver regeneration and CYP3A5 genotype
    Itohara Kotaro, Yano Ikuko, Tsuzuki Tetsunori, Nakagawa Shunsaku, Yonezawa Atsushi, Okajima Hideaki, Kaido Toshimi, Uemoto Shinji, Matsubara Kazuo
    日本薬物動態学会第31回年会, Oct. 2016, Japanese, 日本薬物動態学会, 松本, Domestic conference
    Oral presentation

  • 白内障手術前後における患者の薬識に関する調査
    西川 光, 森田 洋亮, 田澤 晃太朗, 中川 俊作, 吉田 優子, 米澤 淳, Yano Ikuko, 中川 貴之, 赤木 忠道, 松原 和夫
    第26回日本医療薬学会年会, Sep. 2016, Japanese, 日本医療薬学会, 京都, Domestic conference
    Oral presentation

  • 全病棟での担当薬剤師による抗MRSA薬の投与設計体制の構築とその評価
    木全 柾全, 片田 佳希, 杉本 充弘, 都築 徹教, 松原 惇起, 中川 俊作, 深津 祥央, 米澤 淳, Yano Ikuko, 中川 貴之, 松原 和夫
    第26回日本医療薬学会年会, Sep. 2016, Japanese, 日本医療薬学会, 京都, Domestic conference
    Oral presentation

  • 集中治療室における薬剤師専従による薬物治療への安全性貢献の評価
    片田 佳希, 田上 裕美, 中川 俊作, 佐藤 裕紀, 山本 崇, 石塚 良子, 米澤 淳, Yano Ikuko, 中川 貴之, 松村 由美, 松原 和夫
    第26回日本医療薬学会年会, Sep. 2016, Japanese, 日本医療薬学会, 京都, Domestic conference
    Oral presentation

  • 甲状腺癌に対するレンバチニブ治療の現状と薬剤師の関わり
    清水 倫子, 西脇 布貴, 吉田 優子, 池見 泰明, 中川 俊作, 米澤 淳, Yano Ikuko, 中川 貴之, 林 智誠, 北村 守正, 大森 孝一, 松原 和夫
    第26回日本医療薬学会年会, Sep. 2016, Japanese, 日本医療薬学会, 京都, Domestic conference
    Oral presentation

  • 抗体医薬品の薬物動態評価とその変動因子の探索
    大谷 祐基, 米澤 淳, 池見 泰明, 津田 真弘, 礒本 唯, 今井 哲司, 大村 友博, 中川 俊作, 中川 貴之, Yano Ikuko, 北野 俊行, 高折 晃史, 松原 和夫
    第32回京都がん研究会, Sep. 2016, Japanese, 京都がん研究会, 京都, Domestic conference
    Public discourse

  • ファーマメトリクスに基づくタクロリムス投与個別適正化の実践
    都築 徹教, Yano Ikuko, 松原 和夫
    第26回日本医療薬学会年, Sep. 2016, Japanese, 日本医療薬学会, 京都, Domestic conference
    Public symposium

  • テンプレートを活用した周術期管理におけるシームレスな薬学的管理の導入と評価
    江口 舞, 星野 賢悟, 藤田 浩平, 岡崎 裕太朗, 木村 丈司, 西岡 達也, 久米 学, 槇本 博雄, Yano Ikuko, Hirai Midori
    第26回日本医療薬学会年会, Sep. 2016, Japanese, 日本医療薬学会, 京都, Domestic conference
    Poster presentation

  • カバジタキセル投与患者における好中球減少のリスク因子の探索
    漣 航平, 石橋 直哉, 森田 洋亮, 中川 俊作, 池見 泰明, 深津 祥央, 米澤 淳, Yano Ikuko, 中川 貴之, 寺田 直樹, 山崎 俊成, 小川 修, 松原 和夫
    第26回日本医療薬学会年会, Sep. 2016, Japanese, 日本医療薬学会, 京都, Domestic conference
    Oral presentation

  • Up-to-date 抗てんかん薬のTDM
    Yano Ikuko
    第37回三重てんかん研究会, Sep. 2016, Japanese, 三重てんかん研究会, 三重, Domestic conference
    Public discourse

  • 小児領域におけるファーマコメトリクスの活用
    Yano Ikuko
    摂南大学薬学部臨床研究センター設立記念シンポジウム「日本の小児医療環境を考える」, Jul. 2016, Japanese, 摂南大学薬学部, 大阪, Domestic conference
    Public discourse

  • 腎機能低下時におけるフルオロウラシルの体内動態
    田原 三矢郎, 中川 俊作, 大村 友博, 今井 哲司, 米澤 淳, 中川 貴之, Yano Ikuko, 松原 和夫
    医療薬学フォーラム2016, Jun. 2016, Japanese, 日本薬学会, 滋賀, Domestic conference
    Poster presentation

  • 術前外来における薬剤師の取り組み〜術前休薬基準の作成と運用
    尾崎 淳子, 山本 浩貴, 櫻井 香織, 上杉 美和, 石塚 良子, Yano Ikuko, 小石 奈月, 竹下 麻美, 安彦 郁, 松村 由美, 松原 和夫
    第19回日本医薬品情報学会総会・学術大会, Jun. 2016, Japanese, 日本医薬品情報学会, 東京, Domestic conference
    Oral presentation

  • 社会的挫折ストレス負荷によるうつ病モデルマウスにおけるブロチゾラム誘発睡眠作用の効力変化に関する行動薬理学的研究
    宮山 大, 今井 哲司, 辻 光貴, 重面 雄紀, 米澤 淳, 大村 友博, 中川 俊作, Yano Ikuko, 中川 貴之, 松原 和夫
    医療薬学フォーラム2016, Jun. 2016, Japanese, 日本薬学会, 滋賀, Domestic conference
    Poster presentation

  • 実臨床データを用いた新規抗てんかん薬のファーマコメトリクス
    Yano Ikuko
    医療薬学フォーラム2016, Jun. 2016, Japanese, 日本薬学会, 滋賀, Domestic conference
    Public symposium

  • ワルファリンの抗凝固作用に及ぼす食事摂取量の影響
    西村 明子, 片田 佳希, 中川 俊作, 佐藤 裕紀, 田上 裕美, 米澤 淳, Yano Ikuko, 山崎 和裕, 南方 謙二, 松原 和夫, 中川 貴之
    医療薬学フォーラム2016, Jun. 2016, Japanese, 日本薬学会, 滋賀, Domestic conference
    Poster presentation

  • 生体肝移植術後のタクロリムス静脈内投与から経口投与への切り替え換算量に関する検討
    都築 徹教, Yano Ikuko, 中川 俊作, 杉本 充弘, 佐藤 裕紀, 津田 真弘, 上杉 美和, 岡島 英明, 海道 利実, 上本 伸二, 松原 和夫
    第33回日本TDM学会・学術大会, May 2016, Japanese, 日本TDM学会, 宇都宮, Domestic conference
    Oral presentation

  • ひょっとして「副作用」!?見逃さない薬剤師になるための第一歩
    小出 慶子, 西岡 達也, 久米 学, 槇本 博雄, Yano Ikuko, Hirai Midori
    第10回日本ファーマシューティカルコミュニケーション学会大会, May 2016, Japanese, 日本ファーマシューティカルコミュニケーション学会, 名古屋, Domestic conference
    Oral presentation

  • 免疫抑制剤のPK-PD解析と個別化投与設計
    矢野 育子
    医療薬学フォーラム2015/第23回クリニカルファーマシーシンポジウム, Jul. 2015
    [Invited]

  • 京都大学におけるTDM分析事例〜抗てんかん薬について〜
    矢野 育子
    第22回クロマトグラフィーシンポジウム, May 2015
    [Invited]

  • Pharmacist Roles in the Individualized Pharmacotherapy
    Ikuko Yano
    The13th CJK Joint Symposium for Clinical Information on Parenteral Drugs, Apr. 2015
    [Invited]

  • 新規抗てんかん薬のTDM
    矢野 育子
    東邦大学大森病院TDM委員会勉強会, Mar. 2015
    [Invited]

  • 新規抗てんかん薬のTDMとPK/PD
    矢野 育子
    第２１回「TDM研修会, Feb. 2015
    [Invited]

  • 臨床系教員の立場から
    矢野 育子
    第36回日本病院薬剤師会近畿学術大会, Jan. 2015
    [Invited]

  • 新規抗てんかん薬のTDMと臨床薬理
    矢野 育子
    第35回日本臨床薬理学会学術総会, Dec. 2014
    [Invited]

  • 新規抗てんかん薬のTDM
    矢野 育子
    第31回日本TDM学会・学術大会, May 2014
    [Invited]

  • Up-to-date抗てんかん薬のTDM
    矢野 育子
    薬物治療モニタリング研究会第102回例会, Feb. 2014
    [Invited]

  • 小児医薬品評価におけるModeling and Simulationの活用について
    矢野 育子
    第34回日本臨床薬理学会学術総会, Dec. 2013
    [Invited]

  • From Bench to Bedside”-Application of Science to Clinical Practice
    Ikuko Yano
    6th Asian Association of Schools of Pharmacy Conference Pre-conference Pharmacy Education Forum and Workshops, Nov. 2013
    [Invited]

  • The role of pharmacists in organ transplantation
    Ikuko Yano
    The 13th Congress of the Asian Society of Transplantation, Sep. 2013
    [Invited]

  • これからの薬剤師レジデントプログラムに望む事〜大学の立場から〜
    矢野 育子
    薬剤師レジデント交流会, Mar. 2012
    [Invited]

■ Research Themes
  • 周産期母児における抗精神病薬治療の適正化のためのファーマコメトリクス
    矢野 育子, 山本 和宏
    日本学術振興会, 科学研究費助成事業, 基盤研究(C), 神戸大学, 01 Apr. 2022 - 31 Mar. 2025

  • 専門薬剤師が医療の質に与える効果とその評価に関する研究
    益山光一、矢野育子
    厚生労働省, 厚生労働科学研究費補助金（医薬品・医療機器等レギュラトリーサイエンス政策研究事業）, 神戸大学, Apr. 2024 - Mar. 2025, Coinvestigator

  • microRNAを介した小胞体ストレス関連分子SEL1L/HRD1の機能解析とパーキンソン病治療への応用
    神戸薬科大学, 学長裁量経費による学内共同研究経費, Apr. 2022 - Mar. 2025, Principal investigator

  • 国民のニーズに応える薬剤師の専門性のあり方に関する調査研究
    矢野育子、入江徹美
    厚生労働省, 医薬品・医療機器等レギュラトリーサイエンス政策研究事業, Apr. 2020 - Mar. 2023, Principal investigator

  • Pharmacometrics of newer antiepileptics for the optimization in pregnant women
    Yano Ikuko
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Grant-in-Aid for Scientific Research (C), Kobe University, Apr. 2019 - Mar. 2022
    This study aimed to determine the effects of pregnancy and ontogeny on risperidone and its active metabolite paliperidone pharmacokinetics by constructing a physiologically based pharmacokinetic (PBPK) model. A constructed PBPK model accurately predicted both drug pharmacokinetics in adults, pediatric, and pregnant populations. Sensitive analyses showed that decreased serum albumin, increased CYP2D6 activity, increased fetoplacental volume, and increased glomerular filtration rate (GFR) influenced the risperidone and paliperidone pharmacokinetics during pregnancy. The Simcyp model was superior in predicting the eGFR in neonate compared to Rhodin and Schwartz models.

  • Yano Ikuko, ITOHARA Kotaro, INOUE Miho, YAMAMOTO Kazuhiro
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Grant-in-Aid for Scientific Research (C), Kobe University, 01 Apr. 2016 - 31 Mar. 2019, Principal investigator
    In adult patients after living-donor liver transplantation (LDLT), postoperative days and CYP3A5 genotype are known to affect tacrolimus pharmacokinetics. We constructed a physiologically based pharmacokinetic (PBPK) model adapted to the clinical data, and evaluated the contribution of liver regeneration as well as hepatic and intestine CYP3A5 genotypes on tacrolimus pharmacokinetics. As a result, liver function recovered immediately and affected the total body clearance of tacrolimus during only limited periods after LDLT. The constructed PBPK model clarified the oral clearance of tacrolimus was affected by the CYP3A5 genotypes in both the liver and intestine to the same extent. The recommended initial dosage of tacrolimus guided by genotype using PBPK simulations would be useful to maintain the therapeutic range quickly.
    Competitive research funding

  • （AMED）高齢者の多剤処方見直しのための医師・薬剤師連携ガイド作成に関する研究/病院薬剤師主導による多剤処方の是正を目指した医師・薬剤師連携モデルの構築と医師・薬剤師連携ガイドの作成
    矢野 育子
    国立大学法人東京大学, 長寿・障害総合研究事業, 2017, Principal investigator
    Competitive research funding

  • Pharmacokinetics and Pharmacodynamics of Mycophenolic Acid and Individualized Therapy
    Yano Ikuko
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Grant-in-Aid for Scientific Research (C), Kyoto University, 01 Apr. 2013 - 31 Mar. 2016
    The experimental data obtained from Nagase analbuminemic rats showed that the free mycophenolic acid (MPA) concentration was suitable for the biomarker of immunosuppressive effect of MPA. Simulations based on the obtained pharmacokinetic and pharmacodynamic parameters showed that the pharmacological marker IMPDH activity decreased non-linearly according to the increase in free fraction of MPA, although the area under the concentration-time curve of free MPA increased linearly.Population pharmacokinetic and pharmacodynamic analyses using clinical data obtained from hematopoietic stem cell transplant patients showed that the decreased renal failure increased the MPA concentration by the increased enterohepatic circulation of the accumulated metabolite, but scarcely affected the pharmacological effects. In conclusion, since the pharmacodynamics of MPA was non-linear, the increased MPA concentration has a limited effect on the pharmacological effects of MPA.

  • Full-automatic PopPK modeling utilizing an evolutionary algorithm
    YAMASHITA Fumiyoshi, YANO Ikuko, AMANO Akira
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Challenging Exploratory Research, Grant-in-Aid for Challenging Exploratory Research, Kyoto University, 01 Apr. 2013 - 31 Mar. 2015
    A population pharmacokinetic model is composed of average pharmacokinetic parameters, their inter- and intra-individual variabilities. In order to predict blood concentration profile of a drug in each individual, we have to develop an accurate covariate model that represents quantitative relationship between pharmacokinetic parameters and patient information. However, it is a labor-intensive process because there are too many possibilities comprising covariate candidates. In the present study a full-automatic system for covariate modeling was developed, that utilizes an algorithm of evolving mathematical formulae on computers.

  • Population pharmacokinetics and pharmacodynamics and individualized therapy in patients with refractory epilepsy
    YANO Ikuko, FUKUDO Masahide, IKEDA Akio, MASUDA Satohiro
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Grant-in-Aid for Scientific Research (C), Kyoto University, 2009 - 2011
    We quantitatively evaluated the effects of CYP2C19 genotype and co-administered antiepileptics on clobazam and N-desmethylclobazam pharmacokinetics. The high N-desmethylclobazam concentration in CYP2C19 poor metabolizers suggested a higher possibility of response to low-dose clobazam, and genotyping of CYP2C19 might be useful in individualized therapy with this drug.

  • Standardization of tailor-made chemotherapy based on pharmacokinetics and pharmacogenomics
    ISHIGURO Hiroshi, YANO Ikuko, YANAGIHARA Kazuhiro
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Grant-in-Aid for Scientific Research (C), Kyoto University, 2007 - 2011
    Anti-neoplastics metabolized by liver has not only with narrow safety margin but also large inter-individual variation in pharmacokinetics. Dosing based on the knowledge of pharmacogenomics, drug interaction and pharmacokinetics are the most simple and reliable methods. We have conducted several investigator-initiated clinical pharmacology trial under approval of ethics committee of Kyoto University Hospital and searched for possibility for minimizing inter-individual variation in pharmacokinetics.

  • Dosage schedule based on pharmacokinetic and pharmacodynamic interaction of immunosuppressants
    YANO Ikuko, FUKUDO Masahide
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Grant-in-Aid for Scientific Research (C), Kyoto University, 2007 - 2008
    新規免疫抑制剤であるエベロリムス体内動態についてラットを用いて検討した結果、小腸での高い初回通過効果のためバイオアベイラビリティが低いこと、併用したタクロリムスとは相互作用しないが、シクロスポリンとは小腸部位で相互作用を起こすことが判明した.さらに、タクロリムス併用膵島移植患者では薬物間相互作用が期待できないため、エベロリムスではシロリムスに比べて約3倍の投与量を必要とすることが示唆された.

  • 抗リン酸化ペプチド抗体を用いた高感度カルシニューリン活性測定法の開発と臨床応用
    乾 賢一, 矢野 育子, 増田 智先
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Exploratory Research, Grant-in-Aid for Exploratory Research, Kyoto University, 2006 - 2007
    研究代表者等はこれまでに、生体肝移植患者において、シクロスポリンやタクロリムスの標的分子であるカルシニューリンの酵素活性が、これら薬物の免疫抑制効果の指標となり得ることを明らかにしてきた。本研究では、臨床応用可能な迅速かつ高感度な新規カルシニューリン活性測定法の開発を目指して、ELISA法を用いた測定系について検討した。現在までに、カルシニューリンの特異的基質であるリン酸化RIIペプチドに対する抗リン酸化ペプチド抗体の作成に成功し、さらに抗体の特異性が確認された。続いて、抗リン酸化RIIペプチド抗体をプレートに固相化し、FLAG付リン酸化RIIペプチドを標準物質として、サンドイッチELISA測定系を確立した。FLAG付リン酸化RIIペプチドの定量性は、0.125-4ng/mLの範囲であった。本法は、カルシニューリンによるリン酸化RIIペプチドの脱リン酸化反応(ステップ1)と、FLAG付リン酸化RIIペプチドによる反応終了液中に含まれるリン酸化RIIペプチドの定量(ステップ2)を行うことを特徴とし、反応前後のリン酸化RIIペプチドの物質収支からカルシニューリンの脱リン酸化活性が算出できる。 本年度は、リン酸化RIIペプチド定量のための条件検討を実施した。まず、ステップ1の停止液のステップ2に対する影響を調べた結果、常用の5%トリクロロ酢酸/0.lMリン酸二水素カリウム溶液を用いた場合、FLAG付リン酸化RIIペプチド(4ng/mL)の検出が不可能であった。そこで次に、5mM EGTA(カルシニューリンの阻害剤)をステップ1の停止液として用いた場合、ステップ2には影響せず、FLAG付リン酸化RIIペプチドの検出が可能であることが示された。今後、開発したnon-RI ELISA測定系の臨床応用に向けて、カルシニューリン活性測定の最適化及び全自動化を目指す予定である。

  • Population Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors and Development of Individualized Therapy
    YANO Ikuko, MASUDA Satohiro
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Grant-in-Aid for Scientific Research (C), Kyoto University, 2005 - 2006
    To compare the pharmacological characteristics of calcineurin inhibitors tacrolimus and cyclosporine, we measured the calcineurin activity in peripheral blood mononuclear cells as well as blood drug concentrations in living-donor liver transplant patients. Population Pharmacodynamic analysis using the nonlinear mixed-effects modeling program NONMEM showed that the calcineurin activity was almost completely inhibited over 700 ng/mL of cyclosporine which corresponded to the peak concentration. On the other hand, the calcineurin activity was partially inhibited over 20 ng/mL of tacrolimus which was the upper limit of therapeutic range, indicating that the pharmacological characteristics were different between tacrolimus and cyclosporine. Since the calcineurin inhibition by both drugs showed a large interindividual variability, the monitoring of calcineurin activity in addition to drug concentrations might be useful for individualized therapy. To clarify the factors affecting interindividual variability in tacrolimus pharmacokinetics, effects of P-glycoprotein (MDR1) and drug metabolizing enzymes (CYP3A4, CYP3A5) were analyzed by the population approach. As a result, mRNA levels of MDR1 in the intestine affected the oral clearance of tacrolimus immediately after the transplantation, while CYP3A5^*3 allele in the grafted liver influenced the recovery of oral clearance accompaning the postoperative days. Based on these results, the measurement of calcineurin activity in each patient and taking pharmacogenomic factors into consideration of pharmacokinetic changes will promote the precise individualized pharmacotherapy of tacrolimus.

  • Evaluation of drug interaction and interindividual differences of renal drug excretion based on the genetic polymorphism analysis
    INUI Ken-ichi, MASUDA Satohiro, KATSURA Toshiya, OKUDA Masahiro, TERADA Tomohiro, MOTOHASHI Hideyuki
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (A), Grant-in-Aid for Scientific Research (A), KYOTO UNIVERSTTY, 2001 - 2003
    Drug transporters expressed in the kidney play important roles for elimination of number of hydrophilic compounds such as drugs, toxins and endogenous compounds. In the present study, we evaluated interindividual differences of pharmacokinetic (PK) properties based on the genetic information and expression profiles of human renal drug transporters. We have identified and characterized novel renal specific transporters hOCT2-A and NaGLT1. Expression profiles for various drug transporters such as organic ion transporters in the human kidney were constructed. We have identified single nucleotide polymorphisms for coding region (cSNPs) of hOCT1 and hPEPT2 with decreasing the functional activities, but the appearance rates of these SNPs were very low. The correlation analyses between expression of drug transporters and PK properties in renal failure patients and model animals indicated that expression levels of renal drug transporters are responsible for interindividual differences of drug renal excretion. These findings could provide information for quantitative prediction and evaluation of PK based on the expression levels of renal drug transporters.

  • 免疫抑制剤の体内動態・薬効の母集団速度論的解析と個別化処方設計支援システムの開発
    矢野 育子
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Grant-in-Aid for Scientific Research (C), Kyoto University, 2002 - 2002

  • 病態時における薬物腎排泄の変動とその分子機構に基づく科学的投与設計の構築
    矢野 育子
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Encouragement of Young Scientists (A), Grant-in-Aid for Encouragement of Young Scientists (A), Kyoto University, 2000 - 2001
    生体に投与されたイオン性薬物の多くは、腎臓において尿細管分泌を受け尿中に排泄されることが知られているが、腎障害時におけるこれら薬物の腎排泄変化と薬物トランスポータの発現変動に関する情報は少ない。本研究課題では、平成12年度にシスプラチン惹起腎障害モデルラットを用いた検討を行い、このモデルにおいては有機アニオンの腎皮質切片への取り込みは有意に低下するものの、有機カチオンの取り込みは有意に変化していないこと、さらに側底膜有機アニオントランスポータrOAT1及び有機カチオントランスポータrOCT2の発現変動を伴わないことが判明した。本年度は、既報に準じ5%オキソン酸と2.5%尿酸の混合飼料を10日間与えることによって高尿酸血症モデルラットを作成し検討したところ、糸球体濾過速度の減少と共に、有機アニオンメトトレキサートや有機カチオンシメチジン腎クリアランスの減少が観察された。さらに腎切片へのこれら薬物の取り込みは減少したことから、血管側側底膜を介した輸送活性の低下が示唆された。ラット腎粗膜画分を調製し、側定膜有機アニオントランスポータrOAT1、rOAT3並びに有機カチオントランスポータrOCT1、rOCT2特異抗体を用いてウェスタンプロッティングを行ったところ、rOCT1蛋白量は変動していないものの、rOAT1、rOAT3、rOCT2蛋白量の減少が観察された。さらに、ラット腎total RNAを調製し、rOAT1、rOAT3、rOCT2の特異的プローブを用いノーザンブロッティングを行ったところ、rOAT1、rOCT2 mRNA発現量の有意な低下が認められた。従って、高尿酸血症モデルラットの腎側底膜における有機アニオン及び有機カチオン輸送活性の低下に、rOAT1、rOAT3及びrOCT2の特異的な発現量低下が寄与していることが示唆された。 以上の結果、腎障害時におけるイオン性薬物の腎排泄への影響は多様であるものの、一部は薬物トランスポータの特異的な発現変動で説明できると考えられる。

  • Analysis of barrier function of intestinal drug-metabolizing enzymes and transporters
    YUKIYA Hashimoto, TETSUYA Aiba, IKUKO Yano
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Grant-in-Aid for Scientific Research (C), 1999 - 2000
    It has been suggested that cytochrome P450 (CYP) 3A is expressed in the intestine as well as liver, and that the intestinal metabolism contributes largely to the oral bioavailability of tacrolimus and other CYP3A substrates in clinical studies. We investigated the contribution of intestinal metabolism to the first-pass effect of tacrolims in rats. Tacrolimus was administered intravenously, intraportally or intraintestinally to rats. Blood samples were collected over a 240-min period, and blood tacrolimus concentrations were measured. The extraction ratios of tacrolimus in the intestine and liver were investigated. The rate of absorption of tacrolimus in the intestine was rapid, and the drug was almost completely absorbed after intestinal administration. The bioavailability of tacrolimus was about 40% and 25% after intraportal and intraintestinal administration, respectively, indicating that tacrolimus is metabolized in both the intestine and the liver. Tacrolimus was significantly metabolized in the everted sac of the rat intestine. The present study suggested that the metabolism of tacrolimus in the intestine contributes to its extensive and variable first-pass metabolism following the oral administration. In addition, the exorption by P-glycoprotein, as well as metabolism by CYP3A in the intestine, may contribute to the first pass effects of some drugs, which are substrates of these proteins.

  • 薬物トランスポータ分子認識を利用した薬物動態制御システムの構築
    乾 賢一, 矢野 育子, 増田 智先, 齋藤 秀之
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research on Priority Areas (A), Grant-in-Aid for Scientific Research on Priority Areas (A), Kyoto University, 1999 - 1999
    本研究では、臓器特異的に発現する薬物トランスポータ群の分子認識能に基づき、薬物の生体内利用率を高めるドラックデリバリーの開発、あるいは薬物相互作用発現機構の分子的解明について検討を加えた。 1.H^+駆動型ペプチドトランスポータ(PEPT)とエステル型化合物との相互作用 従来ペプチド結合を待つ化合物のみPEPTの基質になると考えられてきたが、ペプチド結合をエステル結合にした化合物も、PEPTの基質になることを明らかにした。これらの結果より、経口吸収性の低い薬物をアミノ酸でエステル化し、小腸に発現するPEPT1の基質とすることによって、消化管吸収の改善が可能になった。従って、PEPTの分子認識能を利用した、新規薬物送達システムの実用化に向けて大きく前進したと考えられる。 2.PEPTと糖尿病治療薬との相互作用 新規経口血糖降下剤nateglinideは、D-フェニルアラニンを有するジペプチド様構造をしている。また、臨床上繁用されている経口血糖降下剤glibenclamideは、構造的に多様なイオンチャネルやトランスポータを阻害することが知られている。そこで、これら糖尿病治療薬とPEPTとの相互作用について検討した結果、両薬物ともPEPTの機能を非競合的に阻害すること、並びにPEPTを介して輸送されないことが判明した。従って、これら経口血糖降下剤がPEPTの生理及び薬物動態学的機能を阻害し、臨床的問題を引き起こす可能性が示唆された。 3.有機イオントランスポータを介する薬物相互作用発現機構の評価・解析 新規腎局在性有機アニオントランスポータOAT-K2のcDNAクローニングに成功し、OAT-K1並びにOAT-K2の機能的異同について検討した。その結果、両トランスポータは互いに異なる薬物認識特性を有することがわかった。また、有機カチオントランスポータOCT1及びOCT2の機能特性について比較したところ、両トランスポータは互いに類似した薬物認識能を有するものの、その発現調節において異なる調節を受けることが判明した。これらの分子的情報をもとに、現在、薬物相互作用発現機構の予測システムを構築中である。

  • Development of novel systems for evaluation and prediction of drug inteactions based on the reconstruction of drug excretion systems in vitro.
    INUI Ken-ichi, KATSURA Toshiga, SAITO Hideyuki, HASHIMOTO Yukiga, YANO Ikuko
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B), Grant-in-Aid for Scientific Research (B), KYOTO UNIVERSITY, 1997 - 1999
    We have studied the development of novel systems for evaluation and prediction of drug interactions based on the reconstruction of drug excretion systems in vitro. First, we cloned and characterized two renal organic anion transporters, OAT1 and OAT-K2. Using X enopus oocyte expression system, OAT1 mediated various organic anion uptake, and the OAT1-mediated p-aminohippuric acid uptake was markedly inhibited in the presence of various anionic diuretics. In addition, OAT-K2 mediated transport of hydrophobic organic anions (Masuda et al., Mol. Pharmacol., 55,743-752,1999). Second, We have constructed the various transfectants, stably expressing OAT-K1, OAT-K2, renal organic cation transporter OCT1 and OCT2, respectively. The OAT-K1-mediated methotrexate transport was competitively inhibited by nonsteroidal antiinflammatory drugs such as indomethacin and ketoprofen (Masuda et al., J. Pharmacol. Exp. Ther., 283, 1039-1043, 1997), The OCT1-and OCT2-mediated tetraethylammonium uptake was markedly inhibited by various cationic drugs, such as tetraalkylammoniums, antiarrthythmis, endogenous metabolite NィイD11ィエD1-methylnicotinamide and guanidine (Urakami et al., J. Pharmacol. Exp. Ther., 287, 800-805, 1998). In addition, we demonstrated the inhibitory effect of clarithromycin on renal excretion of digoxin via P-glycoprotein (Wakasugi et al., Clin. Ther., 64, 123-128,1998). These results suggest that the drug transporter expressing systems appeared to be useful for evaluating and predicting the transporter-mediated drug interactions.

  • Individual dosage regimen based on population pharmacokinetics and genotyping of drug metabolizing enzymes
    HASHIMOTO Yukiya, OKUDA Masahiro, YANO Ikuko
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Grant-in-Aid for Scientific Research (C), KYOTO UNIVERSITY, 1997 - 1998
    We have estimated the population pharmacokinetic parameters of phenytoin in Japanese patients with epilepsy (Biol. Pharm. Bull., 19, 444, 1996), and examined the effect of cytochrome P450 (CYP) 2C9/19 polymorphisms on the pharmacokinetics of phenytoin (Clin. Pharmacol. Ther., 62, 287, 1997). In this study, we evaluated the phenytoin dosage regimen based on the simple polymerase chain reaction-based genetic test of CYP2C isozymes. The population pharmacokinetic parameters without the information of CYP2C genotypes failed to predict the serum phenytoin concentration in patients with the mutation in CYP2C9 (Ile^<359>*Leu). In contrast, the genotyping of CYP2C9/19 in individual patients was useful in determining which patients are at risk for drug intoxication. In addition, the precision of the predicted serum phenytoin concentrations was improved by the baysian analysis based on the population pharmacokinetic parameters involving the polymorphism of CYP2C subfamily. The genetic test for the CYP2C isozymes will be useful in designing the dosage of phenytoin.

  • 緑内障治療剤投与の適正化を目指した薬物体内動態・薬効の母集団解析
    矢野 育子
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Encouragement of Young Scientists (A), Grant-in-Aid for Encouragement of Young Scientists (A), Kyoto University, 1996 - 1996
    炭酸脱水酵素阻害剤であるアセタゾラミドは、唯一の内服用緑内障治療剤として眼科領域で広く使用されているものの、副作用の発現頻度は高く、その使用には困難を伴っていた。本研究では、アセタゾラミド投与の適正化を目指して、医師との連携により、患者におけるアセタゾラミドの体内動態と薬効の母集団解析を行った。 京都大学医学部附属病院眼科入院中でアセタゾラミド内服している一過性の高眼圧患者17名を対象に、経時的な眼圧測定と採血を行った。眼圧はGoldmann圧平眼圧計により測定し、アセタゾラミド血漿中濃度は、HPLC法により定量した。体内動態は繰り返し投与を含む1次吸収1-コンパートメントモデルを、薬効はEmaxモデルを仮定し、拡張最小二乗法プログラムNONMEMにより解析した。見かけのクリアランス(CL,L/hr)は、個々の患者の体重(BW)と血清クレアチニン値(Scr)と以下の関係にあった:CL=0.0255・BW/Scr。また、アセタゾラミドによる眼圧最大下降値(Emax)は、7.2±1.5mmHg(mean±SE)であり、Emaxの半分の薬効をもたらす濃度(EC50)は、1.64±1.43μg/mlであることから、アセタゾラミドによる十分な眼圧下降効果は、血漿中濃度5〜10μg/mlで期待でき、それ以上の血中濃度の上昇は薬効の増強にはつながらないことが明らかとなった。さらに、得られた体内動態・薬効の速度論パラメータに基づき、個々の患者の体重と血清クレアチニン値を用いたアセタゾラミド投与量のノモグラムを作成した。本研究で得られた知見は、個々の患者に適した安全かつ有効なアセタゾラミド治療を推進する上で有用な情報となると考える。

  • Kietic analysis and evaluation of drug absorption and excretion using cultured cells.
    INUI Ken-ichi, OKUDA Masahiro, YANO Ikuko, SAITO Hideyuki, HASHIMOTO Yukiya
    Japan Society for the Promotion of Science, Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (B), Grant-in-Aid for Scientific Research (B), KYOTO UNIVERSITY, 1995 - 1996
    The characterization of absorption, distribution, metabolism, excretion of xenobiotics is a important process to evaluate the drug efficacy and safety in preclinical stages. We developed the in vitro experimental systems, the intestinal/renal membrane vesicles and the cultured epithelial cells, to save the use of experimental animals. In this study, we tried to analyze the drug transport across monolayrs of renal (LLC-PK_1, OK,MDCK) and intestinal (Caco-2) cells, and to evaluate the rate limiting step in drug absorption and excretion, as follows : 1.Experimental system using cultured cell monolayrs : The intestinal and renal epithelial cells were grown on the microporous membrane filters. We examined the apical-to-basolateral and basolateral-to apical transport of drugs in relation to the cellular accumulation. This experimental system was shown to be useful for evaluate the drug transport in intestinal/renal epithelial cells. 2.Toxicity of drugs in cultured cell : The toxicity of drug in renal cells was evaluated by measuring enzyme activities of apical membrane and lysosome. We established the optimal conditions to estimate the nephrotixicity of drugs. 3.Kinetic analysis of drug transport in cell monolayrs : We developed a simple model to estimate the clearance from apical medium to cells, cells to apical medium, cells to basolateral medium, and basolateral medium to cells. The kinetic analysis of drug transport in cell monolayrs gave the useful information about the rate limiting step of drug transport and the activity of drug transporter in intestinal and renal epithelium.

TOP